Developing a projection model for diabetic end stage renal disease in Saskatchewan using an agent based model by Gao, Yu
DEVELOPING A PROJECTION MODEL FOR DIABETIC END STAGE RENAL 
DISEASE IN SASKATCHEWAN USING AN AGENT BASED MODEL 
 
A Thesis Submitted to the College of 
Graduate Studies and Research 
In Partial Fulfillment of the Requirements 
For the Degree of Master of Science 
In the Department of Computer Science 
University of Saskatchewan 
Saskatoon 
 
By 
 
Amy Yu Gao 
 
 
 
 
© Copyright Amy Yu Gao, July, 2013. All rights reserved. 
 
 
 
i 
PERMISSION TO USE 
In presenting this thesis in partial fulfilment of the requirements for a Postgraduate 
degree from the University of Saskatchewan, I agree that the Libraries of this University may 
make it freely available for inspection.  I further agree that permission for copying of this thesis 
in any manner, in whole or in part, for scholarly purposes may be granted by the professor or 
professors who supervised my thesis work or, in their absence, by the Head of the Department or 
the Dean of the College in which my thesis work was done.  It is understood that any copying or 
publication or use of this thesis or parts thereof for financial gain shall not be allowed without 
my written permission.  It is also understood that due recognition shall be given to me and to the 
University of Saskatchewan in any scholarly use which may be made of any material in my 
thesis. 
Requests for permission to copy or to make other use of material in this thesis in whole or 
part should be addressed to: 
 
Head of the Department of Computer Science 
176 Thorvaldson Building 110 Science Place 
University of Saskatchewan 
Saskatoon, Saskatchewan Canada S7N 5C9 
 
 
 
ii 
ABSTRACT 
Our epidemiology research found that the incident and prevalent rates for Diabetes 
mellitus (DM) and Diabetic End Stage Renal Disease (DM-ESRD) were at rise in Saskatchewan 
between year 1980 and 2005.  Combining concerns regarding the rising trends reported by 
research studies with the concerns of the significant health and financial burden imposed by DM-
ESRD on individuals and societies, we sought to project the number of DM-ESRD patients in 
Saskatchewan up to year 2025 with the cost required for caring for those patients. 
An agent-based model (ABM) is developed to simulate DM to ESRD progression, 
treatments for DM-ESRD patients, and the assessments and waiting list processes preparing 
patients for kidney transplants.  The model parameters were estimated from a wide variety of 
data sources.  The agent based modeling approach is chosen for projections regarding the DM-
ESRD situation in Saskatchewan because of its advantage in capturing heterogeneities of 
individual patients, ability to retain biographical information on patients, capacity to capture 
time-varying competing risks, better presentations features and easy integration with existing 
models built in either agent based or System Dynamic methods.  The approach was also 
attractive due to its flexibility for future expansion to represent social networks. 
The model projects the incident and prevalent case count, cost, and person years lived for 
the DM-ESRD population in Saskatchewan between year 1980 and 2025.  The projections 
captured the great challenges brought by the fast growing number of DM-ESRD patients and 
substantial cost associated with managing the disease.  In addition to producing projection results, 
the research presented here demonstrates how the model can be used by policy makers to 
experiment and evaluate different policy/interventions in a safe context.  By capturing both the 
individual level records and population level statistics, the model provide a wealth of data for 
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detailed analysis, which can help health policy makers gain insights in the current and future 
diabetic-ESRD situation in the province, aiding in resources planning for managing the fast-
growing ESRD population and the growing need for dialysis services. 
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CHAPTER 1  
BACKGROUND AND INTRODUCTION 
 The first chapter of the thesis provides background information regarding diabetic end 
stage renal disease (DM-ESRD), the cause, and treatment options.  The local health care system 
is discussed next as it is responsible for providing care to the DM-ESRD patients in the province.  
In the last two sections of this chapter, the motivations, the goal and the methodology selected 
for the thesis research are presented. 
1.1 Diabetic-ESRD and Treatment Options 
1.1.1 Diabetic Mellitus (DM) 
 Diabetes is a condition in which the glucose levels in the blood are poorly regulated, 
leading to periods with abnormally high blood sugar.   The human body uses insulin to break 
down sugar in order to produce energy.  When the pancreas is not able to produce enough insulin 
or the body cannot use the insulin effectively, the glucose level in the blood will rise and exceed 
the normal range. There are three types of diabetes: Type 1, Type 2, and gestational diabetes.  
Type 1 diabetes refers to cases in which the pancreas is not producing enough insulin for the 
body to use.   Research has shown that genetics play an important role in developing Type 1 
diabetes [1].   Type 1 diabetes is commonly seen in childhood or early adulthood.  Less than ten 
per cent of cases of diabetes fall into this category.   Type 2 diabetes refers to cases in which the 
body either cannot produce enough insulin and/or cannot use the insulin effectively [1].   Several 
risk factors for Type 2 diabetes have been identified including body weight, ethnicity, age, sex, 
family history, history of gestational diabetes and life style.  Type 2 diabetes is mainly found in 
patients who are in their 40s and older.  Type 2 diabetes forms more than 90% of all diabetes 
cases in the general population.   Unlike Type 1 or Type 2 diabetes, gestational diabetes mellitus 
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(GDM) is usually a temporary condition during pregnancy.  It takes place in 2% to 4% of all 
pregnancies.  For most of the patients the condition will go away after the birth of the child.  
Having gestational diabetes increases the chance of developing type 2 diabetes later in life for 
both the mothers and babies [3]. 
 Most people with Type 2 diabetes can be managed by medications, improved diet and 
healthier life styles. However, improper management of diabetes can result in prolonged 
exposure to high blood glucose levels, which can lead to serious complications in organs such as 
the cardiovascular system, kidneys, eyes, and nerves.   Moreover, diabetes patients are twice as 
likely to have premature death as those without diabetes.    
 Another challenge presented by diabetes is that as many as one third of all diabetes cases 
remain undiagnosed.  Patients with undiagnosed diabetes are at increased risk of developing 
diabetes-related complications [2].  Therefore, it is important to have screening programs 
developed for people who are at higher risk for developing diabetes so as to enhance early 
detection.   
 Diabetes has become a prevailing epidemic worldwide, including Canada.  In fiscal year 
2006 - 2007, there were two million people living with diagnosed diabetes in Canada.  The 
prevalence of diagnosed diabetes has increased by 21% from fiscal year 2002 - 2003 to fiscal 
year 2006 – 2007 [1]. As baby boomers enter older age and with increased survival of people 
with diabetes, it is likely we will see even bigger increases in diabetes prevalence in the next few 
years.   Among Canadians, it has been reported that people of aboriginal background are 
experiencing a more severe epidemic of diabetes.   Aboriginal people have higher diabetes 
prevalence and incidence rates, and also have diabetes at an earlier age.  Compared to other 
provinces in Canada, we have a higher proportion of First Nation people in Saskatchewan.  Thus, 
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we are particularly interested in seeing how the epidemic of diabetes presents itself in 
Saskatchewan and impacts the provincial health care system. 
1.1.2 Diabetic End Stage Renal Disease (DM-ESRD) 
 Diabetes is the leading cause for ESRD in Canada, and serves as the underlying factor for 
more than 35% of the new ESRD cases [7].  Kidneys are damaged by the exposure to high 
glucose levels over years.   One serious complication of diabetes is ESRD or kidney failure, 
which occurs when kidneys can no longer remove waste products from the blood.  Not all people 
with diabetes will develop ESRD.   Some can live with earlier stages of chronic kidney disease 
(CKD) without reaching kidney failure.  Past studies found that people from certain ethnic 
subgroups like African American, American Indian, and Hispanics/Latinos are at higher rate for 
developing ESRD [4].  Other research has shown risk factors for developing ESRD include 
obesity, medical conditions, older age and male sex [7]. 
 In Canada, there are three main types of treatments for patients with ESRD: 
Haemodialysis (HD), Peritoneal Dialysis (PD) and Kidney Transplantation.  As reported by 
CORR, in 2008, among all ESRD treatments, HD accounts for 48.5%, PD accounts for 10.9%, 
and kidney transplantation accounts for 41% [7] of the treatments.  More details about these 
treatments are discussed in the following section.   
1.1.3 Haemodialysis (HD) 
 During HD sessions, a dialysis machine is connected to the patient to remove waste 
products, excess minerals and fluid from the blood [5].  Blood is pumped from a patient’s vein, 
into a dialysis machine, and then back into the patient. Usually, patients on HD go for three 3 – 5 
hour sessions a week.   In Canada, HD can be performed in-center (hospital or community based) 
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or at home.  In-Center HD is the predominant form of dialysis when compared with HD 
performed at home and PD [7].    
1.1.4 Peritoneal Dialysis (PD) 
 PD uses a patient’s peritoneal membrane to filter the waste and extra fluid from the blood 
[6].  A dialysis solution is instilled into the patient’s abdominal cavity, where waste products and 
fluid are filtered from the blood through the peritoneal membrane into the dialysis solution 
before it is drained from the body.  This process is usually repeated four times a day, and each 
time the dialysis solution stays in the body for four to six hours.   There are two forms of PD: 
continuous ambulatory peritoneal dialysis (CAPD) and continuous cycler-assisted peritoneal 
dialysis (CCPD).  CAPD fills and drains the dialysis solution using gravity.  On the other hand, 
the CCPD automates the filling and draining process by using a machine called a cycler. 
  Compared to HD, PD is a less resource intensive treatment.  It can be carried out at home, 
and patients do not have to be connected to a dialysis machine inside a clinic for the length of a 
HD session.  Patients on PD can have much greater mobility than patients on HD.     
 As for switching between dialysis treatments, it was reported that 60% of patients 
underwent only one type of dialysis treatments, 28% have experienced two different types of 
treatments; 9% have three different treatments and the rest have four or more different treatments 
[25]. 
1.1.5 Kidney Transplantation. 
 Kidney transplantation is a surgical operation in which a working kidney from a donor is 
implanted into a person with ESRD.  The donor can be a deceased person or a living person 
(related or unrelated).   Most of the ESRD patients receive dialysis treatments prior to getting 
kidney transplants.  However, a small portion of the ESRD patients receive kidney transplant 
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without ever getting dialysed, which is referred as “Pre-Emptive” kidney transplants.  ESRD 
patients who are eligible to receive kidney transplants will be put on a waiting list because of the 
limited availability of organs.   In more recent decades, the number of living donor kidney 
transplants has been growing steadily but the number of cadaveric kidney transplants has 
remained stable [20].   With a growing number of ESRD patients requiring transplants, the 
available organs from living and deceased donors are not meeting the demand.  The current wait 
time taken from the 2008 CORR report is shown below. 
 
Table 1-1. Transplant Wait Time Spent on Dialysis Prior to First Kidney Transplant by Province 
of Treatment, Adult Kidney Transplant Recipients, Canada, 2006 – 2008. Image of the table was 
taken from [9]. 
 
 
 Though facing post-transplant challenges like rejections and other complications, kidney 
transplantation has become a more favourable choice for ESRD patients compared to dialysis.  
As shown in Figure 1-1 and Figure 1-2 from CORR, the five year survival outcome is much 
better for transplant patients than for dialysis patients.   
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Figure 1-1.  Five Year Survival in ESRD Patients on Dialysis, with or without Diabetes, by Age, 
2004 - 2008 Period Survival. Figure was taken from [22] 
 
 
Figure 1-2.  Five Year Survival in Patients with Kidney Transplant, with or without Diabetes, 
by Age, 2004 - 2008 Period Survival [23] 
 
 HD, PD and Kidney Transplantations are all costly and resource intensive treatments.  
Any of the three treatments greatly impacts patients and their families, and also puts a heavy 
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financial burden on the health care system and society.  In the next section, the regional ESRD 
program and funding structure in Saskatchewan will be discussed.  
1.2 Local Health Care System in Saskatchewan 
 In Saskatchewan, ESRD care is carried out by the regional renal programs.  The 
outpatient HD service is provided in the two hospital renal units at St. Paul’s and Regina General 
Hospital, as well as in several satellite dialysis clinics throughout the province.  The renal 
programs also train patients to perform dialysis at home.  Currently in Saskatchewan, living 
donor transplants are performed in St. Paul’s hospital and, temporarily, deceased donor kidney 
transplants are carried out in Edmonton, Alberta.   Shown below is a detailed report provided by 
CORR on the prevalence of ESRD patients by location of treatment in Saskatchewan. 
Table 1-2.  Prevalent End-Stage Renal Disease Patients by Location of Treatment in 
Saskatchewan. Image of table was taken from [24]. 
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 In Saskatchewan, the regional renal program funded by the provincial health care budget 
completely covers the cost of outpatient dialysis, medications and inpatient hospitalizations for 
ESRD patients who are eligible for the Saskatchewan Health Insurance Plan.  Disability benefits 
are not covered by the Saskatchewan Health Plan but are rather provided by either private 
insurance, a federal government program such as CPP, or unemployment insurance.  
1.3 Research Motivation and Goal 
 As discussed in previous sections, ESRD is a major complication of diabetes and is both 
serious and costly.  In Saskatchewan, it is the responsibility of the provincial government to 
provide health care for ESRD patients and to bear the associated cost.  For planning purposes, we 
want to know the future demands resulting from the care of DM-ESRD patients in the years to 
come.  Factors like demographic changes and epidemiological characteristics of diabetes and 
diabetic – ESRD could all impact the DM- ESRD situation in Saskatchewan.    
 Demographic studies have shown that Saskatchewan is one of two provinces in Canada 
which have the highest Aboriginal (a term that includes First Nations, Metis and Inuit people) 
population concentrations.  From the epidemiological studies conducted in this province and 
elsewhere, we know that the First Nation population exhibits different patterns for diabetes and 
its complications like ESRD.  Here are some findings from various demographics projections for 
the next 15 years, and some highlights from our previous epidemiological studies on diabetes 
and diabetic – ESRD conducted in Saskatchewan. 
 Our previous research found that the prevalence and incidence for diabetes and diabetic – 
ESRD are higher in certain population subgroups.  As we found in our Saskatchewan Diabetic-
ESRD study [19], between 1981 and 2005, most of the DM-ESRD cases occurred in the 40 - 59 
age group for FN and the 60 plus age group for OSK.  In the Saskatchewan Diabetes study [18], 
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between 1980 to 2005, we found that diabetes incident cases are highest in the 40 - 49 age group 
for FN and the age 70 plus group for OSK.  Moreover, it was found that the prevalence rates of 
diabetes increased at different rates for different genders and ethnicities.  The diabetes 
prevalence increased from 9.5% to 20.3% in FN females and from 4.9% to 16.0% in FN males. 
Among OSK, diabetes prevalence increased from 2.0% to 5.5% among females and from 2.0% 
to 6.2% among males.   
 In demographic studies for Saskatchewan, it is predicted that there will be rapid 
population growth for the same age and ethnic groups as noted by the above epidemiological 
researches.  In the Registered Indian (i.e. FN) population projection (medium growth scenario) 
conducted by Indian and Northern Affairs Canada [33], from 2009 to 2024, the population for 
Registered Indians in the 40 - 59 age group will increase by a range of 8.5% to 18.5% every 5 
years, and a total of 42.4% across the 15 years projection period; for people who are in the 40 -
49 age group, the five year growth rate is from 2.3% to 9.8%, yielding a total growth of 20.6%.   
 In the Saskatchewan general population projection (medium growth scenario; included 
both FN and OSK) conducted by Stats Canada [31], from 2011 to 2026, there will be a 9.5% to 
13% population growth every 5 years for people over 60 years old, and a total of 39.2% growth 
across the 15 years projection period; for people 70 years and over, there will be a 4% to 18% 
growth every 5 years, yielding a total of 39.6%.  
  With the above findings in diabetes and diabetic - ESRD rates and the trends in 
population projections, it follows that we will likely face a substantial increase in DM-ESRD 
prevalence and incidence as well as related health care spending in Saskatchewan.  However, due 
to the complexity of this problem, it will be difficult to obtain a good approximation of the future 
situation without a suitable methodology.  We chose to use dynamic modelling approach for our 
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research problem because it offers several advantages, which will be discussed in the next 
section. 
1.4 The Choice of a Dynamic Modeling Approach for this Research 
 In the last 10 years, there has been an increasing application of system science methods to 
study problems in the public health domain because system science methods have offered many 
benefits for investigating public health problem [27]. 
 First of all, system science methods can better capture the structured complexity and the 
dynamic complexity of public health problems. Public health problems could have many 
components in their scope.  For instance, one health economic problem usually involves the 
disease itself, demographics, risk factor dynamics, local and/or global economy, facilities, 
equipment, human resources, policy, budgets, transportation, and much more.  The traditional 
scientific approach follows a reductionist strategy, which focuses on one aspect of the health 
problem.   The reductionist strategy is great for gaining insights into the working mechanisms 
behind a set of components in a particular area of the public health.  However, it often misses 
many interactions between sets of disparate components.  In comparison, system science 
methods take all components and the context into consideration; therefore it can facilitate 
reasoning regarding the complex and dynamic behaviour found in a public health question.   
When public health problems are studied as complex systems, emergent behaviours like 
exponential growth, delays, oscillations, and tipping points can be explained by the collective 
interactions of all the components within the system.  As stated above, the traditional 
epidemiological methods aren’t by themselves equipped to help us understand the dynamic 
complexity present within the public health problem.  System science methods complement such 
traditional methods in providing insights.  
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 Secondly, system methods can help address many challenges presented in public health 
research: communications, misperceptions, and prioritization of research and data collection.  
Nowadays, collective efforts are normally required from a team of researchers with different 
knowledge backgrounds for solving public health problems.  A System Dynamics Model which 
is based on system science is a great communication tool.   It helps with the visualizations of 
conceptual model for discussion and collective refinements from modellers, health care 
practitioners and policy makers.  It presents all the components in the scope, and the 
hypothesized causal relationship between components.  Moreover, the values for the parameters 
in the System Dynamics model explicitly lay out the assumptions for particular epidemiological 
contexts.  All of the above facilitates communications among the research team members. 
 In addition to aiding communication among team members, the simulation of the System 
Dynamics model can help our hypotheses regarding factors contributing to the problem.  The 
simulation of a System Dynamics model can be used to gain insights on how changes in the 
system structures and contexts can affect the overall system behaviour over time.  The 
inconsistency found between the simulation results and expected behaviours from the system can 
help us identify and correct misperceptions of the underlying mechanisms.   
 Another challenge often faced by public health researchers is prioritizing research and 
data collections.  One important note is that system methods do not depend on the completeness 
of data.  The calibration process can systemically estimate some missing data input.  This being 
said, a sufficient amount of data input is still required to start meaningful calibration.  Examining 
sensitivity of the model results and interpreting trade-offs to various pieces of data can help 
researchers identify which missing data  would contribute the most value to our decision making 
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and understanding of future system evolution.  Based on that, we can decide which missing data 
are most needed for our research. 
 In addition to the benefits being mentioned above, system methods are used for 
understanding future system evolution, either with a default “status quo” or in response to 
possible interventions. 
 Finally, simulations of the dynamic model can also help policy makers to select and 
evaluate policies. Consequences of varying scenarios can be observed through the simulation of 
the model, and they can be used to answer the what-if questions that cannot normally be tried out 
in reality due to ethical and resource constraints.  Also, finding the drivers for trends observed in 
the simulations can be used to identify the leverage points in the system and formulate cost 
effective policies.   As shown above, by using dynamic model simulations, the formulation and 
emulations of the cost effective and robust policies can be done transparently.   
 As one type of dynamic modeling, agent based modeling (ABM) offers all of the 
advantages noted above.  Nevertheless, ABM also has a different focus, which makes it better to 
address certain type of public health problem.   It can capture the interactions between 
individuals within the populations at a greater level of detail, so it is a better candidate for doing 
social network analysis than other types of dynamic models.  It can also record all the historical 
events for individuals in a population, which allows comparisons of statistics on such histories 
and on real world individual data.  In addition, ABM is designed to preserve the heterogeneity 
among individuals.  It can capture transition probabilities that vary with the length of time spent 
in a state.   
 Compared with Markov models which are frequently applied for making projections, 
ABM models have several distinct features.  First of all, ABM can easily retain a memory of past 
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states an agent has transitioned as well as the length of time it spent in those states.  Unlike 
Markov models where the decisions are made only based on the last state, simulated 
interventions in ABM can be made contingent upon the history information, and this information 
can be compared with empirical data.  Secondly, ABM can easily capture the heterogeneities 
within the modelled population.  Population characteristics like age, sex, and ethnicity can be 
captured as parameters in ABM, where in a Markov model those would require multiple copies 
of similar states, with each copy of a given state being specific to a particular subgroup of the 
population.  A heterogeneous characteristic like age can have continuous value in ABM, but not 
in a Markov model.  Another distinct feature is that a traditional Markov model usually follows a 
cohort without having birth or immigration into the model, whereas ABM can simulate new 
person flowing into the model by adding members into the agent population.  Moreover, 
probabilities defined for a particular transition can vary with time in an ABM (for instance, the 
rate for getting infected can vary depending on the counts of infected neighbours for an agent at 
any given time), where in a traditional Markov model transitions are fixed throughout the 
simulation.  In addition to those features noted above, ABM is a better candidate when a 
projection is involved with interactions among diverse populations or spatial or geographical 
planning. 
 For my thesis project, an ABM will be used to project the DM-ESRD cost in 
Saskatchewan from the year 2011 to 2025.  We chose an ABM because we might extend the 
model to capture more additional attributes -- especially continuous ones like body mass index 
(BMI) -- and possibly add connections between individuals (e.g. capturing influences of parents 
on children via imitative behavior, or via intra-uterine exposure to high blood sugar) in the future.   
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Since ABM is better for keeping the heterogeneity for individuals, detailed interactions between 
individuals, history dependent processes, we made it our choice for this thesis project. 
15 
 
CHAPTER 2  
LITERATURE REVIEW 
 In this chapter, a literature search was performed to find other research work on the 
projections of prevalence, incidence and cost for diabetic-ESRD.  I used sets of keywords like 
“projections diabetes complications prevalence”, “projection end stage renal disease prevalence”, 
“projections diabetes cost”, and “projections end stage renal disease cost” to search for 
publications in PubMed online database.  Four studies from the returned search results were 
selected because they were conducted more recently and the methodologies applied were popular 
in producing similar projections.  Those papers are chosen for review because they are either 
done in Canada or U.S, which share close geographical location and similar health care settings 
with our research.  In addition, the two papers from the U.S are included in our literature review 
because their model incorporated more risk factors for diabetes, and produced projections for 
finer population subgroups.   
2.1 Research Focusing on the Prevalence and Cost of Diabetes and Diabetes ESRD  
 Ohinmaa et al. [Error! Reference source not found.].  In 2004 Ohinmaa A et al. 
projected that the number of diabetes patients in Canada would increase from 1.4 million in 2000 
to 2.4 million in 2016, and the direct health care cost for diabetes and its complications would 
increase from $4.66 billion Canadian dollars in 2000 to $8.14 billion Canadian dollars in 2016.  
The projection of yearly diabetes prevalence was performed by applying the population 
projection by Statistics Canada to the projections of diabetes prevalence, incidence and mortality 
rates from a simulation model by Blanchard in Manitoba [20].  The total diabetes related health 
cost each year was calculated by applying the direct health care cost per capita to the projected 
number of diabetes patients in that year.  The direct health care cost for diabetes and its 
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complications came from a previous study conducted by the author using the Saskatchewan 
Administrative databases. The projected prevalence and health care cost for diabetes and its 
complications covered the period from 2000 to 2016.  The projections were for subpopulation 
groups which are broken down by age groups and gender.  One major limitation noted by the 
authors was that the current projection did not separate Aboriginal people from the general 
population. This is important since it was shown in other studies that Aboriginal people have 
higher diabetes prevalence and costs than the general population, as well as higher rates of 
population growth.  
 Schaubel et al. [10].  In 1999 the authors projected that the number of End Stage Renal 
Disease patients will increase from 17,807 at the end of 1996 to 32,952 at the end of 2005 basing 
on Canadian Organ Replacement Register (CORR) data from 1981 and 1996,.  The annual 
increase in the prevalence of each ESRD treatment were as follows: 6.0% for PD, 5.9% for HD, 
and 5.7% for functioning kidney transplants.  The projection of ESRD prevalence was conducted 
for each province in Canada.  The patients were broken down into three age groups (<=44 years, 
45-64 years, >=65 years), and by province and diabetes status.   The incident rates by province, 
age groups and diabetes status were projected from 1997 to 2005 using a Poisson regression 
model.   A special Markov model was then used to project the number of patients on different 
ESRD treatments through the projection periods.   The projection showed that the ESRD incident 
rates were increased more in diabetes patients than those without diabetes.   However, the cause 
of such increase could not be clearly pinpointed to either a sole increase in ESRD incidence rates 
or to a simultaneous increase in the prevalence of diabetes and incident rates in ESRD. 
 Gilbertson et al. [11].  In their study published in 2005, Gilbertson and et al used a 
Markov model to predict ESRD prevalence, ESRD incidence and mortality from 1978 to 2015 in 
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United States.   The model consists of four major states: ESRD incidence with Diabetes Mellitus 
(DM), ESRD incidence without DM, ESRD prevalent cases with DM, and ESRD prevalence 
cases without DM.  Each of those states has 21 sub-states: 7 age groups (0 to 18, 19 to 40, 41 to 
64, 65 to 69, 70 to 74, 75 to 79 and >=80 years old) x 3 racial groups (white, black and other).  
The counts of ESRD incident cases from 1978 to 2015 by age, race and DM status were obtained 
using various data sources and explorations.  The actual ESRD prevalence in 1978 from USRD 
2002 report was fed into the model.   The probabilities of transition to death were calculated for 
each of the 42 groups (age, race, and DM status) within the prevalence and incidence state from 
1978 to 2000, and then extrapolated to 2015.  The model predicted that from year 2000 to 2015, 
ESRD incident cases will increase by 44 % (136,166 incident cases in 2015), and ESRD 
prevalent cases will increase by 85% (712,290 prevalent cases in 2015).  Annual deaths with 
ESRD will reach 107,760 in 2015.  One limitation with the model is that it assumes the death 
probability is the same for all prevalent ESRD patients despite the different number of years for 
which they have been under treatments. 
 Huang et al.  [12].   In 2009 the authors used a Markov model to project prevalence and 
incidence of diabetes (both diagnosed and undiagnosed) and associated spending for caring for 
diabetes and its complications from 2009 to 2034 in U.S.  The model accounted for important 
diabetes risk factor like BMI changes over the projection years in addition to other factors like 
gender, ethnicities, and age (from 24 to 85 years).  The cohort in the model consisted of the 
prevalence cohort and the incidence cohort.  The prevalence cohort were people with diabetes in 
2008 in the U.S.  The incidence cohort were the newly diagnosed cases for every year after 2008.  
A Markov model was developed to estimate the incidence of diabetes.  For diabetes incidence, 
the BMI will change with age, which will then affect people’s transitions into diabetes.   The 
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model considered both diagnosed and undiagnosed diabetes cases as well as the transitions 
between them.  The model also kept track of the duration of diabetes, which is important for 
complications development and therefore calculating cost for complications.  In the lifetime 
simulation model of diabetes complications within the study, it accounted for the effect of using 
medications to manage different complications.  The result of running the model showed that the 
BMI distributions in  population without diabetes will remain relatively stable in the next 25 
years.  Between 2009 and 2034, the prevalent cases of diabetes will increase from 23.7 million to 
44.1 million, and the related spending will rise from $113 billion per year to $336 billion per 
year.   The model also reported prevalence and spending for people who are eligible for 
receiving Medicare over the projection period.    
2.2 Research Focusing on the Cost of ESRD Treatments in Canada 
 To obtain cost information regarding ESRD treatments in Canada, I surveyed the 
Canadian medical literature by searching the PubMed online database using two sets of 
keywords, “cost, ESRD, Canada” and “cost, diabetes, complications, Canada”.  I selected five 
relevant papers from the search results.  The cost of ESRD treatments in Canada will be used in 
my simulation model to project the cost of treating DM-ESRD patients in Saskatchewan during 
the projection period.  
 Zelmer et al. [13].  In their study published in 2007, Zelmer et al. estimated the 
economic burden of ESRD in Canada would be $1.9 billion in year 2000.  All the costs came 
from three categories: direct cost ($1,273 million, 69%), mortality cost ($434 million, 23%) and 
morbidity cost ($149 million, 8%).  Based on the information collected from other research 
studies and Ontario health administrative systems, the direct health care cost per capita per year 
was summarized for each renal replacement therapy: center HD was $66,259, self/home HD was 
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$50,982, PD was $45,400, the first transplant year cost was $96,040, and the functioning 
transplant care cost was $31,222.  For living kidney transplant procedure, it cost $5,890 to care 
for the kidney donor.  For cadaveric kidney transplantation, it cost $5,850 to retrieve a kidney.  
The number of patients who had undergone different treatments was obtained from CORR, 
which is listed under column “n” in Table 2-1.  Using the number of patients treated with each 
renal replacement therapy and the cost per capita information, the total of direct health care cost 
was $1273 million in 2000. 
Table 2-1.  Direct health-Care cost of end stage renal disease in Canada in 2000. Image of table 
was taken from [13] 
 
 
 In addition to reporting the direct cost, the indirect cost was also estimated for mortality 
and morbidity, which accounts for up to 31% of the total economic burden.  The mortality cost 
was based on the loss of productivity due to premature death, which counts both paid work and 
unpaid work (e.g. housekeeping).   A sex and age specific profile was drawn on to obtain data on 
average income, workforce participation, unpaid work and life expectancy.  For a patient who 
died in 2000, the mortality cost was the sum of the value of lost production from mid year 2000, 
and all the subsequent years until reaching the end of life expectancy year for the general 
population without ESRD. 
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 The cost of living with morbidity and loss of productivity due to receiving RRT were also 
estimated using a human capital approach.  The author assigned a different disability weight for 
patients with functional transplant, transplant recipients who recently received transplant surgery, 
and dialysis patients.  Among them, some of the dialysis patients experienced a more severe and 
long-term impact of their illness than patients in the other two groups. 
 Simpson et al. [14].  In 2003 the authors published the results from their study on the 
cost of diabetes and its complications. Based on data extracted from the Saskatchewan Health 
administrative database on prescription drugs, hospital records, and physician services, a total of 
$134.3 million was spent on caring for 38,124 (3.6% of the provincial population) diabetes 
patients in the province in 1996.  The total expenditures were broken down into different 
resource categories and co-morbidities in Table 2-2.  It also listed per capita cost for general 
population and Registered Indians separately.  It did not include the prescription drug cost for 
Registered Indians because of the lack of data availability.  The average yearly expenditure for 
caring for a diabetes patient excluding prescription drug costs is $2,768.  As reported in the study, 
many diabetes patients have one or more comorbidities:  46.6% of the patients had a 
cardiovascular-related history, 19.8% of them had an ophthalmic-related history and 6.6% had a 
renal-related history.  The cost for caring for these three major comorbidities added up to 36.4% 
of the total expenditures (26.4% for cardiovascular related; 7.5% for renal related; 2.5% for 
ophthalmic related).    The study found differences in patient characteristics between Registered 
Indian and the general population.  Registered Indian diabetes patients were younger, and there 
were more females having diabetes.   Also, Registered Indians were more likely to develop renal 
complications (11.7% v. 6.0%), but those in the general population had more cardiovascular and 
ophthalmic comorbidities (cardiovascular, 35.1% v. 47.9%; ophthalmic, 12.0% v. 20.0%).  In 
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terms of expenditures, before the age of 60, the median expenditures were similar for general 
population and Registered Indians; however, after the age of 60, the median expenditure 
increased more rapidly for Registered Indians than the general population.  Also, it cost more to 
care for Registered Indian diabetes patients with cardiovascular and renal complications than 
their general population counterparts.  Using a multivariate regression model, Simpson et al. 
showed the relationship between major co- morbidities with health care expenditures in Table 
2-2 from their paper.   The results showed that the expenditures go up as the patient has more 
comorbidities.  The study also found that sex, age and Registered Indian status each had their 
own important impact on the cost. 
Table 2-2.  Health care expenditures among Saskatchewan residents with diabetes mellitus in 
1996.  Image of table was taken from [14]  
 
 Lee et al.  [15].  Based on the data collected from a Calgary dialysis clinic, Lee et al. 
reported the annual direct health care cost for patients on different dialysis modalities in year 
2000 U.S. dollars. The results were listed in Table 2-3:  in-center HD $51,252, satellite HD 
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$42,057, home/self-care HD $29,961, and PD $26,959.  The study, published in the year 2002, 
also applied a multiple linear regression model to uncover the predictors of cost.  Comorbidities 
of patients in this study were measured using the Charlson comorbidity score, which predicted 
the cumulative increased likelihood of death based on the number and severities of the 
comorbidities [30].   Higher Charlson comorbidity score predicts higher mortality.  In the study 
by Lee et al, among all predictors (age, sex, need for assisted living, work status, education, 
Charlson comobidity score, and dialysis modality), the Charlson comorbidity score and dialysis 
modalities were the two variables independently associated with the total cost.  Each increase in 
Charlson score by 1 will bring an additional $2,234 in direct health care cost.  For ESRD patients 
with diabetes, their direct health cost per year is $8,016 more than those ESRD patients without 
diabetes.  Interestingly, other patient characteristics like age, sex, work status and educations 
status are not the predictors of the direct health care cost.  The study showed that the cost 
discrepancy between in center dialysis and home/self care dialysis persisted even after removing 
the comorbidity variable.  The difference in cost between the above two modalities mostly arose 
from the differences in the level of nursing care required.  Based on cost findings in the study, 
the authors strongly promoted higher ratio of self-care/home HD and PD as treatment options to 
allow more resources to be released for treating awaiting patients. 
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Table 2-3.  Annual Health Care Related Costs Per Patient by Modality. Image of table was taken 
from [13] 
 
 Pohar et al. [16].  In 2007, Pohar et al. compared the per capita health care utilization 
and expenditures among four subgroups according to diabetes and Registered Indian status using 
Saskatchewan Health databases.  The total health care cost came from four health care services: 
physician visits, hospitalizations, day surgeries, and dialysis.   People with diabetes used more 
services in all four categories, resulting in more than two times higher cost than people without 
the disease.  With the sole exception of day surgery, Registered Indian people with and without 
diabetes had much higher utilization in all other three health care services and incurred 40% to 
60% higher overall health care expenditures compared to their general population counterparts.  
The Registered Indian diabetes cohort had two distinct characteristics in terms of age and sex.  
First, they were about 13 years younger than the general population cohort.  Second, there were 
more diabetes cases among registered Indian females than males (57.7% of the cohort are 
female); whereas diabetes cases were predominantly males within the general population 
subgroup (46.8% of the total general population diabetes case were females).    Diabetes status 
increased the chance of using all four health care services, and it was especially prominent in HD.  
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The odds of receiving HD was 8.6 times higher for diabetics in the general population, and 14.2 
times higher for registered Indian diabetics when compared with their controls without the 
disease.  People with diabetes also had 5 to 6 times more physician visits, twice as many 
hospitalization and 40 - 50% more day surgeries.  As a consequence of the heavy usage in all 
four health care services, diabetes patients had more than two times higher per capita health care 
expenditures than their controls.  
 Barnieh et al. [34].  O’Brien et al. compared the direct health care costs for living donor 
kidney transplants with the cost for deceased donor transplants. From the database for the 
Southern Alberta Transplant Program, a total of 357 patients who received first time kidney-only 
transplants (at the age of 18 and older) between April 1st, 1998 and March 31, 2006 were 
identified.  Among them, 130 received living donor transplant, and the remaining 227 patients 
received deceased donor transplants.  The cost included both costs for recipient and donor.  The 
direct health care cost for the recipients included the following items: outpatient care, inpatient 
care, transplant surgery, physician services, imaging and tests, and medications post-transplant 
(i.e. immunosuppressant and anti-infective medications).  On the donor side, the cost accounted 
for were surgery cost, physician fees, and inpatient and outpatient costs (only accounted for 
living donors).  As shown in Table 6, the cost for the recipient was categorized and summarized 
into five time periods based on time of occurrence: pre-transplant work up, transplantation, post-
transplant to 90 days, 91 days to 365 days and 366 days to 730 days.  In addition to direct costs, 
the living donor transplant recipients waited a shorter time to be transplanted than the deceased 
donor transplant: living donor recipient spent 1.2 years on dialysis whereas the deceased donor 
transplant recipients spent 3.2 years on dialysis prior to being transplanted.  Removing the time 
spent during transplant work up, living donor transplant recipients spent less a year on the 
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waiting list compared with 2.5 years of waiting on the waiting list for deceased donor transplant 
recipients.   
Table 2-4.  Cost for Transplants categorized by donor type and time period.  Image of table was 
taken from [34] 
 
 O'Brien et al. [17].  In 2003, using information drawn primarily from Canadian sources, 
O’Brien et al estimated the cost for managing each complication of diabetes by applying the unit 
cost to a typical patient profile of that complication.  The cost for a complication was organized 
into event cost (the cost for the episode and the subsequent care in the year following the event) 
and state cost (the yearly cost for continually managing the condition).  For kidney complications, 
the event cost and state cost for microalbuminuria were $62 and $10; for gross proteinuria, they 
were $54 and $18.  The cost for managing microalbuminuria and gross proteinuria included only 
laboratory tests and physician visits.  Drug cost was excluded from the total cost, even though 
drugs such as ACE inhibitors were considered to bring benefits to certain patients.  For ESRD, 
the state cost was $63,045, which was derived from the distributions of the patients receiving the 
different modalities of ESRD treatments (HD, PD and renal transplantation).   The related cost 
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information for all ESRD treatments were collected from literatures and updated to year 2000 
values. 
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CHAPTER 3  
MODEL POPULATION 
 This chapter describes the cohort in the model.  There are three sections in this chapter, 
and each section focuses on one sub group of the cohort.  The cohort (model population) 
includes all diabetes patients in Saskatchewan -- historic and projected -- between year 1980 and 
2025.  The whole cohort was categorized into three groups: “Saskatchewan DM prevalent 
patients in 1980”, “Saskatchewan DM-ESRD prevalent patients in 1980”, and “the DM incident 
patients between year 1980 and 2025”.   
 As model start on Jan 1st, 1980, previously diagnosed prevalent diabetes patients were 
added to the model as the starting population.  Those people received a diabetes diagnosis prior 
to Jan 1, 1980 and were alive on that date.  Among them, some had already developed ESRD and 
were receiving ESRD treatments (referred as “DM-ESRD Prevalent cases in 1980”); others had 
been living with diabetes but without ESRD (referred as “DM Prevalent Cases in 1980”).   
 In addition to the prevalent diabetes patients on Jan 1st, 1980, each year there were new 
patients in Saskatchewan who were diagnosed with diabetes and added to our model population.  
The new diabetes cases between 1980 and 2005 (inclusive) were obtained from the 
Saskatchewan Health Databases (referred to as “Diabetes Incident Patients between 1980 to 
2005”).  Yet the new diabetes cases from 2006 to 2025 (inclusive) were estimated based on 
scaled-up output from the previously constructed Saskatoon Diabetes Model (referred as 
“Diabetes Incident Patients from year 2006 to 2025”).  
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 Each of these three groups of patients will be discussed in detail in the sections below 
regarding the information sources used to create them, their life cycle in the model, and the 
assumptions we made regarding them. 
3.1 The Saskatchewan DM-ESRD Prevalent Patients in 1980 
 To start the model simulation on Jan 1st, 1980, the DM-ESRD prevalent cases at that time 
are required for initializing the model population.  The DM-ESRD prevalent cases at the model 
start time include those who had diabetes and had developed ESRD prior to Jan 1st, 1980 in 
Saskatchewan.  We gathered the DM-ESRD prevalent cases as of Jan 1st, 1980 from the 
Saskatchewan DM population between 1970 and 2005 retrieved from the Saskatchewan Ministry 
of Health databases.  Table 3-1 shows the sample data format of the DM-ESRD prevalent cases 
at Jan 1st, 1980.  
Table 3-1.  Data Format of DM-ESRD Prevalent Cases as of Jan1st, 1980 
Ethnicity 
(FN=1, 
OSK=0) 
Gender 
(Male=0, 
Female=1) 
Age of 
Receiving Diabetes 
Diagnosis 
Year of 
Receiving 
Diabetes 
Diagnosis 
Year of 
Receiving 
ESRD 
Diagnosis 
Year of 
Death 
0 0 44 1978 1978 1981 
0 0 55 1974 1979 1981 
 
 There were a total of twelve DM-ESRD prevalent cases as of Jan 1st, 1980 and the 
database provided the specified year of death, as well as characteristics like ethnicity, gender and 
age of receiving diabetes diagnosis.  Treatment information for those patients were not available 
to us, but is required for assigning each patient to an ESRD modality at model start time.  We 
decided to estimate the ESRD modality for those patients by using the treatment data from 1985 
to 1989 which was the closest empirical treatment data in time available to us.  We first 
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calculated the distribution of DM-ESRD patients on different ESRD treatments (HD, PD, and 
Transplant) for each year between 1985 and 1989 [38].  Then an average from the distributions 
in those five years was obtained.  Later, the averaged distribution was used in the model for 
assigning an ESRD treatment to each DM-ESRD prevalent patient at the model start time (as in 
model event “add1980ESRDPrevalentCase” in the Main Class).  In the Person Class, the 1980 
DM-ESRD prevalent patient entered their assigned treatment modality states immediately after 
they were created by following either transition “prevalent1980_Dialysis” or 
“prevalent1980_Tx”.  
 Also, according to death information in the historical data, most of the twelve DM-ESRD 
patients died within one or two years of 1980.  Since most of those patients only survived a short 
period of time after the model start date, their health was unlikely to be sufficiently robust to be 
considered for treatment, and we decided to simplify their activities in the model by not allowing 
those on dialysis treatments to go through the transplant assessment process or receive a 
transplant.  As shown in the statechart “assessmentStages” of Figure 3-1, the 1980 DM-ESRD 
prevalent patients were placed in a special state named “NoAssessment” that side-steps the 
assessment process.  Moreover, while the timing (including year) of death is normally 
determined dynamically within the model, the timing of deaths for 1980 DM-ESRD prevalent 
patients are determined by the death year recorded in the historical data rather than via a 
mortality risk calculated daily in the model.  This choice is partly motivated by the fact that the 
mortality risk calculated in the model for a patient normally requires as an input the duration that 
the patient has been receiving the treatment.  For those prevalent ESRD cases at the time of 
model start, we would have to derive an estimate of this quantity because of the absence of 
historical data to directly inform it.  Thus we chose to use the death year to determine when the 
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patient will die.  Since the specific date of the death is not given in the historical data, a date 
within the death year is selected by the model from a uniform distribution spanning the entire 
year.  Because it leverages more accurate information when it is available (rather than imposing 
questionable assumptions applicable only to this subset of participants), this mechanism reduces 
the risk to calibration discrepancies that could be caused by less grounded assumptions. 
 
Figure 3-1.  Statechart of the Person Object in Saskatchewan DM-ESRD Model 
 
3.2 The Saskatchewan DM Prevalent Patients in 1980 
 Along with the twelve DM-ESRD prevalent patients discussed in the above section, a 
total of 14,151 DM prevalent patients form the starting population for the model.  The 
Saskatchewan DM prevalent patients are patients who had received DM diagnosis but not ESRD 
diagnosis as of Jan 1st, 1980.  Those patients were followed until the end of 2005, and 
information from the Saskatchewan Administrative database was used for an epidemiology study 
conducted by the thesis author and other researchers.  As shown in Table 3-2, information 
available on the DM prevalent cases included year of birth, ethnicity, gender, year of receiving 
diabetes diagnosis, year of receiving ESRD diagnosis, age of receiving diabetes diagnosis, year 
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of exiting the study, reason for exiting the study (death/end of coverage/end of study) and age 
when exiting the study.  This information was used in the model for initialization of the patient’s 
characteristics, and determination of the occurrence of important events such as receiving ESRD 
diagnosis and treatment, termination of coverage and death.   
Table 3-2.  Sample Data for the 1980 Prevalent Patients 
Ethnicity  Gender  
DM 
Diagnosis 
Year 
ESRD 
Diagnosis 
Year 
Exit 
Reason 
Exit 
Year 
Age at 
Exit 
Age at DM 
Diagnosis 
0 1 1975 1986 1 1988 39 26 
0 1 1979      1 1994 93 78 
0 1 1979      0 2005 58 32 
0 1 1979      2 1980 29 28 
0 1 1971      1 1980 95 86 
 
3.2.1 The 1980 DM Prevalent Patients in the Diabetes States 
 At the model start time of Jan 1, 1980, all DM prevalent patients begin their life in the 
model in the “HavingDM_1980Prevalent” state, which is a special state designed for holding the 
DM prevalent cases of 1980 between Jan 1st, 1980 and Dec 31st, 2005.  While in the 
“HavingDM_1980Prevalent” state, the diabetes prevalent patient could either die without ESRD 
(moving to the “DeathBeforeESRD” state), receive ESRD diagnosis (moving to the “ESRD” 
state), or patients could end their health coverage in Saskatchewan (moving from 
“HavingDM_1980Prevalent” to “EndOfCoverage” state).  For this special class of population 
(those patients who were recorded as having diabetes as of the model start), these movements are 
dictated by the patient’s administrative data (See Table 3-2).  If a patient hadn’t died or 
developed ESRD by the end of year 2005, the person will still stay in the 
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“HavingDM_1980Prevalent” state.  As soon as the model clock strikes Jan 1st, 2006, the patient 
will move from “HavingDM_1980Prevalent” state to “DM25to27YBeyond” state because the 
patient will have already spent at least 25 years in the model (i.e. 1980 to 2005).  Once in the 
“DM25to27YBeyond” state, the determination of death before ESRD and development of ESRD 
are no longer based on patients’ historical records; rather those are based on risks associated with 
the number of years of having diabetes.  The “DM25to27YBeyond” is the most advanced DM 
state in the model.  There is no other state defined for diabetes patients who have had diabetes 
more than 27 years.  Even if a patient ended up having diabetes for 40 years, that patient will 
remain in the “DM25to27YBeyond” state until he either dies or develops ESRD.  This also 
means that the risk for death before ESRD and developing ESRD will remain unchanged for the 
1980 DM prevalent patients after Dec 31, 2005 up until the time they leave 
“DM25to27YBeyond”.  As was the case in the last section, the mechanisms used here are 
motivated by the desire to avoid important calibration findings (which focus on mechanisms 
applicable for patients looking forward in time) being thrown off by the vagaries of assumptions 
(far less central to model operation) concerning this initial group of patients. 
3.2.2 The Year 1980 DM Prevalent Patients in the ESRD States and Transplant Assessment 
State 
 Once patients receive ESRD diagnosis, they begin ESRD treatment right away.  In the 
model, the person will flow from “ESRD” state to “DialysisModalities” State.  Based on the year, 
the chance of starting with either PD or HD is different as found in the historical data (reference 
to data source), which is used for selecting the initial dialysis treatment for a patient.  People can 
also switch between PD and HD based on the probabilities observed in the ESRD treatment data 
in Saskatchewan from January 2006 to December 2010 (reference to the “switch modality 
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calculation”).  For example, a patient can start in “Peritonealdialysis” state, later move to the 
“Hemodialysis” state, and move back to “Peritonealdialysis” state.  
 When the patient is not yet diagnosed with ESRD, they have functioning kidneys, which 
is represented by the  “FunctionalKidney” state in the “AssessmentStages” start chart. As soon as 
patients start on dialysis, they move from “FunctionalKidney” state to the 
“AssessmentAndWaiting” state.  If patients successfully pass the transplant assessments, they 
will be put on the waiting list for a transplant. The corresponding state is the “AwaitingTx” state.  
When a patient gets transplanted, they will move to the “Transplant” state in the “diabetesESRD” 
statechart.  Simultaneously, the patient will also move to the “Functional Transplant” state in the 
“AssessmentStages” statechart.  
 The death for patients who were among the initial diabetic population receiving ESRD 
treatments was determined differently over time.  If the model time is prior to Jan 1st, 2006, the 
death of the patient occurs at a time point drawn from a uniform distribution spanning the death 
year recorded in the historical data.  If it is Jan 1st, 2006 or after, the death will depend on the 
mortality risks dependent upon a patient’s characteristics, type of treatment and duration of 
treatments.   
 In theory, those patients who developed ESRD can also leave the Saskatchewan Health 
plan, and transitions should be built for allowing patients to move from ESRD treatments states 
into the “EndofCoverage” state.  However, among the 14,000 DM prevalent patients, there are 
only three patients who have later developed ESRD and ended their coverage before the end of 
2005. This likely reflects the fact that very ill individuals are less likely to undergo the 
dislocation of a move.  Since this is a very small number of patients, we decided not to build the 
transitions from ESRD treatments to the “EndOfCoverage” state.  We instead made the 
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assumption that those three patients did not leave the plan, and that their death will be 
determined the same way as others who are also receiving ESRD treatments. 
3.3 The DM Incident Patients between Year 1980 and 2025 
 The DM incident patients enter the model upon receiving DM diagnosis.  Between year 
1980 and 2005, the DM incident patients are initialized with detailed historical records; whereas 
between year 2006 and 2025, the DM incident patients were provided by a System Dynamics 
model.  Corresponding to the different sources, DM incident patients are discussed in two sub-
sections: 3.3.1 for DM incident patients from year 1980 to 2005 and 3.3.2 for DM incident 
patients from year 2006 to 2025.  Despite the differences in sources, the state charts and 
transitions are the same for all DM incident patients as illustrated in section 3.3.3.     
3.3.1 DM Incident patients from Year 1980 to 2005 
 In addition to those who had already received diabetes diagnosis prior to Jan 1st, 1980 in 
Saskatchewan, each year there were new patients who developed diabetes (received a diabetes 
diagnosis). Those diabetes incident cases should be added to the model population.  From the 
Saskatchewan Administrative database, the DM incident case count was obtained for each 
subpopulation group (defined by ethnicity, gender, age at DM diagnosis) in Saskatchewan for 
each year between 1980 and 2005.  As shown in the first row of Table 3-3 , in 1980, there were a 
total of thirty three patients who received a diabetes diagnosis, and they were all in the 
subpopulation group characterized as “OSK,MALE, and 54 years old at year 1980”.  The model 
uses the dynamic event mechanism to select with uniform probability a specific date and time in 
year 1980 for each of the thirty three patients to receive their diabetes diagnosis.  At that point, 
the patient will enter the model.  The life cycle for the DM incident patients will be explained in 
the next section (“Life Cycle of Diabetes Incident Patients”).  
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Table 3-3.  Sample data regarding Diabetes Incident Patients from 1980 to 2005. 
Ethnicity 
(OSK=0, 
FN=1) 
Gender  
(MALE=0, 
FEMALE=1) 
Age at 
DM 
Diagnosis 
Year Receive 
DM Diagnosis 
Count of People 
0 0 54 1980 33 
0 0 55 1980 36 
0 0 56 1980 33 
0 0 57 1980 33 
0 0 58 1980 35 
 
3.3.2 DM Incident Patients from Year 2006 to 2025 
 To use the model for projecting the DM-ESRD situation in Saskatchewan for the years 
2006 to 2025, information on the diabetes incident cases for that same projection period are 
required as an input in the model. Such input data are not readily available. Neither is the 
historical data from year 2006 to 2013 (the current year) or the future diabetes incident cases 
from year 2013 and beyond.  While searching for those data, the Saskatoon Diabetes Model [36] 
was found to be a well-fit candidate to provide the input for reasons laid out as follows.  First of 
all, it is a System Dynamics model which can run forward to project the diabetes incident cases 
covering all the projection years.  Secondly, the output from the model includes details regarding 
ethnicity, gender and age (category) of receiving diabetes diagnosis, which meet our input data 
requirements.  Moreover, the design and implementation of the Saskatoon Diabetes Model was 
informed by the diabetes epidemiology in the Saskatoon Health Region, which shares significant 
similarities with the province. Thus, the result from the Saskatoon Diabetes Model can be scaled 
up to resemble diabetes epidemiology in Saskatchewan.  Most importantly, the Saskatoon 
Diabetes Model allows us to try out upstream policy (e.g. varying assumptions regarding obesity 
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incidence or diagnosis rates for pre-diabetics) to see how that will impact the ESRD incident 
rates and associated costs in our model. 
 The population of the Saskatoon Diabetes Model includes residents of the Saskatoon 
Health Region.  The diabetes incident case counts from the Saskatoon Diabetes Model need to be 
scaled up to reflect the diabetes situation for the province of Saskatchewan.  The Saskatchewan 
diabetes cases can be estimated by applying a scaling ratio to the diabetes case count for the 
Saskatoon Health Region.  The yearly case count for each sub-population group for Saskatoon is 
shown below in the last column of Table 3-4. 
Table 3-4.  Sample Output from the Saskatoon Diabetes Model. 
Year Age Group Ethnicity(OSK=0, 
FN=1) 
Gender 
(MALE=0, 
FEMALE=1) 
Case 
Count 
2024 65to69 1 0 2 
2024 65to69 1 1 3 
2024 65to69 0 0 50 
2024 65to69 0 1 52 
2024 70to74 1 0 2 
2024 70to74 1 1 2 
2024 70to74 0 0 39 
2024 70to74 0 1 43 
2024 75to79 1 0 1 
2024 75to79 1 1 1 
2024 75to79 0 0 28 
2024 75to79 0 1 33 
2024 80plus 1 0 1 
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2024 80plus 1 1 1 
2024 80plus 0 0 34 
2024 80plus 0 1 55 
 
 The scaling ratio is obtained by comparing the diabetes incident case counts from the 
Saskatoon Diabetes Model with the historical data on diabetic incident cases in Saskatchewan 
from year 2001 to 2005.  To be more specific, for each year between 2001 and 2005, the case 
count for every sub population group (stratified by gender and ethnicity) were compared, and a 
scaling ratio was calculated.  For instance, for year 2001, the diabetes incident case count for 
Aboriginal females from the Saskatoon Diabetes Model is 50, and the count from the historical 
data for Saskatchewan is 298.  Thus the scaling ratio for aboriginal female in year 2001 is 5.96 
(298 divided by 50).  The scaling ratios for each subpopulation group from different years are 
listed in the  below.  To consolidate the ratios for those 5 years (2001 to 2005) into one ratio for 
each sub population group, we used the average of the scaling ratio from year 2001 to 2005.  For 
instance, the scaling ratio for aboriginal female is 6.008 (which is the average of 5.96, 6.22, 6.24, 
5.93 and 5.96).  The ratio for every sub population group is listed in , in which the ratios are 
assumed to stay the same for the entire projection period (i.e. 2006 to 2025).  
Table 3-5.  The Scaling Ratio Calculated by Comparing the Historical Saskatchewan Data with 
the Output from the Saskatoon Diabetes Model (data were from year 2001 to 2005). 
Ethnicity [0=OSK, 1= 
FN] 
Sex [0=Male,1=Female] Year SK Vs 
STooRatio 
0 0 2001 5.343529 
0 1 2001 5.122857 
1 0 2001 5.219512 
1 1 2001 5.96 
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0 0 2002 5.656109 
0 1 2002 5.242667 
1 0 2002 6.421053 
1 1 2002 6.222222 
0 0 2003 5.079295 
0 1 2003 4.751899 
1 0 2003 6.888889 
1 1 2003 6.238095 
0 0 2004 4.927195 
0 1 2004 4.683453 
1 0 2004 6.914286 
1 1 2004 5.928571 
0 0 2005 3.900415 
0 1 2005 3.622426 
1 0 2005 6.121212 
1 1 2005 5.692308 
Table 3-6.  The Average Scaling Ratio Used in the model for converting Diabetes Incident Case 
Count for Saskatoon to Saskatchewan. 
Sub Population Group Scaling Ratio 
OSK MALE 4.981 
OSK FEMALE 4.685 
FN MALE 6.313 
FN FEMALE 6.008 
 
 In addition to scaling up the diabetes case counts for Saskatchewan, the age of receiving a 
diabetes diagnosis obtained from the Saskatoon Diabetes Model needs further refinement as well.  
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The Saskatchewan DM-ESRD model requires the case count for a specific age rather than for an 
age group such as provided by the Saskatoon Diabetes model.  Using the total case count for an 
age group, we can estimate the diabetes case count for a specific age within the group.  In order 
to this, we have made assumptions on how cases would be distributed within its group.  For ages 
younger than 70, we assume the cases are uniformly distributed among the ages within its five 
year group.  For instance, at year 2024, for OSK women whose ages are between 65 and 69, the 
total number of diabetic incident case count is 52 in Saskatoon.  After applying the 
corresponding scaling ratio 4.685, the count for this sub-population group in Saskatchewan is 
244.  In the Saskatchewan DM-ESRD model, the total count of 244 diabetes incident cases were 
uniformly distributed within the age group (i.e. 65, 66, 67, 68 and 69).  Each model simulation 
might have generated different counts for those ages because the model is stochastic.  However, 
over many simulations, the case count for the ages should follow the uniform distribution we 
have assumed.  For the ages older than 70, we also made assumption about how the cases would 
be distributed among the ages within their age group.   Rather than assuming a uniform 
distribution as with the younger age groups, we assumed that they would follow the distribution 
existing in the historical data for the projection years.  To obtain the distribution from the 
historical data, we studied the historical diabetes incident cases from 2001 to 2005 for older than 
70 years in Saskatchewan.   The distribution for those aged 70 and older was then applied to the 
Saskatchewan DM-ESRD model to generate the case count for each specific age for the four 
sub-population groups defined by ethnicity and gender.  Finally, we obtained the yearly diabetes 
incident case counts for all subpopulation groups (stratified by diabetes diagnosis age, ethnicity 
and gender) in Saskatchewan over the projection years.  The DM incident patients from 2006 to 
2025 would have the same information available to the model as the DM incident patients from 
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1980 to 2005.  Moreover, the life cycle for the DM incident patients are the same in the model 
regardless which time period and data source they were from.  The details about the life cycle of 
DM incident patients can be found in the earlier section “Life Cycle of Diabetes Patients”.  
3.3.3 Life Cycle of Diabetes Incident Patients 
 Patients will go through both the “DiabetesESRD” statechart (Figure 3-2) and the 
“AssessmentStages” statechart (Figure 3-3) for their time in the model.  Upon entering the model, 
patients will start their journey in the “DM1to3Y” state of the “DiabetesESRD” statechart, and in 
the “FunctionalKidney” state of the “AssessmentStages” statechart.  In a diabetes state, a patient 
can either die, receive ESRD diagnosis or live with diabetes beyond three years.  If a death 
occurred before developing ESRD, patients will move from the diabetes state to the 
“DeathBeforeESRD” state in the “DiabetesESRD” statechart; also, at the same time, they will 
move from the “FunctionalKidney” state to the “DeathState” in the “AssessmentStages” 
statechart.   If the patient hasn’t died or developed ESRD, they will move to the next Diabetes 
state after exactly three years of time (e.g. moving from the “DM1to3Y” state to “DM4to6Y” 
state).   
 If patients develop ESRD, they will start receiving ESRD treatments.  Occasionally, 
patients can receive a preemptive transplant (transitioning from the “ESRD” state to “Transplant” 
state).  More likely, people will start with either PD (moving from the “ESRD” state to the 
“Peritonealdialysis” state) or HD (moving from the “ESRD” state to the “Hemodialysis” state).  
As soon as they start on dialysis, patients will undergo a transplant assessment process, as 
illustrated in the “AssessmentAndWaiting” state of the “AssessmentStages” statechart.  Once 
approved by assessments, patients will be put on a waiting list for transplant (move from 
“WorkUpStage” to “AwaitingTx” state of the “AssessmentStages” statechart). When a transplant 
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has taken place, patient will move from the “DialysisModalities” State (either “Hemodialysis” 
state or “Peritonealdialysis” state) into the “Transplant” state.  Patients will move to the 
“DeathAfterESRD” state and the “Death” state of the “AssessmentStages” statechart if they die 
while getting dialysis or after receiving transplant.  Upon death, patients complete the last step of 
their cycle in the model.  The life cycle for diabetes incident patients is the same regardless of  
the time period when they enter the model.           
 
Figure 3-2.  The “DiabetesESRD” Statechart of A Person Object 
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Figure 3-3.  The “AssessmentStages” Statechart of A Person Object 
 
 DM incident patients from year 2006 to 2025 were projected from the Saskatoon diabetes 
model [36] and scaled up to reflect the total Saskatchewan population.  The life cycle of such 
patients in the model is the same as for the DM incident patients obtained from the Saskatchewan 
Administrative database for year 1980 to 2005.  The next section will focus on how we estimated 
the diabetes incident case counts from the Saskatoon Diabetes Model.  
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CHAPTER 4  
MODEL STRUCTURE 
 This chapter presents the model structures for simulating the important processes in a 
diabetic patient's life.  There are four processes which are of interest in this thesis and are 
represented in the model: progression of diabetes to develop ESRD, receiving ESRD treatments, 
assessment for a kidney transplant, and waiting for a transplant on a waiting list after an 
approved assessment.   Figure 4-1 presents the overview of a person statechart in the model, 
which illustrates the life cycle of a patient in the model.   The three blue boxes enclose the state 
charts and transitions for the four critical processes in a patient’s life.  The left one corresponds 
to “DM to ESRD progression”.  The middle one represents to “ESRD treatment options”.  The 
right one is for both “transplant assessment” and “waiting list” process. 
 
Figure 4-1.  Overview of Model Structure 
 
4.1 DM to ESRD progression  
 The statecharts and transitions used to simulate patient’s DM to ESRD progression is 
discussed in this section.  Since the DM incident patients and the DM prevalent patients at 1980 
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require different model structures, so each group of patients are discussed in a distinct sub-
section.   
4.1.1 DM Incident patients 
 Diabetes patients start their journey in the model at the time they receive the DM 
diagnosis.   As diabetes progresses, patients either die or develop ESRD as a complication.  Only 
a small portion of DM patients will develop ESRD.   The majority will continue living without 
ESRD or die from causes other than ESRD.  In reality, there are DM patients who end their 
Saskatchewan health coverage because they move out of the province.  Correspondingly, at the 
time of ending their coverage, they have neither died without ESRD nor developed ESRD.  
There should have been a transition from the DM states to the “End of Coverage” state.  
However, such transitions are not currently built for DM incident patients, which is one of the 
limitations of the model.  The “End of Coverage” state is only for “the DM prevalent patients at 
year 1980” as marked in the red box in Figure 4-3.  More details regarding the DM prevalent 
patients at year 1980’s move to the end of coverage state will be discussed in section 4.1.2. 
 This thesis focused on that subset of DM patients who eventually developed ESRD, and 
the treatments and services provided to them.  Yet the diabetes progression process cannot be left 
out of this model because it determines a person’s chance of developing ESRD, and represents a 
key area on which to focus prevention efforts.  We adopted the representation of progression of 
diabetes from another – much smaller – agent based model created as part of student Ying 
Jiang’s M.Sc. thesis work (conducted under the supervision of Dr. Osgood and Dr. Hyun Lim of 
the Department of Community Health & Epidemiology).  In Ying’s Master’s thesis [37], a 
competing risks analysis was conducted to quantify the risk of dying (prior to having ESRD) and 
the risk of developing ESRD at various DM stages.  Using the results of the analysis, an agent 
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based model was built by Ying to simulate the process for diabetics progressing to either ESRD 
or Death.  Figure 4-2 shows the original statechart from Ying’s model.  Figure 4-3 shows the 
adopted form of the statechart in our model.  
Figure 4-2.  Original Statechart in Ying’s Model on Diabetes Progression to ESRD and Death 
 
 
Figure 4-3.  Adopted Statechart in Saskatchewan DM-ESRD Model Regarding Progression of 
Diabetes to ESRD or Death  
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 As marked in the green box in Figure 4-3, there are a total of nine diabetes stages (i.e. 
“DM1to3Y” state, “DM4to6Y” state, etc.), which were defined based on the duration with which 
a patient has experienced diabetes.  The first eight stages are each associated with a three year 
interval, whereas the last stage is for patients who have had diabetes for 25 years and beyond.  
The diabetes stages were divided in this manner due to the way the competing risks analysis was 
conducted on the Saskatchewan diabetes population between 1980 and 2005.  That research 
determined a patient’s hazard (chance per unit time) of dying prior to getting ESRD and hazard 
of developing ESRD at each diabetes state.  These hazards were then used for triggering a 
patient’s transition from the diabetes states to either the “DeathBeforeESRD” state or the “ESRD” 
state.  If a patient remained in a 3-year diabetes state for three years without having died or 
developed ESRD, they would move to the next more advanced diabetes state that is next to it.  
For patients who were already in the last DM state (“DM25to27Beyond” state), there is no more 
advanced DM state.  Thus patients remain in the last DM state until either death or developing 
ESRD.  As patients move through diabetes states, both mortality and ESRD hazard are increased, 
and are recalculated every time patients move to the next DM state.  The hazards depend on a 
number of factors: the DM stage, and patient’s age, gender and ethnicity. 
 The diabetes states and the related transitions were only used for modeling diabetic 
progression for patients who developed ESRD within the model.  As discussed in the next 
section, for the year 1980 DM prevalent patients, the diabetes progression was handled 
differently in the model than for subsequent incident patients. 
4.1.2 Special Handling for the 1980 DM Prevalent Cases  
 In contrast to the DM incident patients progressing through the Nine DM States, the year 
1980 DM prevalent patients start their lives in the model in a special state named 
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“HavingDM_1980Prevalent”, as marked in a blue box in Figure 4-3.  Upon entering the model, 
the year 1980 DM prevalent patients branch into the “HavingDM_1980Prevalent” state while the 
DM incident patients go to the “DM1to3Y” state.  The reason for using a designated state for the 
year 1980 DM patients was due to the concerns regarding the reliability of the inferences instead 
of “DM diagnosis time” for those patients.  We now provide additional details on the associated 
design considerations. .   
 In theory, the 1980 diabetes patients can start their life in the standard sequence of 
diabetes states (e.g. “DM1to3Y”) at model start time.  By using patient’s DM diagnosis time, the 
duration of having diabetes could be calculated and used for assigning patients to DM states.   
For instance, a patient who received DM diagnosis at year 1972 would have had diabetes for 8 
years by Jan 1st 1980, and the patient could start in the “DM7to9Y” state.  However, while 
examining the historical data for the DM prevalent patients, we found that the reported years of 
receiving DM diagnosis only ranged from 1970 to 1979 among the 14,000 DM prevalent patients 
at 1980.  The fact that not even one DM patient was reported as receiving a DM diagnosis prior 
to 1970 is highly suspect.  After consulting with the experts, we learned that the DM diagnosis 
prior to 1970 were not properly recorded, and were instead assumed to fall into years following 
1970.  Because the reported DM diagnosis time for those who began the study period with 
diabetes are inaccurate, reliance on this data would mean that many of the year 1980 DM 
prevalent patients would not start in the correct DM states.   As discussed in the earlier section, 
the risk for death prior to ESRD and risk for developing ESRD both depend on the DM state a 
patient is in.  Consequently, the chance of death and receiving ESRD diagnosis wouldn’t be 
correct for those patients with an inaccurate DM diagnosis time.  Incorrect mortality and ESRD 
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hazards could, in turn, cause problems for the calibration of other model processes.  We therefore 
sought an alternative way for determining those risks. 
 Rather than relying on risk calculations based on inaccurate DM diagnosis times,  we 
sought to take advantage of the fact that for virtually all 1980 prevalent diabetics, we have highly 
accurate individual-level information available on recorded year of death, end of coverage and 
development of ESRD from the individual-level historical data. Between Jan 1st, 1980 and Dec 
31, 2005, the year of death, end of coverage and ESRD diagnosis were recorded for the 1980 
prevalent cohort.  Although the specific dates within a year for a given event were not available 
in the historical data, the inaccuracies associated with those uncertainties were expected to be 
comparatively minor compared to what would result from uncertainties concerning the year of 
diabetes incidence. Operationally, such dates can be randomly generated in the model and used 
together with the given year for scheduling events in the model.  When the prescheduled “Death”, 
“ESRD” and “End of Coverage” events take place, patients will move to the corresponding states.   
For example, suppose one patient has a prescheduled “ESRD” event on Feb 3, 1982, and another 
pre-scheduled “End of Coverage” event on May 15, 1986.  The corresponding scenario in the 
model will be as follows: When the model begins on Jan 1st, 1980, the patient starts in the 
“HavingDM_1980Prevalent” state.  When the model clock reaches Feb 3, 1982, the patient 
moves from the “HavingDM_1980Prevalent” state to the “ESRD” state; no transition to ESRD is 
possible for the patient prior to that point.  The patient then moves from the “ESRD” state to 
some treatment states or might proceed through some transplant assessment states.  However, 
when being treated with the RRT, the patient would not be subject to risk of death which is only 
applicable to DM-ESRD patients receiving ESRD diagnosis after Jan 1st, 1980 (the DM-ESRD 
incident patients in the model).  And no matter which state the patient was in, on May 15, 1986, 
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the patient would move from his/her state at the moment (e.g. HD) to the “End of Coverage” 
state.  Similarly, when a patient has a death event scheduled, if the historical data reveals that the 
death occurred before the patient developed ESRD, the patient would move from the 
“HavingDM_1980Prevalent” to the “DeathBeforeESRD” state. Or if the death event took place 
after patient’s ESRD diagnosis, the patient would move from one of the ESRD treatment states 
(e.g. “FunctionalTx”) to the “DeathAfterESRD” state. Prior to Dec 31, 2005, those patients’ 
chances of receiving certain ESRD treatments and getting through the transplant assessment 
process were determined by the logic built within the model transitions.  However, their death, 
ending health coverage and developing ESRD were all prescheduled according to historical data. 
 After Dec 31, 2005, there are no more pre-scheduled events for the year 1980 prevalent 
patients, because there is no historical data available.  As a result and following that point, those 
patients’ mortality and  ESRD hazards are  handled in the same way as the incident patients as 
discussed above in the section “Diabetes to ESRD progression - DM Incident patients”.  To be 
more specific, as soon as the model time strikes Jan 1st, 2006, patients who are still in the 
“HavingDM_1980Prevalent” state move to the “DM25to27YBeyond” state; this movement 
reflects the fact that they had already been having diabetes for at least 26 years (from 1980 to 
2005).  Once patients are in the “DM25to27YBeyond” state, their risks of death or developing 
ESRD are based on the formula from Ying’s competing risk analysis. 
 For patients who have received ESRD diagnosis, they move from a DM state into the 
“ESRD” state.  Such patients then initiate Renal Replacement Therapy (RRT), the details of 
which will be discussed in the following section.
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4.2 ESRD treatment Options and Death   
 Depending on an ESRD patient’s medical condition and treatment availability, renal 
replacement therapy options include HD, PD, or kidney transplantation.  Very few ESRD 
patients receive a pre-emptive transplant – a kidney transplant before being dialysed.  Most 
patients begin with either PD or HD as their initial treatment, followed by kidney transplantation.  
4.2.1 Selection between PD and HD 
 For most patients with ESRD, a dialysis type must be selected.  In reality, the choice 
between PD and HD is made based on several factors including patient attributes and availability 
of treatment. However, in the model, the selection of treatments was simplified as a draw from a 
Bernoulli distribution.  The probability of receiving PD (as an initial treatment in Saskatchewan) 
used for that Bernoulli draw was obtained from CIHI through a special data request.  The details 
about probability distribution and data source can be found in the section “Model Data Source”. 
 As shown in Figure 4-4, if PD is selected as the initial treatment, the patient will move 
out of the “ESRD” state and branch into the “Peritonealdialysis” state inside of the 
“DialysisModalities” composite state.  By contrast, if PD is not selected, then the patient will 
move to the “Hemodialysis” state.  
4.2.2 Switching between PD and HD 
 Patients will sometimes switch between PD and HD for medical and personal reasons.  
As shown in the Figure 4-4, transitions were set up between “Peritonealdialysis” state and 
“Hemodialysis” state, allowing patients to change from one type of dialysis to another.  Rates 
(hazards) used in those transitions were calculated based on the dialysis treatments received 
between Jan 1st, 2006 and Dec 31, 2010 by the Saskatchewan DM-ESRD patients.  The details 
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on the rates and the data source used here can be found in the section “Model Data Source” of 
this thesis. 
4.2.3 Pre-emptive Kidney Transplantation   
 In Saskatchewan, very few ESRD patients receive pre-emptive kidney transplantation.  
Most of the patients receive dialysis first and then some are transplanted.  Occasionally, a patient 
may receive a pre-emptive transplant, and it is most likely to be a living donor kidney transplant.  
A kidney from a deceased donor would virtually always be given to a dialysis patient on the 
waiting list, unless a match cannot be found among patients on the waiting list.  Despite being 
uncommon, the pre-emptive transplant process was included in the model for the purpose of 
facilitating policy experiments.  The transitions marked in blue in Figure 4-4 showed the choices 
between pre-emptive transplantation and dialysis treatments for patients who just received ESRD 
diagnosis.  The probability of receiving a pre-emptive transplant over dialysis as initial treatment 
is used to control which treatment the patient would receive.  The type of the kidney transplant 
will be based on the supplied probability distribution of living donor and deceased donor pre-
emptive transplantations.  Once a pre-emptive transplant operation takes place, the patient will 
move to the “Transplant” composite state, which is the same designated state as for those 
transplant recipients who went through dialysis prior to transplant.  The “Transplant” composite 
state will be discussed in the next section. 
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Figure 4-4.  Statechart Regarding ESRD Treatments and Death 
 
4.2.4 Post Kidney Transplantation 
 While patients are receiving dialysis, they might go through the transplant assessment 
process and wait for a transplant on the waiting list.  The transplant assessment and waiting list 
process was represented in a separate statechart, the details of which are discussed in the sections 
“Transplant Assessment” and ”Waiting list and Transplant”.  The inclusion of those processes in 
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a separate statechart reflects the fact that when patients are waiting for kidney transplantation, 
they remain on dialysis.   In the model, when it is a patient’s turn to be transplanted, a message is 
sent to the patient (agent) to notify them.  Upon receiving the “getting transplant” message, the 
patient will move from the dialysis state to the transplant state via the “receiveTransplant” 
transition.   As shown in Figure 5, the time following kidney transplantation was divided into 
three states: “TxFirst90days”, “Tx91daysToYearEnd”, and “FunctionalTx”.  The reason for 
breaking the time into those states is due to the cost difference associated with the three periods 
following the transplant operation [34].  After kidney transplantation, a patient would first start 
in the “TxFirst90days” state.  After 90 days post transplantation, the patient would move from 
the “TxFirst90days” state to the “Tx91daysToYearEnd” state, and remain in that state for the 
balance of the year following transplant.  Finally, one year after having received the kidney 
transplant, the patient would move to the “FunctionalTx” state. 
4.2.5 Return to Dialysis after Graft failure 
 When a transplanted kidney fails, the patient needs to restart dialysis treatment.  In the 
“DiabetesESRD” statechart, the patient will move from the transplant state back to the dialysis 
state via the transition “reEnterDialysis”.  The hazard of returning from transplant to dialysis was 
based on graft failure rates, which were calculated from the graft survival rates for ESRD 
patients (not specific to DM-ESRD patients) given in the 2011 CORR Annual Reports [38].  The 
graft failure rates were computed for eight sub-population groups stratified by transplant donor 
type (living and deceased) and four age groups (age 18 to 44, age 45 to 54, age 55- 64 and age 
65+).   The details about the rate calculation and data sources can be found in section “Model 
Data Source”.  For patients whose transplanted kidney fails, upon re-entering the dialysis state, 
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the type of dialysis would be drawn from the same probability distribution used by patients who 
undergo dialysis for the first time. 
4.2.6 Mortality Risks on ESRD Treatments 
 Patients are at risk of dying while they receive ESRD treatments.  A patient’s daily 
mortality risk on an ESRD treatment was calculated by a hazard function, which required input 
such as gender, ethnicity, age when initializing the treatment, type of treatment, and the length of 
time on the treatment.  The hazard function in the model was derived from a risk adjusted 
survival analysis conducted by CIHI upon our request.  Because the mortality hazard changes 
significantly over time since transplant, mortality hazard varying on a day-by-day basis was used 
in the model.  When the patient died while receiving ESRD treatment, he or she will move to the 
“DeathAfterESRD” state in the “DiabetesESRD” statechart.  Correspondingly, the same patient 
will also move into the “Death” state in the “AssessmentStages” statechart, as marked in the blue 
box in Figure 4-5. 
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Figure 4-5.  Transplant Assessment and Waiting List 
 
4.3 Transplant Assessment  
 The transplant assessment process evaluates a dialysis patient’s eligibility for kidney 
transplantation.  This process is used for patients who first receive dialysis treatments and then 
receive a transplant, but not for patients who receive pre-emptive transplantation (although the 
latter patients also require pre-transplant assessment).  The assessment for a dialysis patient 
consists of three important processes: evaluation of the patient’s suitability for transplant 
assessment, determination of the type of kidney transplant, and assessment of the patient’s 
eligibility for transplant.  
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4.3.1 Evaluation of Patient’s Suitability for Transplant Assessment 
 While receiving dialysis, most patients are sent for a transplant assessment, except those 
who are very old.  After consulting a specialist, we have implemented the following selection 
criteria for sending patients for transplant assessment in the model.  First, since most patients 
over 75 years old are deemed not suitable for transplant, they won’t be assessed in the model.  
Second, patients between age 66 and age 75 have a 25% chance of receiving transplant 
assessment.  Finally, patients who are 65 years old or younger will always be assessed. 
4.3.2 Determination of the Type of Kidney Transplantation 
 The type of the transplant is important to our study because candidates for living donor 
transplantation and deceased donor transplantation may be on separate waiting lists.  Moreover, 
in addition to the examinations required for the recipient, donors for living donor transplantation 
need to be evaluated as well, which means the cost for assessment would be not be the same for 
living and deceased donor transplants.  Reflecting these factors, the selection of transplant type is 
made at an early stage of the assessment in the model.  The choice between living and deceased 
donor transplants are made based on the proportion of living and deceased donor transplants 
among all kidney transplants that took place in Saskatchewan from year 1981 to 1999.  This data 
was located in the CORR annual reports [38], and the rates were for all ESRD patients who 
received transplants rather than being specific to DM-ESRD patients (more information about 
the data is in the “Model Data Source” section).  Once the type of the transplant is chosen, the 
patient will begin the assessment for that type of transplant.  As shown in Figure 4-5, living 
donor transplant candidates will start their assessment in the “LDKTWorkup” state, whereas the 
deceased donor transplant candidate will stay in the “DDKTWorkup” state during the transplant 
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assessment process.  Further details on the transplant assessment process are discussed in the 
next section.  
4.3.3 Assessing Patient’s Eligibility for Kidney Transplantation 
 The assessment process evaluates a patient’s health by conducting a number of 
examinations, which seek to determine if that patient is a suitable candidate for a kidney 
transplant.  In the model, two considerations come out of the assessment process: the length of 
time the assessment takes, and whether the patient is deemed eligible for a transplant.  The 
duration of the assessment is used to control how long the patient remains in the “Workup Stage” 
state in the “AssessmentStages” statechart.  In the real world, appointments and examinations 
with different specialists during assessment might vary in number and length of time.  Thus, the 
total time for completing the assessment can be different for different individuals.  In the model, 
an Erlang distribution function was used to estimate the duration of the assessment for patients 
who never received transplant before, or their last but failed transplant was more than a year ago.  
The Erlang distribution considered two input parameters: the total number of appointments and 
examinations required for the individual to complete the assessment, and the average time to 
complete a test.  For patients who had a kidney transplant within a year, we assume it would take 
them the minimum time to go through the assessment process again.  Since we have limited data 
on the assessment process, we made our guesses on the number of examinations required, and 
the minimum time required for those patients who were transplanted within a year.  We 
calibrated those values so that patient’s time spent on assessment together with the time that 
approved patients spent on the waiting list would match with the historical data (see the 
“Calibration Section”).  
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 By the time patients complete their assessment, their eligibility for transplant should be 
determined.  In the model, we didn’t implement the methodology used in the real world situation 
for evaluating patient’s suitability for kidney transplantation, due to the scope of this thesis.  
Rather we simply used an abstract “health coefficient” to represent patient’s overall health level, 
and used a calibrated cut off value of the health coefficient to determine a patient’s eligibility for 
a kidney transplant.  Those who are deemed suitable for kidney transplant are then put on the 
waiting list for the appropriate type of transplant.  Correspondingly, in the model, patients would 
move into the “AwaitingTx” state.  Those who are not eligible to have a transplant would be 
moved to the “NotSuitableForTx” state.  
4.4 Transplant Waiting List and Kidney Transplant  
 When patients complete the transplant assessment and meet the eligibility requirements 
for a transplant, they will be placed onto a waiting list.  While awaiting a transplant, patients may 
leave the waiting list either by receiving a transplant, withdrawal from the waiting list, or due to 
death prior to receiving a transplant.  A number of factors work together to decide when a 
transplant will take place and who will get a transplant.  The following sections discuss each of 
those determinants.  
4.4.1 Priority on Transplant Waiting List 
 Based on the donor type, there are effectively two waiting lists for kidney transplant: one 
for living donor transplant candidates and one for deceased donor transplant candidates (although 
the same person could potentially be on both lists).  Living donor transplants typically involve a 
much shorter wait, because the wait is primarily for surgical resources (e.g. surgeon availability 
and operation room). On the other hand, for a deceased donor transplant, patients mainly wait for 
availability of an organ. For both deceased donor and living donor transplant candidates, the 
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length of wait for a transplant operation is also determined by their priorities on the waiting list.   
In reality, the priority on the waiting list is calculated based on a number of health related factors 
for a patient.  In Canada, provinces have their own methods for determining the priorities, and 
maintain their own waiting lists for kidney transplantation.  Currently in the model, the priority is 
randomly generated and is assigned to patients when they are added to the waiting list.  An 
algorithm for determining the priority based on patient’s health state is beyond the scope of this 
thesis; we anticipate the implementation of such an algorithm as future work.  The priority sets 
the order in which patients receive transplants. Moreover, a patient's status on the waiting list has 
to be “active” in order to receive kidney transplantation; this notion is described further below.  
The patients selected for kidney transplant must have the highest priority on the waiting list to 
which they belong and an active status; ties are handled according to the timing with which they 
were added to the queue.   
4.4.2 On hold and Active Status on Waiting List 
 The “On hold” and “Active” status of the waiting list mark a patient’s short-term 
suitability for transplant.  Some patients, who have passed the transplant assessment phase and 
are deemed suitable for kidney transplant, might be temporarily prevented from receiving a 
kidney transplant operation due to a new but transient medical condition (e.g. an infection). 
Under such conditions, their status on the waiting list will be put “on hold”.  In the model, the 
patient will move to the “OnHold” state. As soon as the patient recovers from the condition, their 
status on the waiting list will be restored to “Active”.  Correspondingly, in the model, the agent 
representing the patient will move back to the “Active” state in the model.  The historical data on 
waiting list status was studied.  Patients on the waiting list were randomly marked as “On Hold” 
according to the probabilities of being on hold based on the historical data.  The priority of the 
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patients and their status on the waiting list were used for selecting candidate for the next 
transplant when the resource (e.g. a donor kidney) is ready.  The numbers of kidneys available 
determine how frequently kidney transplants can take place. 
4.4.3 Kidney Transplantation 
 The frequency of kidney transplants is restricted by the availability of resources required 
for performing the transplant; these resource constraints are different for living donor and 
deceased donor transplant.  The frequency of deceased donor transplantation depends on when a 
kidney is available.  The frequency of performing living donor transplant also depends on the 
surgical resources (surgeon and operation room).  In the model, two rates representing the 
frequency of living donor and deceased donor transplants were used to schedule the occurrences 
of the two types of kidney transplants.  Patients with the highest priority and an active status on 
the waiting list will be called to receive a transplant..  In the model, when a transplant operation 
takes place, the patient would move out of the “AssessmentAndWaiting” state and go to the 
“FunctioningKidney” state in the “AssessmentStages” statechart, as shown in Figure 4-5.  
Simultaneously, in the “DiabetesESRD” statechart as shown in Figure 4-4, a patient will move 
from the dialysis states to the “Transplant” state.   
 
 
61 
CHAPTER 5  
MODEL PARAMETERS 
 As described in the previous chapter, model transitions move patients from one state to 
another.  The driving forces behind them are the various formulae and parameters.  This chapter 
is devoted to describing those model transitions where the data and formulae came from sound 
historical sources such as CORR annual reports, CIHI data requests, the Saskatchewan health 
administrative database, and Saskatchewan renal program reports.  
5.1 Mortality Risks for Dialysis and Transplant Patients. 
 The mortality risk at a given time for individuals receiving dialysis treatment or post 
kidney transplantation is calculated by using a Cox Proportional Hazards model whose parameter 
values were provided by CORR.  Upon our request, CORR conducted survival analysis on the 
ESRD patients on dialysis or after kidney transplantation in Canada between 1999 and 2008.  For 
dialysis patients, the hazard ratios were estimated for covariates such as treatment modalities 
(HD or PD), diabetes status, ethnicities (FN, OSK, and other), gender and age groups (every 5 
years are grouped together for the age 20 to 75, and one group for age over 75).   The covariates 
and coefficient estimates are listed in Table 5-1 below.   Moreover, the baseline survival and the 
cumulative hazard for day 0 to day 3581 were provided. 
Table 5-1.  Regression Coefficients used in Cox Proportional Hazard Model for Mortality Risks, 
Dialysis Patients, Canada, 1999- 2008. Provided by CORR based through A Data Request 
Parameter Estimate 
Standard 
Error Coding 
PD -0.2135 0.0188 HD:0, PD: 1 
Diabetes 0.2168 0.0138 
Non-diabetes:0, 
diabetes:1 
Male 0.0755 0.0137 Female:0, Male:1 
Aboriginal 0.1653 0.0327 
Caucasian:0, 
Aboriginal:1, other:2 
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Other race -0.2296 0.0170   
25 - 29 years 0.1266 0.2200 20 - 24 years:0 
30 - 34 years 0.6794 0.1944   
35 - 39 years 0.8886 0.1856   
40 - 44 years 1.0855 0.1809   
45 - 49 years 1.2224 0.1782   
50 - 54 years 1.3968 0.1769   
55 - 59 years 1.6663 0.1758   
60 - 64 years 1.8005 0.1754   
65 - 69 years 1.9834 0.1751   
70 - 75 years 2.2071 0.1748   
>75 years 2.5042 0.1744   
 
 For each individual, mortality risk on a given day can be calculated using the hazard 
model (5.1). !! ! = ℎ! !   ×  !(!!×!!!⋯!!!×!!) 
• !!…!! is the log of the hazard ratio (coefficient estimates) 
• !!…!!are the covariates. 
 (5.1) 
 Since the baseline hazard rate h0(t) generally varies over time, the estimated mortality 
risk for a person H! t  gets updated at every model time unit (day) by a function named 
“setDialysisDeathHazard” in the Person object.  The updated mortality risk is then used in the 
rate based event “dialysisPatientDie” to determine person’s hazard (probability density of death) 
at the moment while the patients is getting dialysed. 
 For estimating the mortality risks for transplant patients, a Cox Proportional Hazards 
model was provided by CORR as well.  The survival study was conducted on ESRD patients 
living with a functioning kidney between year 1999 and 2008.  The hazard ratio was provided for 
covariates including diabetes status, ethnicities, gender and age groups as shown in Table 5-2.  
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The hazard rates for transplant patients were calculated in similar fashion as for the dialysis 
patients.  The base line hazard rate is updated every day in a function called 
“setTransplantDeathHazard” based on the number of days which transplant patients have 
survived following their transplant, and the resultant hazard rate is used in event 
“transplantPatientDie” for determining the mortality hazard for patients living with functioning 
transplants.  
Table 5-2.  Regression Coefficients used in Cox Proportional Hazard Model for Mortality Risks, 
Transplant Patients, Canada, 1999- 2008. Provided by CORR through A Data Request. 
Parameter Estimate 
Standard 
Error Code 
Diabetes 0.6809 0.0762 
Non-diabetes:0, 
diabetes:1 
Male 0.1883 0.0791 Female:0, Male:1 
Aboriginal 0.2567 0.1914 
Caucasian:0, 
Aboriginal:1, other:2 
Other race -0.3187 0.0949   
25 - 29 years -0.4852 0.4005 20 - 24 years:0 
30 - 34 years -0.2992 0.3690   
35 - 39 years 0.0040 0.3353   
40 - 44 years 0.2937 0.3186   
45 - 49 years 0.3453 0.3120   
50 - 54 years 0.6417 0.3080   
55 - 59 years 0.9368 0.3030   
60 - 64 years 1.3649 0.3022   
65 - 69 years 1.5031 0.3057   
70 - 75 years 1.9382 0.3143   
>75 years 2.5485 0.3844   
 
 Based on the calculated hazard rates, the function “transplantPatientDie” and 
“dialysisPatientDie” will send a message to trigger the movement from either the 
“Peritonealdialysis” state, “Hemodialysis” state or “Transplant” state to the “DeathAfterESRD” 
state in the “DiabeticESRD” statechart.  Simultaneously, in the “AssessmentStages” statechart, 
patients will move to the “Death” state. 
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5.2 Selection between PD and HD  
 In the model, the selection between PD and HD for DM-ESRD incident patients depends 
on the empirical probability of receiving one type of treatment modality over another found in 
the historical data on treatment modalities.  Through a special data request, CIHI provided the 
count of DM-ESRD patients who received HD or PD as their initial treatments in Saskatchewan 
from year 1981 to 2011.  The historical counts were used for calculating the probabilities of 
receiving PD vs. HD treatment as an initial dialysis treatment for DM-ESRD patients.  The year 
and probability rate pairs for year 1981 to 2011 were saved in the table function1 named 
“PDInitialProb”.  For years between 1981 and 2011, the probability of having PD as initial 
treatment can be directly retrieved from the table function “PDInitialProb”.  For the years outside 
that range (i.e. 1980 and years after 2011), we made the assumption that the probability of 
having PD is the same as the values in the nearest year for which data is available.  For instance, 
the probability of having PD for year 2012 or 2013 will be the same as in year 2011.  We could 
also change the assumption so that the probability of having PD in the future years is estimated 
based on the extrapolation of the historical data.  The AnyLogic table function can accommodate 
such change in assumption by modifying the values supplied to the “Interpolation” and “Out of 
Range” parameters, as shown in Figure 5-2.  The probability of receiving PD is passed as an 
input parameter to the AnyLogic build-in probability distribution function “randomTrue” to 
perform a Random draw from a Bernoulli distribution based on this probability.  The transition 
“dialysis” (highlighted in green, on the left in Figure 5-1) makes use of this mechanism to 
determine whether the first treatment for DM-ESRD patients will be PD or HD.  The transition 
“reEnterDialysis” (highlighted in green, on the right in Figure 5-1) also uses the same 
                                                
1 A Table Function in AnyLogic is table form function which can be used for defining non-
linear relationship. 
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mechanism to choose HD or PD treatment for transplant patients returning to dialysis treatment.  
If the result of the “randomTrue” function is true (corresponding to a value of 1 from the 
Bernoulli Distribution), then the patient will start PD as initial treatment; otherwise, the patient 
will begin with HD treatment. 
 
Figure 5-1.  Transitions in which the Dialysis Modalities were Determined 
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 The selection of dialysis modalities for DM-ESRD patients was based on the probabilities 
of receiving PD as an initial treatment found among the Saskatchewan DM-ESRD patients 
between year 1981 and 2005.  However, when initializing the year 1980 DM-Prevalent cases at 
model start time, assigning patients to HD, PD and Transplant as ongoing treatment was based 
on the distribution of DM-ESRD prevalent patients among those treatments modalities on Dec 
31, 1981.  Ideally, the distribution of DM-Prevalent patients on treatment at year end of 1979 
should be used, rather than based on the distribution found at the end of year 1981.  However, 
due to the lack of information on prevalent case in 1979, we had to use the corresponding data 
from year 1981.  The distribution of DM-ESRD patients on different modalities was saved in the 
table function named “modalityDistri1980DMESRDPrevalent”, which was used in a custom 
distribution function for assigning patients to treatments according to the historical distribution 
found in the year 1981 DM-ESRD prevalent patients. 
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Figure 5-2.  Setting up table function “PDInitialProb” 
 
5.3 Hazard of Switching between HD and PD 
 The hazard (per day probability density) for switching from one type of dialysis to 
another is estimated using information regarding dialysis treatments received by DM-ESRD 
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patients in Saskatchewan between January 1st , 2006 and December 31st,  2010.  The historical 
data on dialysis treatments was provided by Dr. J. Kappel.  The method for estimating the 
probability of switching from HD to PD based on historical treatment information is illustrated in 
detail below, with an aim towards the hazard of switching from HD to PD.  
 
 
                                                                
                                                   
  
  
Figure 5-3.  Out flow of Patients Receiving HD Treatments 
 
 As shown in Figure 5-3 above, for patients receiving HD, there are three ways of leaving 
the treatment: transplantation, switching from HD to PD and death. The first step is to estimate 
the hazard of leaving HD regardless of reasons (transplantation, switching treatment or death).  
Normally, if a person starts in a specific dialysis modality at time 0, and if that person has a 
hazard rate  of leaving that modality to any other modality, the probability of that person 
remaining in that state at time t is given by the formula .  In this case, patients started HD at 
various times between 2006 and 2010.  Suppose that we approximate the continuous time at 
which patients arrive as a series of discrete days τ, and consider the patients starting dialysis iτ on 
each successive day.  Then the fraction of people who remain under that dialysis modality is 
given by:  
Start HD at time τ 
Patients Receiving 
Hemodialysis                                         
Kidney Transplant 
Switch from HD to PD 
Death 
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i!  !!(!!!!!!!!)(!!!)!!!!  
• t is the last day of the study 
•  is when patients begin on HD 
•  is the proportion of all patients who start HD at time  
• h! is the hazard rate of leaving HD due to transplant. 
• h! is the hazard rate of leaving HD due to death. 
• h! is the hazard rate of leaving HD due to switching toPD. 
 (5.2) 
 By analysing the treatment information between 2006 and 2010, the probability of 
leaving HD (h! + h! + h!) can be solved.  The counts of patients who began HD at various days 
τ determine the values for iτ.  Also, the proportion of patients who remain without changing from 
HD at the end of 2010 can be calculated from the historical data. By setting the formula in (5.2) 
equal to this proportion and using the values of iτ, the sum of h!, h!, andh! can be found. 
 To further derive the value of h!, the proportion of patients switching to PD among all 
patients leaving HD were applied to the sum of the hazard rates for leaving HD due to all causes, 
as shown in (5.3), the proportion of patients switching to PD among all patients leaving HD were 
obtained by dividing the count of patients switching to PD by the count of all patients leaving 
HD (  !!(!!!!!!!!) ).   
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ℎ! = ℎ! + ℎ! + ℎ! × !!(!! + !! + !!) 
• N! is the number of patients who switched from HD to PD. 
• N! is the number of patients who received transplant following HD. 
• N! is the number of patients who died while receiving HD. 
(5.3) 
 The probability of switching from PD to HD is calculated in the same way as for the 
probability of switching from HD to PD, and both rates were the driving forces for the 
“switchHDtoPD” and “switchPDtoHD” transitions between HD and PD. 
 It should be recognized that the derivation done above for the hazard rates of switching 
dialysis modalities is an important approximation.  Specifically, the formula assumes that the 
sum of hazard rates of leaving HD due to PD, transplant and death (h! + h! + h!) is constant, 
but in fact this rate varies over time. 
5.4. Graft Failure Rate 
 The graft failure rate (hazard) is used in the model for determining when a transplanted 
graft fails and patients return to dialysis.  The graft failure rate was estimated based on the graft 
survival levels published in the 2012 CORR annual reports - the unadjusted three month, one 
year, three year, and five year graft survival rates for adult kidney transplant patients (living 
donor or deceased donor).  The estimated graft failure rates were applied to entire projection 
periods including those earlier years back to year 1980.  Since the graft failure rates from later 
years are lower than from the earlier years, our assumption of using later year’s graft failure rates 
for the entire projection period will result less graft failed for earlier years.  We realized that it is 
not ideal to have a unified graft failure rates.  In the sensitivity analysis chapter, we verified the 
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impact of setting graft failure rates to zero in section 8.2.6.  The details of deriving the graft 
failure rates from graft survival data are discussed next.  Table 5-3 below shows the graft 
survival levels taken directly from the year 2012 CORR reports.  By assuming the graft failure 
among transplant patients followed a curve locally characterized by an exponential decay 
(reflecting a memoryless process, where the hazard is a fixed rate), the graft failure rate at 
different points can be calculated over time.   
Table 5-3.  Unadjusted one month, three month, one year, three year and five year graft survival 
rates for transplant patients (living and deceased donor) in Canada between year 2000 and 2010 
Donor Type Age 
Group 
0 3 
Months 
1 
Year 
3 
Years 
5 
Years 
Living 
Age 18–
44  
99.8 98.0 96.8 94.7 90.3 
Age 45–
54  
99.9 98.4 97.6 94.4 90.8 
Age 55–
64  
99.9 98.3 96.6 91.5 87.8 
Age 65+  99.7 98.4 95.9 92.0 83.0 
Deceased 
Age 18–
44  
99.4 95.9 94.1 88.8 82.2 
Age 45–
54  
99.8 97.0 94.8 90.2 85.3 
Age 55–
64  
99.4 94.7 91.0 84.9 79.6 
Age 65+  99.8 95.0 90.2 81.8 74.3 
 
 Consider a situation where the graft survival levels x(t) are known for two successive 
points, x(t) and x(t+Δt).  Suppose we wish to treat the mortality according to a fixed rate between 
these points.  This means that for each individual who has survived until time t post-transplant, 
the probability of remaining alive following time Δt is declines as e-λΔt.  The total number of 
individuals who remain alive at time t+Δt is x(t+Δt)= x(t)e-λΔt.  Given the empirical values x(t+Δt) 
and x(t) and the value of Δt, we can estimate the rate λ using the following derivation: 
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! ! + ∆! =   ! ! !!!∆! 
!!∆! =    !(!)!(! + Δ!) 
!Δ! = ln !(!)!(! + Δ!) =    ln ! !   − ln(! ! + ∆! ) 
!   =    ln ! ! −    ln(! ! + ∆! )∆!  
 (5.4) 
 In Table 5-3, the graft survival rates are known for day 0, day 90 (3 months), day 365 (1 
year), day 1065 (3 years) and day 1825 (5 years) for each age group and each type of transplant.    
 Using equations (5.4), the graft failure rates (hazards) can be calculated for day 0, day 90 
(3 months), day 365 (1 year), day 1065 (3 years) and day 1825 (5 years).  Further, to get the graft 
failure rates for each day in 5 years, the graft failure rates were interpolated between each nearest 
two days where the graft failure rates were calculated.  For example, the graft failure rates for 
every day falling between day 365 and day 1065 should be interpolated using the graft failure 
rates of day 365 and day 1065.  For the days between year five and year ten, we extrapolated the 
graft failure rates for each day in the last five years based on the graft failures calculated in the 
first five years.  Thus, within the span of a given day interval following transplant, the death 
process is memoryless (independent of the time within that day), but each successive day leads to 
a new rate. 
 Following the steps described in above sections, a total of eight sets of graft failure rates 
were calculated for each of the eight groups of patients stratified by age and transplant donor 
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type, and each set of graft failure rates were saved in a comma separated file and loaded into 
table functions in the model at model start.  Table 5-4 lists the name of the file to which graft 
failure rates were saved and the name of the table function into which the graft failure rates got 
loaded for each group of transplant patients.  And the details regarding the calculation of the 
graft failure rates can be found in the file “Calculation_GraftFailureTxPatients.xlsx”.  
Table 5-4.  Graft Failure Rates, Files and Table Functions for Transplant Patient Groups tratified 
by Age and Donor Type 
Transplant Patient Groups Comma Delimitated file  Name of the Table 
Function 
Living Donor, Age 18 -44 LD18_44GraftFailure.csv GraftFailureTFLD18_44 
Living Donor, Age 45 -54 LD45_54GraftFailure.csv GraftFailureTFLD45_54 
Living Donor, Age 55 -64 LD55_64GraftFailure.csv GraftFailureTFLD55_64 
Living Donor, Age 65+ LD65PlusGraftFailure.csv GraftFailureTFLD65Plus 
Deceased Donor, Age 18 -
44 
DD18_44GraftFailure.csv GraftFailureTFDDKT18_4
4 
Deceased Donor, Age 45 -
54 
DD45_54GraftFailure.csv GraftFailureTFDDKT45_5
4 
Deceased Donor, Age 55 -
64 
DD55_64GraftFailure.csv GraftFailureTFDDKT55_6
4 
Deceased Donor, Age 65+ DD65PlusGraftFailure.csv GraftFailureTFDDKT65Pl
us 
 
 During simulation, the graft failure rate is updated daily for each transplant patient by 
looking up in the corresponding table function based on the number of days post-transplant.  The 
graft failure rates are then passed to an event named “graftFailed” as the hazard (departure rate, 
i.e. chance of departure per day) for transplant graft failure.  When graft failure occurs, the 
“graftFailed” event will send a “Graft Failed” message to the person in the “Transplant” state, 
and the patient will return to the “Dialysis” state in the DiabetesESRD statechart.  At the same 
time, the patient will move from the “FunctioningKidney” state into the 
“AssessmentAndWaiting” state in the “AssessmentStages” statechart. 
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5.5. Rate of Living and Deceased Donor Transplant Operations in Saskatchewan 
 The rates of living and deceased transplants determine how many living and deceased 
donor transplants for DM-ESRD patients will take place each year in Saskatchewan.  Ideally, if 
we know the number of DM-ESRD patients who received transplants each year, then per day 
rates can be calculated by dividing the counts by the number of days in a year.  However, the 
counts of living donor and deceased donor transplants for DM-ESRD patients in Saskatchewan 
are not readily available; we therefore use two piece of historical data for estimating the counts: 
the count of diabetic patients receiving kidney transplants (regardless of transplant type) between 
year 1983 and 2009 in Saskatchewan, and the breakdown of the incident transplant cases 
between living donor type and deceased donor types for ESRD patients in Saskatchewan for the 
years between 1992 and 2007.   
 The total annual number of transplants that have taken place for DM-ESRD patients in 
Saskatchewan between years 1983 and 2009 were provided to us by CORR through a special 
data request as shown in the first column of Table 5-6  This data is specific to DM-ESRD 
patients but it is not broken down by the transplant donor type.  To split the total count of the 
incident transplant cases between living and decease donor type, we used proportion of living 
donor vs. deceased donor transplants for Saskatchewan ESRD patients as a whole (regardless of 
cause) as an estimate. The diabetic transplant patients might not follow the exact breakdown 
between living and deceased donor transplants as ESRD patients with all type of primary 
diagnosis.  However, we were unable to locate data regarding the breakdown on the type of 
transplants specific to DM-ESRD patients.   
 The proportion of transplants for each donor type is calculated based on separate counts 
of ESRD patients receiving living donor and deceased donor type of transplant in Saskatchewan 
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between year 1992 and 2007.  The historical data was found in the “2007 – 2008 Highlights” 
published by the Saskatchewan Renal Program, and is listed under the second and the third 
columns in Table 5-5.  The proportions were calculated and listed in the last two columns in the 
same table.  The historical data only provided data to compute proportions between year 1992 
and 2007.  For years when historical data was not available (i.e. between year 1983 and 1991; 
and year 2008 and 2009), the proportions were extrapolated in Excel based on the rates of known 
years.  The breakdown in transplant type for ESRD patients of all primary diagnoses are applied 
to the total number of the transplant for Diabetic-ESRD patients in Table 5-6,, and the number of 
DM-ESRD patients receiving living and deceased donor transplants were estimated. The split 
count of transplant cases for each donor type were further divided by the number of days in a 
year to obtain per day rates, which were saved into two table functions in the model: 
“LDKTDailyRateLookup” and “DDKTDailyRateLookup”.   
 During simulation, the events “PatientsReceiveDDKT” and “PatientsReceiveLDKT” use 
the transplant hazards from table functions “LDKTDailyRateLookup” and 
“DDKTDailyRateLookup”, then schedule the occurrence of the transplant according to the rates, 
and finally send messages to patients on the transplant waiting list to receive a kidney transplant.  
For the years that fall outside of the years where the rates are known, the table function will use 
the rates from the nearest year as an estimate. 
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Table 5-5.  Historical Count of ESRD Patients Receiving Living and Deceased Donor 
Transplants in Saskatchewan between 1992 and 2007. 
Calen
dar Yr 
Liv
ing 
Donor 
Cadav
eric 
TOTAL Proportion 
of TX is 
Living Donor 
Type 
Proportion of 
TX is Deceased 
Donor Type 
‘92 3 20 23 0.130435 0.869565 
‘93 5 19 24 0.208333 0.791667 
‘94 8 21 29 0.275862 0.724138 
‘95 3 23 26 0.115385 0.884615 
‘96 13 9 22 0.590909 0.409091 
‘97 17 16 33 0.515152 0.484848 
‘98 27 35 62 0.435484 0.564516 
‘99 16 35 51 0.313725 0.686275 
‘00  7 20 27 0.259259 0.740741 
‘01 8 28 36 0.222222 0.777778 
‘02 14 22 36 0.388889 0.611111 
‘03 7 25 32 0.21875 0.78125 
‘04 14 18 32 0.4375 0.5625 
‘05 11 20 31 0.354839 0.645161 
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‘06 8 21 29 0.275862 0.724138 
‘07 7 25 32 0.21875 0.78125 
Table 5-6.  The Historical Estimated Count of Diabetic Patients Receiving Living Donor and 
Deceased Donor Transplants in Saskatchewan. 
Year Count of 
Transplant 
for DM-
ESRD 
Proportion of 
living donor TX  
Proportion 
of Deceased 
donor TX 
Count of 
DM-ESRD 
Receiving 
Living Donor 
TX 
Count 
of DM-
ESRD 
Receiving 
Deceased 
Donor TX 
1983 2 0.260592 0.739408 1 1 
1984 6 0.263591 0.736409 2 4 
1985 5 0.266591 0.733409 1 4 
1986 5 0.269591 0.730409 1 4 
1987 7 0.27259 0.72741 2 5 
1988 8 0.27559 0.72441 2 6 
1989 7 0.278589 0.721411 2 5 
1990 6 0.281589 0.718411 2 4 
1991 5 0.284588 0.715412 1 4 
1992 7 0.130435 0.869565 1 6 
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1993 3 0.208333 0.791667 1 2 
1994 4 0.275862 0.724138 1 3 
1995 7 0.115385 0.884615 1 6 
1996 5 0.590909 0.409091 3 2 
1997 6 0.515152 0.484848 3 3 
1998 13 0.435484 0.564516 6 7 
1999 12 0.313725 0.686275 4 8 
2000 7 0.259259 0.740741 2 5 
2001 6 0.222222 0.777778 1 5 
2002 8 0.388889 0.611111 3 5 
2003 13 0.21875 0.78125 3 10 
2004 4 0.4375 0.5625 2 2 
2005 7 0.354839 0.645161 2 5 
2006 5 0.275862 0.724138 1 4 
2007 3 0.21875 0.78125 1 2 
2008 6 0.335581 0.664419 2 4 
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2009 4 0.338581 0.661419 1 3 
 
5.6 Cost of Treatment 
 The various costs for treating ESRD patients were taken from one single data source, a 
published research study [34] reporting the direct medical cost for the recipients and donor of 
both living and deceased donor transplant based on data from the database for the Southern 
Alberta Transplant Program.  Table 5-7 shows the cost item, the amount of cost in year 2008 
dollars, and the corresponding model element. The transplant related cost was taken directly 
from the results of the above mentioned study, whereas the cost of HD and PD were not part of 
the study results but were used for comparisons with the transplant cost by the authors.  In the 
model, the cost items were given as cost per year and were converted into per day cost because 
the accumulated costs are updated daily. This function is named “personDaysLivedCostUpdate”. 
The function counted the number of patients in each treatment modality at the end of the day, 
and calculated the daily total operation cost using formula (5.5). !"#$!   =   !"#$%!   ×  !"#$!    
• Cost! is the total cost for caring patients on a particular treatment modalities  in 
the model at a particular day.  Cost! does not include cost of transplant 
operations occur in that day. 
• Count! is the number of patients receiving a particular treatment modality in the 
model at the end of day. 
• Cost! is the average cost per day for caring patients in particular treatment 
modalities. 
  (5.5) 
 
 
80 
Table 5-7.  Item, Cost, Sources, Dollar Value in Original Year, and Corresponding Model 
Element. 
Cost Item Original value 
(Year 2008 Value) 
Model Element 
 
Per-year cost for HD Patients $83,398  Variable named 
“HDperDayCost” 
Per-year cost for PD (CAPD or CCPD) 
Patients 
$48,472  Variable named 
“PDperDayCost” 
Cost for Living Donor Transplant 
Operation 
$ 20,108  Variable named 
“LDKTOpCost” 
Donor related cost (living donor) $20,988 
 
Variable named 
“LDKTDonorCost” 
Cost for caring for patients who received a 
living donor transplant from day 0 to the 
day 90 after transplant operation 
$31,618 
 
Variable named 
“LDKTFirst90PerDayCost
” 
Cost for caring patients who received a 
living donor transplant from day 91 to day 
365 
$21,932  Variable named 
“LDKT91to365PerDay
Cost” 
Per-year cost for caring patients who 
received a living donor transplant after the 
1st year 
$19,974  Variable named  
“LDKTAfter1stYearPer
DayCost” 
Cost for deceased donor transplant 
operation 
$23,818  Variable named  
 “DDKTOpCost” 
Donor related cost (deceased donor) $37,198 
 
Variable named  
“DDKTDonorCost” 
Cost for caring for patients who received a 
deceased donor transplant from day 0 to 
the day 90 after transplant operation 
$28,200 
 
Variable named  
“DDKTFirst90PerDay
Cost” 
 
Cost for caring for patients who received a 
deceased donor transplant from day 91 to 
day 365 
$25,903 
 
Variable named  
“DDKT91to365PerDay
Cost” 
Per-year cost for caring for patients who 
received deceased donor after the 1st year 
$ 22,233 
 
Variable named  
“DDKTAfter1stYearPe
rDayCost” 
 
 Year 2008 is chosen to be the year for reporting the cost output from the model.  The 
costs projected by the model are in both the absolute value term and the discounted present value 
term, which is calculated basing on the standard 3% discount rate [40].
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5.7 Risk of Death Prior to Developing ESRD and Risk of Developing ESRD 
 The risks of developing ESRD or dying prior to developing ESRD for diabetes patients 
were studied in a competing risk analysis by Ying Jiang in her Master’s thesis [37]   Ying studied 
the diabetes population in Saskatchewan from 1980 and 2005.  Hazards of death prior to 
developing ESRD (5.6), shows the form of the three year interval based Piecewise Exponential 
Hazard Model resulting from Ying’s research: ℎ! ! = !!!!"#(!!!!! + !!!!! +⋯+ !!!!"  ) 
• hi(t) represents the hazard function of a particular ith patient at time t for time 
interval Ij , with t∈ Ij, and j=1,…p representing indices of time intervals  
• λ0j is the baseline hazard for time interval Ij . 
• β1, β2,…., βk are coefficients of exploratory variables. 
 (5.6) 
 Table 5-8 and Table 5-9, list the Coefficients for covariates in the three year interval 
based Piecewise Exponential Hazard Model.  In the model, the risk of dying prior to developing 
ESRD and the risk of developing ESRD are both calculated using Ying’s piecewise exponential 
hazard model, which were firstly converted into per-day hazards and supplied to the model 
transitions from the diabetes states (i.e. state named “DM1to3Y”, “DM25to27YBeyond”, etc.) to 
the “DeathBeforeESRD” state or the “ESRD” state in the “DiabeticESRD” statechart. 
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Table 5-8.  Coefficients for variables in the Piecewise Exponential Hazard Model for Risks of 
Developing ESRD 
Variable β estimate 
Intercept -4.55 
Male 0.49 
FN 1.09 
Diabetes age -0.01 
j1 -2.17 
j2 -2.21 
j3 -1.93 
j4 -1.50 
j5 -1.07 
j6 -0.48 
j7 -0.34 
j8 -0.45 
 
Table 5-9.  Coefficients for variables in the Piecewise Exponential Hazard Model for Risks of 
Death Prior to Developing ESRD. 
Variable β estimate 
Intercept  -6.71  
Male  0.82  
FN  1.20  
Diabetes age 0.08 
Male*Diabetes age -0.01  
FN*Diabetes age -0.015 
j1 -1.75  
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j2 -1.76  
j3 -1.47  
j4 -1.16   
j5 -0.86 
j6 -0.59 
j7 -0.30  
j8 -0.06  
 
5.8 Probability Density Used for Selecting Patients for Kidney Transplant Assessment 
 Not every patient on dialysis will get sent for transplant assessment because their age and 
health condition.  In general, younger patients tend to be healthier, and thus have a greater 
chance to be sent for assessment.  In the model, based on the suggestion of Drs. Kappel and 
Dyck, we implemented a simple logic representing the relationship between age and percentage 
of patients in that age range that will be sent for transplant assessment, as shown in Table 5-10. 
Table 5-10.  Percentage of Patients getting assessed for Transplant based on Age 
Age  Percentage of Patients Sent for Transplant 
Assessment 
65 and younger  100% 
66 to 75 25% 
76 and older 0% 
 
 The estimated percentage of patients who are sent for assessment is then used as the 
probability that an individual patient (of a particular age) will be assessed.  The logic is 
implemented in the function named “isEligibleForTransplantAssessment”, which yields a true or 
false value representing whether the patient will be sent for assessment.  Each time when a 
patient enters the assessment stage, their eligibilities for receiving a transplant assessment will be 
re-determined by the same function “isEligibleForTransplantAssessment”.In other words, 
patients with failed kidney transplant, prior to send them for transplant assesment, will get re-
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evaluated following the same logic as those patients who never had a transplant before.  As 
shown in Figure 5-4, if patients are sent for assessment, they will go to the “WorkUpStage”; 
otherwise, they will go to the state named “NotSuitableForTx” in the “AssessmentStages” 
statechart. 
 
Figure 5-4.  Transitions to the  “WorkUpStage” state and “NotSuitableForTx” state 
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CHAPTER 6  
CALIBRATED PARAMETERS 
 This chapter illustrates how parameters lacking reliable historical sources got set by 
calibration process.  The calibration process makes estimates on those parameters by constantly 
re-adjusting the parameters and comparing the model output with desired value until a match is 
achieved.  In this chapter, all the calibrated parameters in the model will be discussed in details, 
including which model transitions are parameterized with them, which model output can be 
affected by a change in those parameters, and the value of those parameters that were estimated 
by the calibration process. 
6.1 Rate of Withdrawing from Transplant Waiting List 
 Patients can withdraw from the waiting list due to health and personal reasons, which is 
represented with a separate transition “withdrawWaitingList” in the model to distinguish with the 
other two causes for leaving the waiting list such as getting kidney transplantation and death 
while on the waiting list.  Following the “withdrawWaitingList” transition, some patients will 
move from the “AwaitingTx” state to the “NotSuitableForTx” state.  The per day rate of 
withdrawing from the transplant waiting list is represented by a variable named 
“withdrawWaitListAjd”, and  is used in the transition “withdrawWaitingList”. There is no data 
on the rate of withdrawing from the waiting list.  However, Table 6-1 shows that for the 
provinces where the number of withdrawals and deaths were tracked for patients on the waiting 
list,  in more than half of the cases, there are more withdrawals than death for the same waiting 
list. 
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Table 6-1.  Death and Withdrawls on Transplant Waiting List in Canadian Provincies Found in 
CORR Annual Reports 
Year Alberta Ontario Quebec 
Death With
drawals 
Death With
drawals 
Death With
drawals 
2011 (ref-table 2C, 
2011 report) 
13 21 36 78 20 58 
2010 (ref-table 2B, 
2010 report) 
16 23 34 149 55 14 
2009 (ref-table 2B, 
2009 report) 
11 14 29 11 42 27 
 
 Based on the observations regarding the count of deaths and withdrawals on the waiting 
list, during calibration, we adjusted the rates of withdrawal so that the number of patients 
withdrawing from the waiting list within a given period is 1.5 to 2 times higher than the number 
of deaths on the waiting list in that same period.  Figure 6-1 is generated based from the 
simulation output, and comparison is made between the annual number of withdrawals and 
deaths on waiting list. 
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Figure 6-1.  Result from Model Simulation Regarding the Withdrawal and Deaths on Waiting 
List 
 
6.2 Assessing the Eligibility for Kidney Transplant  
 The process of assessing patients’ transplant eligibilities is represented in the model in a 
very simplified version.  In practice, thorough examinations and evaluations are conducted to 
assess a patient’s health conditions.  Only suitable patients are sent for transplantation.  As 
observed, healthier patients, more often younger, are more likely to be selected as transplant 
candidates.  In the model, a health indicator is designed to represent a patient’s state of health, 
and it is used in assessing a patient’s eligibility for kidney transplant.  There is not enough 
information available regarding a patient’s health and a valid algorithm has not been developed 
for measuring a patient’s health conditions. Therefore, in this model, a simple formula was 
designed for assigning values to the health indicator based on patient’s age, with an eye towards 
future extendibility to incorporate additional factors. The formula used in the model is shown in 
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equation 6.1.  In general, a patient’s health will decline with age.  A calibrated parameter 
“ageHealthCorr” is used to signify the degree of impact of age on overall heath.  Also, the 
formula takes into consideration the fact that patients’ health conditions might vary among 
individuals even at the same age, and the variable “healthRandom” is used to denote other 
variations in patient’s health not captured by age.  The value of “healthRandom” is drawn from a 
Weibull distribution, however, because the only the ranking -- and not the absolute value -- of 
the parameter is considered, the result is not dependent on the distribution used. HealthIndicator = e(!!.!×!"#$#!%&'()**×!"##$%&'($)×  1000  ×  healthRandom 
(6.1) 
 The value of HealthIndicator is set by the formula when a patient finishes the assessment 
(leaves “WorkUpStage” state), and it is evaluated against the cut off value for passing transplant 
assessment in the function named “isEligibleForTransplant”.  Patients with a value of health 
indicator greater than the cut off value will pass the assessment for transplant and be put on the 
waiting list (go to the “AwaitingTX” state). 
 Both the cut off value for passing assessment and the parameter ageHealthCorr mediating 
the relationship between age and health were calibrated through simulation.  When a higher 
value is set for parameter ageHealthCorr, the health indicator of older patients will get lower 
values.  Thus fewer older patients will pass the assessment, and the average age of receiving 
kidney transplant will be younger.  The historical data regarding the average age of receiving a 
transplant can be used to compare with model results, and aid with making further adjustment of 
the parameter ageHealthCorr.  However, the correlation factor between age and health 
(parameter ageHealthCorr) is not the only force impacting the average age of receiving 
transplant.  Adjusting the cut off value of the health indicator can also change the average age of 
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receiving transplant.  With a lower cut off value of the health indicator, more patients at older 
age will pass the assessment, thus increasing the age of patients receiving transplants.  Moreover, 
as the cutoff drops, with more patients eligible for transplant and placed on waiting list, the 
length of a wait becomes longer, so that a patient’s age will be older at the time of the transplant 
due to the longer wait.   Therefore, the average age of receiving transplant should be matched 
during calibration when adjusting both the parameter ageHealthCorr and the cut off value for 
transplant. 
 In Figure 6-2 and Figure 6-3 below, the calibration results were compared with historical 
data regarding the average age of patients receiving deceased and living donor kidney transplant.  
The model output was shown in 2D histogram, whereas the historical data were plotted as lines 
in blue color. 
Figure 6-2.  Model Result - Mean Age of Receiving DDKT (First Graft) 
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Figure 6-3.  Model Result - Mean Age of Receiving LDKT (First Graft) 
 
 In addition to the mean age of receiving a transplant, there are another two model outputs 
which should be examined while calibrating the cut off value for transplant eligibility: the head 
count on the wait list and the median days spent on dialysis prior to having a kidney transplant.  
Lowering the cut off value will allow more patients on the waiting list, and lengthening the wait 
on dialysis.  However, the wait list head count is not only controlled by the cut off value, but also 
depends on the withdraw rate from waiting list, death on the waiting list (mortality risk for HD 
and PD patients), rate of transplant and the duration of the assessment.  All the factors impacting 
head count on the waiting list also play roles in changing the wait time on dialysis.  
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6.3 Duration of Assessment for Transplant 
 The duration of the assessment is also a calibrated parameter due to the limited amount of 
information available regarding the assessment process.  A few assumptions were made 
regarding the assessment process, and relevant parameters were set through calibration.  Firstly, 
for patients who had a graft failure, return to dialysis and were sent for transplant assessment 
again, if their last transplant was done within a year, we assume that assessment will take less 
time since many tests were completed not long ago.  Secondly, for patients who never had a 
transplant before or whose most recent transplant was over a year ago, the duration of assessment 
were assumed to depend on several factors: the number of the tests taken, the type of transplant 
for which a patient is preparing, and the average time required to complete a test in the 
assessment.  All the above three impacting factors have been formulated into the distribution 
function to draw the days spent on assessment for each patient.  More details can be found in 
Appendix C.  
 The calibrated parameters related to the assessment process are listed in Table 6-2.  As 
discussed earlier, the duration assessment can be calibrated by comparing the model output of 
time spent on dialysis with the historical data (Figure 6-5 and Figure 6-6).  A shorter assessment 
would bring more people on the waiting list, thus the model result regarding head count on 
waiting list (Figure 6-4) should be inspected during calibration. 
Table 6-2.  Calibrated Parameters Related to the Duration of Assessment 
Item Value Model Element 
Minimum days 
required to complete 
assessment for patients 
whose last transplant is 
within a year from the 
current time 
90 minAxDurationRKT 
Average number of 3 Variable named “avgTestsAX” 
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tests for which patients 
were sent during 
assessment 
Average days spent 
on assessment prepared 
for living donor 
transplant based on the 
year when the 
assessment begins. 
From year 1980 to year 
2010, the average days spent 
on assessment ranged from 
120 to 360 days for different 
time periods.  In the earlier 
years, the assessment time was 
shorter. 
Table Function 
“workUpDaysEstimatesLKDT” 
The Ratio of days 
spent on assessment for 
deceased donor 
transplant to days  for 
living donor  transplant 
1.3 Variable named 
“DDvsLDWorkUpDaysRatioAdj” 
 
 
Figure 6-4.  Comparing Model Result with Historical Data Regarding Head Count on Waiting 
List 
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Figure 6-5.  Comparing Model Result with Historical Data - Median Days on Dialysis Prior to 
DDKT 
 
Figure 6-6.  Comparing Model Result with Historical Data - Median Days on Dialysis Prior to 
LDKT 
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 In summary, the health indicator, the cut off for eligibility of transplant, and the duration 
of assessment should all be examined and adjusted together through calibration.  Most of the 
time, those parameters worked together in changing the model outputs.   
6.4 Hazard Ratio of Calendar Period in Death Hazard Model for Dialysis and Transplant 
Patients 
 In the CORR reports published before 2000, the Cox regression analysis for the survival 
of the transplant and dialysis patients both included one important covariate: the calendar period 
when the treatment began in.  As found in the report, patients whose dialysis or transplant  took 
place in later time periods had much lower mortality risk compared to those whose treatments 
were started earlier [38].  The hazard model (6.2) currently used for estimating the hazard of 
death in our model was developed basing on patients who began their treatment from 1999 to 
2008.  Yet the hazard model was done without including the calendar year as a covariate.  
Recognizing that the calendar year covariate is missing from the Cox proportional hazards model 
currently used in the simulation model, an approximation was added back into the hazard 
function using an estimated hazard ratio.   The “Calendar Period” is added as another 
covariateX!, and the value of coefficient  is set through calibration.  !! ! = ℎ! !   ×  !(!!×!!!⋯!!!×!!) 
•  are the parameter estimates 
•  Are the covariates. 
(6.2) 
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 The hazard ratio for the covariate “calendar period” is saved into the table function 
named “dialysisDeathHazardCalendarYearAdj” and “TXDeathHazardCalendarYearAdj” for the 
hazard models for dialysis patients and transplant patients respectively. As shown in Table 6-3, 
estimates of the coefficient for the earlier time period has a much higher value, which will 
increase the mortality hazard for patients who began treatments in earlier years.  When 
calibrating the hazard ratio for covariate “calendar period”, the prevalent case count for 
transplant and dialysis patients can be compared with the corresponding historical data. 
Table 6-3.  Estimates for covariate “Calendar Period” in the Cox proportional hazards model for 
dialysis patients 
Year Estimates of Coefficient  B for 
different value of calendar 
periods 
1985 1.8 
1990 1.6 
1995 1.4 
2000 1.0 
2005 0.3 
2010 0 
 
 Through calibration, we found that by adding the “calendar period” covariate to the 
hazard model for dialysis patients, the prevalent case count of dialysis patients resulting from the 
calibrated simulation run matched better with the historical data in comparison with model 
results of the model realizations without having the “calendar period” covariate.  Therefore, the 
covariate “calendar period” will be added to the hazard function for dialysis patients.   
 On the other hand, the covariate “calendar period” will not be added to the hazard 
function in the simulation model for transplant patients.  As shown in Figure 6-7, there is already 
a gap existing between the prevalent case counts of transplant patients with the historical count 
without adding the “calendar covariate”.  With the “calendar period” covariate added, the gap 
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between model result and historical data will grow even bigger.  Before making further 
adjustment the hazard function with the “calendar covariate”, we prefer to investigate the cause 
of gap between model result and historical data first, which is one of the future works out of the 
scope of this thesis.  The model variable “TXDeathHazardCalendarYearAdj” having the values 
of the hazard ratio for covariate “calendar period” for transplant patients will remain in the 
model as a place holder until investigation of the gap completes. 
 
Figure 6-7.  Gaps in Transplant Prevalent Case Count between model results and the 
historical data 
 
6.5 Pre-Emptive Transplant Rate and Type 
 The pre-emptive transplant rate and type were used to schedule the occurrence of pre-
emptive transplants and the type of pre-emptive transplants in the model.  Currently in the model, 
the rate of pre-emptive transplant is set to zero because it is rare to have pre-emptive transplants 
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in Saskatchewan for all ESRD patients, and it is even rarer for DM-ESRD patients.   Until there 
is data available regarding to the count of the pre-emptive transplant for DM-ESRD patients, the 
rate of the pre-emptive transplant will remain as zero in the model. 
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CHAPTER 7  
MODEL OUTPUT 
 This chapter focuses on the output collected from model realizations. It is broken into 
two sections: section 7.1 is devoted to the high level statistics collected on model population, and 
section 7.2 describes a database designed and created for saving individual level data for each 
patient in the model.  The high level and individual level output each offer different benefits: 
high level statistics provide a quick summary of the simulation results and can be used in model 
validation and sensitivity analysis; whereas individual level data saved in a database offers the 
potential for conducting research on longitudinal data .   
7.1 Statistics Collected on Model Population 
 Many statistics were collected on the model population when patients went through the 
important model process such as the diabetes to ESRD progression, receiving RRT treatments, 
being assessed  for kidney transplant and waiting for the transplant operation.   Due to space 
limit, only a few essential statistics are discussed in this section.  The complete list of statistics 
collected during simulation is explained in Appendix A.  
 The choice of which statistics to be collected in the model is driven by availabilities of 
historical data, need in policy investigation and goal of the thesis.  Since both the incident and 
prevalent case count were widely reported in the historical data, we collected the incident and 
prevalent case counts from many processes in the model.   
 The incident case count is the number of new patients entering a state or starting a 
process between Jan 1st and Dec 31st in a given year.  For instance, the incident case count for 
HD summarized the number of patients beginning HD treatment in a given year 
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 The prevalent case count is the number of the patients alive in a state or a process at Dec 
31st of a given year.   In the model, we collected the prevalent case count for patients having 
DM-ESRD.  When the DM-ESRD prevalent case count reported by the simulation is compared 
with the corresponding historical data, it will help us determine correctness of the model.   
 In addition to the incident and prevalent case count, the cost is another essential output 
from the model because it serves as a metric in evaluating different scenarios in Chapter 8.  
Moreover, it is the goal of this thesis for making projection on cost.  The per year cost measures 
the cost occurred in a given year for caring DM-ESRD patients.  The accumulated cost reported 
the cost for caring DM-ESRD patients accumulated since the beginning of the simulation time 
(i.e. Jan 1st, 1980) to each year end (Dec 31st of a given year) during simulation period and up to 
the end of the simulation time (i.e. Dec 31st, 2025). 
  As mentioned above, there are many more statistics collected by the model but not 
discussed in this section.  Appendix A has the full descriptions of those statistics, what they are 
and how they are collected.   
7.2 Database for the Saskatchewan DM-ESRD Model 
 A relational database was created using MySQL to save the patients’ demographic 
information and their activities during simulation run.  The database offered modellers and 
policy makers the options to retrieve detailed history of individuals as well as to cross check the 
with the population statistics saved in the comma delimited files .  The MySql database 
management system became our choice for implementing database because it is the most widely 
used database system, is open source software (and therefore imposes no cost), and because it 
can be easily integrated with model built in AnyLogic.  A full description of the database created 
for this model can be found in Appendix D.
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CHAPTER 8  
VALIDATION AND RESULTS 
 In this chapter, a few selected model outputs were first compared with the corresponding 
historical trajectories for proving correctness of the model.  Once we had confidence in the 
model results, a total of nine scenarios were set up to run in the model so that the effects of 
varying parameters values can be investigated.  The observed impact on model output is used for 
both sensitivity analysis and policy evaluation.  Lastly, the projections made by the model were 
presented together with limitations in the last two sections of this chapter. 
8.1. Model Validation and Sensitivity Analysis 
 Model outputs were validated against various sources of historical data to enhance 
confidence in the model.  Only a subset of the output listed in section 7.1 was selected for model 
validation.  The selection depended on availability of the corresponding empirical data for the 
Saskatchewan DM-ESRD population.   
 The historical data used for validating model results were from sources such as the 
Saskatchewan Administrative database, the Saskatchewan Renal Program, special data requests 
filled by CIHI, and the data tables published in the CORR Annual Report between year 1981 and 
year 2012.  Some historical data require some degree of processing before it can be used in 
comparisons with model outputs.  As an example, while model output relates to Diabetic – 
ESRD patients, in many cases the empirical data were collected for all ESRD patients rather than 
being restricted to DM-ESRD patients.  Thus, many historical data for Saskatchewan were 
processed so that a count for DM-ESRD patients was estimated from the count for all ESRD 
patients.  The definition and the source of the historical data, and the details regarding how the 
data was processed were captured in the document named as “Technical Report – Historical 
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Data”.  This document is among the supplemental materials of the thesis, and is available upon 
request to the author.   
 The comparisons made between model output and corresponding historical data were 
performed by visually inspecting the alignment of the trajectories created from the output values 
and the historical data values.  A script was written in the statistical package R2 to plot each 
model output and the corresponding historical data on one graph.  To work with the stochastic 
nature of the simulation, we ran the model with 30 realizations, each associated with a different 
random number sequence (as triggered by distinct random number “seeds”).  Each realization 
generated a set of output values.  We decided to plot the values of a given output variable from 
all 30 realizations into a 2D histogram, so the most frequent values of the variable can be easily 
spotted.  Sometimes there are multiple sources of historical data for comparison with a given 
output variable.  However, in many cases, the historical data was only an approximation of what 
the output variable measures and might further involve some degree of approximate corrections.  
We decided to plot the historical data for a given output variable as lines onto the same graph 
where the output from the realizations was shown as 2D histogram.  In this way, the difference 
between model results and historical data -- and even the differences existing among multiple 
historical sources -- can be examined in one place.  
 The prevalent case count of DM-ESRD patients is an essential output to be examined 
while attempting to raise confidence in the model because it is controlled by two main driving 
forces in the model: the inflow of patients who receive DM-ESRD diagnosis and the outflow of 
patients who died while being treated for ESRD.  The inflow of patients receiving DM-ESRD is 
determined by the likelihood with which diabetes patients develop ESRD before death, which 
                                                
2 R is programming language and a software environment, which is used for statistical 
computing and creating graphics.   
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builds atop an already validated model from a previous Master’s thesis [37].  To prove that the 
hazard of developing ESRD from diabetics is correctly built in our Saskatchewan DM-ESRD 
model, Figure 8-1 shows the close alignment between the two lines plotted using the historical 
data (on the one hand) and the 2D histogram plotted from the incident case count output by the 
model (on the other).  When the inflow rates of DM-ESRD patients is matching well with reality, 
as long as the mortality rates of DM-ESRD patients and the initial DM-ESRD population is set 
up right, the number of patients living with DM-ESRD in the model at each year end should 
align with corresponding historical numbers.  As shown in Figure 8-2, the prevalent case count 
output from the model, which counts number of DM-ESRD patients who are alive on Dec. 31 of 
a year, is compared with historical data from multiple historical sources. The names of the 
historical data files were given in the legend, which can be used as an identifier to locate more 
details regarding the historical data in one of the supplemental document for the thesis – 
“Technical Report – Historical Data”.  For instance, in Figure 8-2, the purple line was created 
from historical data recorded in the file named “SK_RenalReport_Prevalent_HD_08_11.csv”, 
and the details regarding that data can be found in section A.3 of the document named 
“Technical Report – Historical Data”.  Figure 8-2 demonstrates that the prevalent case count 
output from the model is in a close match with the historical data collected on the Saskatchewan 
DM-ESRD population, which lends confidence to believe the mortality hazards for DM-ESRD 
patients and the initial DM-ESRD population loading into the model were correct. 
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Figure 8-1.  DM - ESRD Incident Case Count 
 
 
Figure 8-2.  DM-ESRD Prevalent Case Count 
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 The overall incident and prevalent case counts for all the DM-ESRD patients were 
essential for model validation, as are the incident and prevalent case counts broken down for 
DM-ESRD patients receiving different ESRD treatments.  Verification of the incident case count 
for HD and PD patients can help indicate whether the allocation of the incident DM-ESERD 
patients to HD and PD is properly done in the model.  As shown in Figure 8-3 and Figure 8-5, 
the model output on incident case counts of patients receiving HD and PD treatments can be 
compared respectively with the correponding historical data.  The fact that the model output 
matches well with the respective historic data suggests that the selection of HD vs. PD treatments 
is well captured in the model for diabetic-ESRD patients who recently receive ESRD diagnosis 
(DM-ESRD incident patients).  Moreover, the prevalent case counts of model population 
receiving HD and PD aligns well with the respective historical data, as illustrated in Figure 8-4 
and Figure 8-6.  The successful validation of prevalent case counts on HD and PD treatments 
further suggests that the mortality risks for patients on those two treatments were accurate and 
properly implemented in the model.  Other than the mortality rates, the transplant incident rates 
and graft failure rates can both play a role in changing the prevalent case counts of HD and PD 
patients in the model.  As shown in Figure 8-7, the transplant incident case count in the model 
matched well with the historical data.  The graft failure rate was not directly validated because 
the historical data on the failed transplant grafts were not available to us.  So far, for the three 
ESRD treatment modalities, the incident and prevalent case count for HD and PD, and the 
incident case count for transplant were all successfully validated with historical counts.  The 
validation on the transplant prevalent case count in the model is going to be discussed in detail 
below. 
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Figure 8-3.  HD Incident Case Count 
 
 
Figure 8-4.  HD Prevalent Case Count 
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Figure 8-5.  PD Incident Case Count 
 
Figure 8-6.  PD Prevalent Case Count 
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Figure 8-7.  Transplant Incident Case Count 
 
 
Figure 8-8.  Transplant Prevalent Case Count 
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 The transplant prevalent case count is the only model output that exhibits a significant 
disparity with the historical data.  Figure 8-8 shows that the trend of the model output generally 
follows the trend exhibited in the historical data.  However, the actual counts of the transplant 
prevalent cases in the model were consistently lower than the historical records.  We tried to 
investigate the possible factors contributing to such differences such as the processes within the 
model and the quality of the historical data.  
 The list of factors in the model which could affect the transplant prevalent case count 
were each investigated in turn, such as the mortality hazards for transplant patients, the graft 
failure rates, the transplant incident case count, the time spent on assessment and waiting list, and 
selection of transplant candidates for transplants based on health indicators.  After considering 
each of them, it does not appear plausible that reasonable errors in any one of them would be 
sufficient to increase the prevalent case count in the model to match the historical data. 
 In addition to investigating model parameters that could contribute to the discrepancy, the 
historical data was examined to see if they might include patients that are not counted in the 
model.  In the model, the prevalent case counts are restricted to patients who first had diabetes 
and subsequently developed ESRD (presumably as a complication).  All of the historical sources 
of transplant prevalent cases include in their counts patients who have both diabetes and ESRD, 
which means those counts include not only patients who develop ESRD after having diabetes, 
but also patients who first have ESRD and then develop diabetes after receiving a kidney 
transplant (a condition called post-transplant diabetes mellitus).  After consulting with a 
nephrologist (Dr. Dyck), we learned that there are substantial number of kidney transplant 
recipients who will develop diabetes after the transplant, with this number elevated as a side 
effect of some of the treatments involved.  As reported in patients from one Canadian transplant 
 
 
109 
center [35], as many as 9.8% of kidney transplant recipients developed diabetes post-transplant.  
Since the historical data do not single out patients with post-transplant diabetes mellitus, we do 
wonder whether the occurrence of post-transplant diabetes mellitus might account for most of the 
discrepancy between model and historical estimates of transplant prevalent cases.   
 A few other less important model outputs were also selected for model validation in 
addition to the prevalent and incident case count from different ESRD modalities.  The mean age 
of initiating HD, PD or receiving living donor transplant or deceased donor transplant were 
compared with the corresponding historical data, as shown in Figure 8-9, Figure 8-10, Figure 
8-11 and Figure 8-12. Moreover, outputs in relation to the kidney transplant assessment and the 
waiting list such as the median days spent on dialysis prior to kidney transplant and the head 
count on the waiting list were also being validated against historical data, as shown in Figure 
8-13, Figure 8-14 and Figure 8-15.  Above comparisons between model output and historical 
data yield a close match. 
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Figure 8-9.  Mean Age of Patients Initiating HD 
Figure 8-10.  Mean Age of Patients Initiating PD 
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Figure 8-11.  Mean Age of Receiving Deceased Donor Kidney Transplant 
 
Figure 8-12.  Mean Age of Receiving Living Donor Kidney Transplant 
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Figure 8-13.  Median Days On Dialysis Prior to Living Donor Kidney Transplant 
 
Figure 8-14.  Median Days On Dialysis Prior to Deceased Donor Kidney Transplant 
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Figure 8-15.  Waiting List Head Count 
 
 In summary, a number of model outputs were selected for comparison with the 
corresponding historical data for the purpose of validating the correctness of the model.  The 
model output chosen for model validation include: the prevalent and incident case count for all 
DM-ESRD patients, the prevalent and incident case count for patients on each ESRD treatment 
modality (HD, PD, and Transplant), and the mean age of patients initiating HD/PD/Transplant, 
head count on the waiting list and the median days spent on dialysis prior to transplant.  Both the 
model output and the historical data were plotted in graphs and comparisons were made by 
visually inspecting the alignment of plots.  All the model output except the transplant prevalent 
case count align well with the historical data.  One possible explanation for the discrepancy 
uncovered for the transplant prevalent case count is that the historical data include patients who 
developed diabetes post-transplant, which are excluded from the prevalent case count in the 
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model.  Nevertheless, despite the divergence in transplant prevalent case count, all major model 
output has a strong match with historical data, suggesting that the model captures relevant 
processes and is likely to be correctly implemented, with the model output matching historical 
numbers. 
8.2 Scenarios and Sensitivity Analysis 
 The model ran a set of nine scenarios. Each scenario varied some parameters and 
changed some model assumptions.  The models run each scenario with 30 realizations; and each 
scenario took 2.5 to 3 hours to complete.  During the model development phase, we found out 
that the run time can be significantly and adversely impacted by the usage of the population 
statistics function offered in Anylogic software package.  When calling multiple population 
statistics during run time, the length of time required to complete simulation can be dramatically 
longer.  For instance, at one point in time, 30 realizations of a scenario took up to 60 hours to 
complete.  The problem with using population statistics function built-in with Anylogic software 
is that each function call iterates through the entire population and collects only one metric from 
every agent in the population.  When we call several population statistics functions at the end of 
each day to collect multiple metrics from the agents, the computation cost is very high.  To 
achieve better run time efficiency, we redesigned the model with a customized function to go 
through the population once at the end of each day to collect all metrics together rather than 
looping through the population several times.  Such a change allowed us to reduce the run time 
from 60 hours to 3 hours. 
 By comparing the output of scenarios with corresponding output variables from the base 
line scenario, we know how sensitive the critical model output (e.g. prevalent case count, cost, 
personal year lived) are in response to the changes.  Also, some of the scenarios could help us 
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understand the degree of impact by health care policy changes for managing DM-ESRD patients.  
In the sections below, each scenario will be described in detail; the comparisons made with 
baseline outputs will be discussed as well. 
8.2.1 Scenario #1 - All DM-ESRD Patients Receive Pre-Emptive Transplant as Initial 
Treatment  
 In the baseline, the pre-emptive transplant is not available to DM-ESRD patients since it 
is very rare in Saskatchewan.  By contrast, in Scenario #1, when Diabetes patients received 
ESRD diagnosis, the model treats the only treatment available as pre-emptive transplant instead 
of HD and PD.  Also, the scenario is set up in such a way that when transplant patients 
experience graft failures, they will spend a minimum amount of time (i.e. 90 days) on dialysis 
prior to receiving another transplant again.  The purpose for having this scenario is to investigate 
the impact – taken to an extreme – of having a high level of pre-emptive transplants versus 
dialysis on outcomes such as prevalent case count, costs and person years lived.  The 
comparisons made for each outcome variable between scenario #1 and the baseline scenario are 
plotted in Figure 8-16, Figure 8-17 and Figure 8-18 respectively.  As shown in those figures, 
with all of the DM-ESRD incident patients receiving pre-emptive transplants, there is a 
significant increase in the number of patients living with Diabetic-ESRD (DM-ESRD Prevalent 
Case Count as in Figure 8-16) because of the lower mortality hazards experienced by transplant 
patients when compared to dialysis patients.   Correspondingly, as more DM-ESRD patients are 
living longer, both the ESRD prevalent case count and the accumulated values (person-years 
lived) are also much higher in scenario #1 in comparison with the baseline scenario.  Despite a 
larger count of patients living longer, the cost of caring for those patients is actually lower than 
in the baseline scenario, as shown in Figure 8-17.  The reason reflects the fact that the cost for 
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caring transplant patients is significantly lower than the cost associated with those on dialysis, 
especially following the first year of transplant.   Even though in real life it is unlikely that 
resources would be sufficient to provide all patients with pre-emptive transplants, scenario #1 as 
an extreme case does highlight the pronounced benefits of having more pre-emptive transplants 
over dialysis. 
Figure 8-16.  DM-ESRD Prevalent Case Count, Scenario #1 Compared to Baseline 
 
Figure 8-17.  Cost, Accumulated and Per Year, Scenario #1 Compared to Baseline 
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Figure 8-18.  Person Years Lived, Accumulated, Scenario #1 Compared to Baseline 
 
8.2.2 Scenario #2 – All DM-ESRD Incident Patients Receiving HD Only As Initial 
Treatment 
 In the baseline, DM-ESRD incident patients have certain probability of receiving either 
HD or PD as their initial treatment with the fact more patients will start on HD.  By contrast, in 
scenario #2, the only treatment option available to DM-ESRD incident patient is HD rather than 
both HD and PD.  Moreover, patients are not allowed to switch from HD to PD.  Such a set up 
will allow us to see the effects of having more patients receiving HD on the outcomes variables.  
The prevalent case count and person years lived output from scenario #2 did not show any 
significant differences when compared with the baseline scenario as shown in Figure 8-19 and 
Figure 8-21, respectively.  The subtle differences between scenario #2 and baseline could be due 
to the fact that between 80% and 90% of the DM-ESRD patients were already started with HD in 
the baseline scenario; having all of the DM-ESRD patients starting HD in scenario #2 wouldn’t 
produce noticeable differences in results. On the other hand, the per-year and accumulated cost 
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in scenario #2 are higher than what are in the baseline scenario, which could be caused by more 
people receiving the most expensive form of ESRD treatment, HD. 
Figure 8-19.  DM-ESRD Prevalent Case Count, Scenario #2 Compared to Baseline 
Figure 8-20.  Cost, Accumulated and Per Year, Scenario #2 Compared to Baseline 
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Figure 8-21.  Person Years Lived, Accumulated, Scenario #2 Compared to Baseline 
 
8.2.3 Scenario #3 – All DM-ESRD Incident Patients Receiving PD Only As Initial 
Treatment 
 Whereas in the baseline scenario, majority of the DM-ESRD patients start on HD as their 
initial treatment, in scenario #3, all the DM-ESRD incident patients start with PD.  Figure 8-22 
shows the prevalent case count becomes increasingly larger than in the baseline when all DM-
ESRD patients receive PD as initial treatments.  Also, the person year lived outcome from 
scenario #3 demonstrate visible improvement as illustrated in Figure 8-24.  The higher prevalent 
case count and person year lived are a reflection of  the lower mortality rates for patients 
receiving PD over HD.  Also, given that PD is a less expensive treatment than HD, the per-year 
and accumulated cost for treating DM-ESRD patients in scenario #3 are much less than in the 
baseline scenario.  Health policy makers should consider he marked benefits brought by more 
patients receiving PD when develop relevant health policies.  
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Figure 8-22.  DM-ESRD Prevalent Case Count, Scenario #3 Compared to Baseline 
 
Figure 8-23.  Cost, Accumulated and Per Year, Scenario #3 Compared to Baseline 
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Figure 8-24.  Person Year Lived, Accumulated, Scenario #3 Compared to Baseline 
 
8.2.4 Scenario #4 – No DM Incident Patients from Year 2006 to 2025 
 In the baseline scenario, the DM-ESRD incident case count is driven by the number of 
patients living with diabetes which is affected by the diabetes incident cases fed into the model 
as input.   In scenario #4, we set up the experiment in a way so that there are no new diabetes 
cases coming into the model between Jan 1st, 2006 and Dec 31st, 2025.  This can also be seen as 
an extreme case in which diabetes mellitus has been entirely prevented since Jan 1st, 2006.  This 
should cut down a large portion of new DM-ESRD patients because there are no new DM 
patients who would develop ESRD as complication from Jan 1st, 2006 onwards.  Of course, the 
patients who developed DM prior to that date could still develop ESRD as complications.  While 
being extreme in its design, Scenario #4 aids understanding the impact of reducing DM incident 
cases on the outcomes in future years.  As shown in Figure 8-25, the ESRD prevalent case count 
in scenario #4 does not begin to decline until year 2019, which is 13 years after diabetes 
incidence has ceased.   Similar trends were also observed in the plots for cost and person years 
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lived in Figure 8-26 and Figure 8-27.  Even in the extreme case depicted in scenario #4, where 
the DM incident case are cut down to zero at the beginning of year 2006 – and where tremendous 
inertia remains in the system – for many years after that, the resource demands associated with 
caring for the existing patients remain at an elevated level and continue at rise. 
Figure 8-25.  DM-ESRD Prevalent Case Count, Scenario #4 Compared with Baseline 
 
Figure 8-26.  Cost, Accumulated and Per Year, Scenario #4 Compared to Baseline 
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Figure 8-27.  Person Year Lived, Accumulated, Scenario #4 Compared to Baseline 
 
8.2.5 Scenario #5 – Reduce Mortality Hazards by Half for Dialysis and Transplant Patients 
 In scenario #5, the mortality hazards for HD, PD and transplant patients are all reduced to 
half of their original values.  As expected, both the prevalent case count (Figure 8-28) and person 
years lived (Figure 8-30) in scenario #5 were much higher than in the baseline scenario due to 
lower mortality rates.  As patients live and receive ESRD treatments over a longer period, both 
the cost per year and the accumulated cost rise significantly higher, as shown in Figure 8-27.  
This is the situation when the mortality risk was lower but the treatment plan remains the same 
(i.e. similar distribution are chosen among HD, PD and Transplant).  On the other hand, in 
scenario #1, the prevalent case count and the person years lived was as high as in scenario #5, 
due to the lower mortality for transplant patients in the former scenario.  However, astonishing 
differences between scenario #1 and scenario #5 are found in cost. The cost in scenario #1 is less 
than in baseline; whereas the cost is more in scenario #5 than in the baseline.  At the end of year 
2025, the per year cost in scenario #1 is only about half of the cost in scenario #5, given the fact 
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that the prevalence case count in scenarios#1 is even higher than in scenario #5 as shown in 
Figure 8-31 .  When both person years lived and cost are under consideration, the benefits of 
choosing a more cost-effective treatment are very clear.  
 
Figure 8-28.  DM-ESRD Prevalent Case Count, Scenario #5 Compared to Baseline 
 
 
Figure 8-29.  Cost, Accumulated and Per Year, Scenario #5 Compared to Baseline 
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Figure 8-30.  Person Year Lived, Accumulated, Scenario #5 Comparing with Baseline 
 
 
Figure 8-31.  DM-ESRD Prevalent Case count, Scenario #5 compared to Scenario #1 
 
8.2.6 Scenario #6 – Zero Graft Failure Rate 
 In Scenario #6, the graft failure rate in the model is set to zero, which means that 
transplant patients in the model will not experience failure of their transplanted kidney.  The 
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graft failure rates used in the baseline are calculated by us based on some assumptions, the 
details of which can be found in Section 5.4.  Eliminating the graft failure process in the model 
will help us understand how much impact the graft failure rate imposes on outcomes of the 
model.   In Figure 8-32, the count of transplant patients living with a functional transplanted 
kidney graft exhibits elevated levels compared to the baseline after graft failure is set to zero.  
This is as expected because patients won’t experience a graft failure and the number of patients 
living with a functional graft will therefore be higher.  However, the impact of having zero graft 
failure on the central model outcomes is minimal, as shown in Figure 8-33, Figure 8-34 and 
Figure 8-35.  This could be due to fact the transplant patients only comprise a small portion of all 
DM-ESRD patients.  Thus, a small increase in the number of transplant prevalent patients does 
not affect the central outcome of the model very much.  
 
Figure 8-32.  Transplant Prevalent Case Count in Scenario #6 
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Figure 8-33.  DM-ESRD Prevalent Case Count, Scenario #6 Compared to Baseline 
 
 
Figure 8-34.  Cost, Accumulated and Per Year, Scenario #6 Compared to Baseline 
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Figure 8-35.  Person Year Lived, Accumulated and Per Year, Scenario #6 Compared to 
Baseline 
 
8.2.7 Scenario #7 – Shorter Transplant Assessment Time as 90 days, Transplant Rate 
Remain the Same as Baseline Scenario 
 The purpose of scenario #7 is to investigate the impact of assessment time on the overall 
outcome of the model.   In this scenario, it takes 90 days for a patient to complete eligibility 
assessment no matter in which year the assessment was conducted.  By contrast, in the baseline 
scenario, the assessment time is a calibrated parameter which varies for each individual, and with 
its value dependent in the year the assessment was conducted.  The details on the calibrated 
parameter assessment time can be found in Chapter 6.3.  As shown in Figure 8-36, Figure 8-37 
and Figure 8-38, the differences in prevalent case count, cost and person years lived between 
scenario #7 and baseline is not evident.   The reason for not having noteworthy impact by 
varying assessment time is due to the small portion taken by transplant patients among all the 
DM-ESRD patients.   Also, with a shorter assessment time, a larger fraction of patients who was 
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originally in the assessment process will be put on waiting list quicker.  With a longer waiting 
list, it will take longer for patients to receive transplants than before.  Moreover, with the 
unchanged transplant rates and shorter assessment time, patients will die on the transplant 
waiting list rather than during assessment phase.  Thus, the impact of having a shorter 
assessment is proved to be limited on the overall wait time and the receipt of the transplant.  In 
other words, the number of organs available for transplantation rather than assessment time is the 
most important determining factor in the model outcome. 
 
Figure 8-36.  DM-ESRD Prevalent Case Count, Scenario #7 Compared to Baseline 
 
 
Figure 8-37.  Cost, Accumulated and Per Year, Scenario #7 Compared to Baseline 
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Figure 8-38.  Person Year Lived, Accumulated, Scenario #7 Compared to Baseline 
 
8.2.8 Scenario #8 – Regular Assessment Time, Eliminating Transplant Waiting list by 
Increased Transplant Rates 
 In scenario #8, the rates of living donor transplant have been increased dramatically 
comparing to what is in the baseline.  In the baseline scenario, there are fewer than five cases of 
living donor transplants per year, and less than 10 case of deceased donor transplant a year, as 
listed in Table 5-6. By contrast, in scenario #8, there the resources are assumed to be in place to 
allow for up to 365 cases of living donor transplant and 365 deceased donor transplants in a year 
if patients complete the assessment and are placed on the waiting list.  Since the transplant rates 
are set to be so high in scenario #8, in fact there are essentially no patients on the waiting list.  
Despite these dramatic differences in the resources available for transplantation, differences are 
hardly noticeable when comparing the prevalent case count and the person years lived outcome 
in scenario #8 with baseline.  One possible explanation for not seeing a significant increase in the 
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prevalent case count and person years lived despite the increased rates of transplant is due to a 
lengthy assessment process.  When the assessment process took over two years and even longer, 
many patients died while still receiving dialysis.  And even though the transplant rate in Scenario 
#8 is set high enough to essentially eliminate the waiting list, there is simply not that many 
patients ready to be transplanted because the demand (the flow of patients completing the 
assessment process) is far lower than the supply (the in flow of available kidneys).   Since 
patients remain dialyzed while being assessed, the prevalent case count and the person years 
lived was not elevated strongly.  By contrast, the total cost dropped some because per treatment 
cost difference between dialysis and transplant is significant.   Thus with even a small portion of 
patients getting transplant instead of dialysis, the difference in cost is still considerable.   
 
Figure 8-39.  DM-ESRD Prevalent Case Count, Scenario #8 Compared to Baseline 
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Figure 8-40.  Cost, Accumulated and Per Year, Scenario #8 Compared to Baseline 
 
 
Figure 8-41.  Person Year Lived, Accumulated, Scenario #8 Compared to Baseline 
 
8.2.9 Scenario #9 –Shorter Transplant Assessment Time as 90 days, and Eliminate Waiting 
List by Increased Transplant Rates 
 Scenario #9 can be seen as the combination of scenario #7 and #8.  In this experiment, it 
only takes 90 days for patients to complete the assessment process for transplant.   Also, the 
transplant rates are set to have 365 cases of living donor transplant and 365 case of deceased 
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donor in a year, which basically eliminates the waiting list for transplants.   As shown in Figure 
8-42 and Figure 8-44, the differences in prevalent case count and person years lived between 
baseline and scenario #9 is not evident.  Yet the cost has declined further, which could be due to 
patients remaining on dialysis for shorter time and getting transplanted quicker.  Since the 
transplant cost much less than HD, the difference in cost is clear. 
 
Figure 8-42.  DM-ESRD Prevalent Case Count, Scenario #9 Compared to Baseline 
 
 
Figure 8-43.  Cost, Accumulated and Per Year, Scenario #9 Compared to Baseline 
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Figure 8-44.  Person Year Lived, Accumulated, Scenario #9 Compared to Baseline 
 
8.3 Results and Limitation  
 One goal of this thesis is to project the incident and prevalent case count of DM-ESRD 
patients in Saskatchewan and estimate cost for caring those patients through 2025.  In addition, 
because of the high and rapidly rising burden of both DM and DM-ESRD among First Nations 
peoples [18,0], we want to know the prevalent case count, cost and person year lived broken 
down by First Nations status. 
 In section 8.1, while validating the model result with historical data, we presented a series 
of model output for all DM-ESRD patients rather than groups stratified by ethnicity.  Those 
outputs include the incident case count and prevalent case counts for all DM-ERSD patients in 
Saskatchewan, and respective incident and prevalent case counts for patients receiving different 
ESRD modalities.  To be more specific, the output shown in section 8.1 includes the following: 
incident case count ( Figure 8 -1), the prevalent case count (Figure 8-2), the incident case count 
of DM-ESRD patient receiving HD (Figure 8-3), the prevalent case count of DM-ESRD patients 
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receiving HD( Figure 8-4), the incident case count of DM-ESRD patients receiving PD (Figure 
8-5), the prevalent case count of DM-ESRD receiving PD (Figure 8-6), the incident of DM-
ESRD patient receiving kidney transplant ( Figure 8-7), and the prevalent case count of 
transplanted DM-ESRD patients (Figure 8-8).  The output for individual ethnic group is 
presented and discussed next. 
 Due to space limits, only a few of the important ethnicity-specific outputs – such as 
prevalent case count, cost and person years lived –are presented in this thesis.  Figure 8-45  
shows the prevalent case count for First Nation (FN), Other Saskatchewan people (OSK), and all 
Saskatchewan patients (both FN and OSK).  The median of prevalent case count were taken 
among all 30 realizations of the baseline. For both FN and OSK, the prevalent case counts are 75 
in year 1990, 231 in year 2000, 611.5 in year 2012 and 1228.5 in year 2025.  At the same points 
of time, the prevalent case count for FN are 14.5 in year 1990, 62 in year 2000, 176 in year 2012 
and 342 in year 2025.  As observed in Figure 8-45 and confirmed by the prevalent case count 
listed above, the prevalent case count for all Saskatchewan DM-ESRD patients and those in the 
FN subgroup has doubled or even tripled every ten years over the projection period.  Also, by 
comparing the prevalent case count for FN with the count for all DM-ESRD patients, it is found 
that FN patients constituted 19% of all patients in year 1990 among all Saskatchewan DM-ESRD 
patients, and increased to 27% in year 2025.  This finding is to be considered in light of the fact 
that less than 12% of Saskatchewan population are registered as First Nations in year 20063.   .   
The model output confirms the finding that the DM-ESRD as a disease affected FN 
disproportionally comparing to their OSK counterpart as stated in the DM-ESRD paper [19]. 
                                                
3In the year 2006 census, only 12% of people in Saskatchewan are North American Indians 
[28].  Since the definition of North American Indian includes more people than the definition of 
First Nations people, it follows that less than 12% of Saskatchewan population hold First Nations 
status 
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Figure 8-45 DM-ESRD Prevalent Case Count by Ethnicity 
 
 The cost per year for caring for all DM-ESRD patients in Saskatchewan (both FN and 
OSK), and the ethnicity-specific cost of FN and OSK are shown in   Figure 8-46.  The median of 
the cost from 30 realizations of the baseline scenarios are taken at four time points.  The absolute 
cost (i.e. cost not yet converted into discounted present value) for delivering services (delineated 
in Chapter 5.6 to all DM-ESRD patients in Saskatchewan is $4,311,953 in year 1990, 
$15,613,408 in year 2000, $44,576,879 in year 2012, and $89,789,222.  When the absolute cost 
values get converted into the year 2008 Canadian dollar values, the costs associated with 
delivering services to all DM-ESRD patients in Saskatchewan are $7,399,341 in year 1990, 
$19,848,532 in year 2000, $39,536,145 in year 2012, and $53,918,031 in year 2025.  The trend 
in cost per year is similar to the trend found in the prevalent case count because the cost is driven 
by the number of DM-ESRD patients alive, which is the prevalent case count.  For First Nations 
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patients, the cost is $896,629.6 in year 1990, $4,237,449 in year 2000, $12,932,595 in year 2012 
and $25,318,310 in year 2025.   
 The accumulated cost since Jan 1st, 1980 up to each successive year for caring for DM-
ESRD patients and patients in the FN and OSK sub-groups are shown in Figure 8-47.  The 
accumulated cost in absolute term for all DM-ESRD patients in Saskatchewan is $24,183,503 by 
year 1990, $125,742,414 by year 2000, $476,280,951 by year 2012 and $1,352,471,113 by year 
2025.  The above costs are presented in 2008 Canadian dollars as $46,646,935 in year 1990, 
$190,852,390 in year 2000, $549,213,219 in year 2012 and $1,163,473,213 in year 2025.  When 
the cost is broken down for First Nations patients, the cost in absolute form is $4,490,945 in year 
1990, $30,166,558 in year 2000, $128,020,907 in year 2012 and $382,802,510 in year 2025. 
 
Figure 8-46 Cost Per Year by Ethnicity 
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Figure 8-47 Accumulated Cost by Ethnicity  
 
 The accumulated person year lived is shown in Figure 8-48 and for all DM-ESRD 
patients (both FN and OSK), FN patients and OSK patients.   Since the model start, the 
accumulated number of person years lived for all DM-ESRD patients in Saskatchewan are 364 
by year 1990, 1818 by year 2000, 6622 by year 2012 and 18179 by year 2025.  For First Nations 
DM-ESRD patients, the person years lived at corresponding time points are as follows: 66 by 
year 1990, 410 by year 2000, 1759 by year 2012, and 5161 by year 2025.   
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Figure 8-48.  Person Years Lived Accumulated by Ethnicity 
 
 In summary, the prevalent case count, cost and person years lived for the DM-ESRD 
patients in Saskatchewan have continued to rise through the projection years.  Bigger increases 
were seen in the first 20 years prior to year 2000, yet for the later years, the numbers keep 
increasing at slower rates.   Also, the model reported the shocking amount of money required for 
caring for a small group of patients through the projection periods.  For instance, for the set of 
cost items considered in this thesis, it will cost about $54 million dollars (in 2008 dollar values) 
to care for 1229 DM-ESRD patients in Saskatchewan in year 2025. Also, the model findings 
confirmed that First Nations patients will continue to be affected by the DM-ESRD diseases 
disproportionally compared with other Saskatchewan residents. 
8.4 Limitations 
 The results presented in Section 8.3 should be viewed in light of the limitations 
associated with the model structures and the input parameters. First of all, currently in the model, 
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DM incident patients can either die before developing ESRD or developing ESRD. In reality, 
another possible destination yet missing from the model structure is “end of coverage”.  Thus, 
those patients who might end their coverage in reality in the model would be treated as either 
dying without ESRD or developing ESRD, which might result in a slightly more DM-ESRD 
incident patients in the model than would obtain in reality.  Secondly, the model selects 
transplant candidates only based on their age (and a randomly selected age-related factor), 
whereas in reality the patients were selected based on their health condition and suitability for 
transplant.  Without such algorithms in the model, the patients getting transplanted in the model 
might die quicker or slower than the well selected candidates.  The current design for 
determining suitability of transplant based on age is unlikely to have a noticeable impact on the 
outcome from the baseline scenario, as the number of transplant is low and there are many 
patients waiting to be transplanted.  However, in alternative scenario where more patients could 
receive transplant, the selection criteria could make a bigger difference in terms of patient’s 
survival time and other considerations.  In addition to the limitations with model structures, 
misestimates of the input parameters used in the model might affect the model results. 
 When viewing the cost output from the model, it is important to keep in mind that cost 
data input were taken from a research study based on services and costs obtaining in Calgary 
rather than in Saskatchewan, and there might be considerable differences for managing DM-
ESRD patients between those two provinces.  Also, as discussed earlier, the Cox Proportional 
Hazards model used in the model for dialysis patients was conducted on patients from 1999 to 
2008, and we adjusted the values for different time periods by an added calendar covariate.  
Especially for later years in the projection period, the approximation we made with the calendar 
adjustment covariate might diverge from reality, which is likely to impose unrealistically higher 
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or lower mortality rates used in the model for dialysis patients.  Moreover, we used a scaling 
factor for scaling the Saskatoon Diabetes Population to the Saskatchewan Diabetes Population 
starting in year 2006, which is one simple number refined for sub-population groups.  This is 
likely to be significantly off; for example, the proportion of First Nations people in the Saskatoon 
Health Region might be different than the proportion of First Nations people in the province.  
Also, the same scaling ratio used for 2006 were used for all the years between 2006 and 2025.  
This is another oversimplified approximation because it is likely the scaling ratio will change 
over a 20 year’s period, especially given the slowly rising urbanization of the population.  Also, 
many rates (e.g. the selection between HD and PD as initial treatment, the transplant rates) used 
for projection are based on the last several years in which the values are known, and those rates 
remain invariant throughout the projection period.  It is highly likely that those rates in the future 
would be different than in the last several years where we do have data. 
 The model output is generated with the limitations in the model structure and data input 
as discussed above.  Although in Section 8.1 the model output was validated against history data 
successfully, it is important to know that the limitations exists and that model output especially 
in the later years of the projection period should to be viewed with those limitations in mind.  To 
improve model results in the future, refined model structure should be worked on, and more data 
from recent years should be entered into the model.  
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CHAPTER 9  
CONCLUSION 
 This chapter first provides a summary of the development of the Saskatchewan DM-
ESRD model, the results of sensitivity analysis, and the projection made by the model.  We then 
turn to discuss the contribution made by this thesis research.  Finally, areas of future work are 
identified.   
9.1 Summary of Thesis Research  
 Our diabetes study [18] reported that from 1980 to 2005, diabetes prevalence in 
Saskatchewan is rising at an alarming rate, which would inevitably affect the DM-ESERD 
situation in the provinces for many years down the road.  This research helped motivate us to 
develop an agent based model for studying the DM-ESRD situation in Saskatchewan and to use 
the model for projecting the prevalent case count of DM-ESRD patients and associated cost for 
caring for those patients for up to year 2025.  
 Diabetes patients enter the model when they are diagnosed with diabetes and leave the 
model upon their death.  During a simulated diabetic’s life in the model, there are three important 
process represented, including progression of Diabetes to ESRD, ESRD treatment options, and 
the process involving transplant assessment and occupying the waiting list.  The part of the 
model which handles Diabetes to ESRD progress is adopted from a previously built agent based 
model on the basis of competing risk analysis research on the Saskatchewan Diabetic population 
between year 1980 and 2005 [37].  Based on hazards derived from the competing risk analysis, 
Diabetes patients will either die prior to ESRD or develop ESRD.  The ESRD treatment options 
are available to patients developing ESRD as a complication.  After developing ESRD, patients 
start with either HD or PD.  Also, for those patients who undergo kidney transplants, the model 
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used three stages to classify the time post kidney transplant because of the significant cost 
differences among those time periods.  The transplant assessment and waiting list process in the 
model determines a patient’s suitability for transplant, and places eligible patients on the 
transplant waiting list.  Patients then receive transplants based on their priorities on the waiting 
list. 
 The model simulates lives of the diabetic population in Saskatchewan between Jan 1st, 
1980 and Dec 31st, 2025.  Prior to the start of model simulation, diabetic patients who are alive 
and who have not yet developed ESRD (referred as “the year 1980 DM Prevalent patients”) and 
those who are alive and who have developed DM-ESRD (referred as “the year 1980 DM-ESRD 
prevalent patients”) are both loaded into the model as the initial model population.  After the 
simulation begins on Jan 1st, 1980, patients enter the model at the time they receive diabetes 
diagnosis. The diabetes incident patients between 1980 and 2005 were obtained from the 
Saskatchewan Administrative database.  Between 2006 and 2025, the diabetes incident patients 
were projected by the Saskatoon Diabetes Model [36] and adjusted by a scaling ratio for the 
province as a whole.   
 The essential model transitions are parameterized with rates based on historical data from 
reliable data sources. The deaths of patients receiving HD, PD and Transplant were based on a 
Cox Proportional Hazards model provided by a data request fulfilled by CIHI.  The itemized cost 
data is from a published study carried out in Calgary [34].   The graft failure rates were from the 
year 2012 CORR annual report.  The hazard of switching between HD and PD treatment were 
calculated based on the dialysis treatment data between 2006 and 2010 provided by Dr. Kappel 
of the Saskatchewan Renal Program. The rates of living and deceased donor transplant for DM-
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ESRD patients in Saskatchewan were calculated based on data from a data request fulfilled by 
CIHI and the data on “2007 – 2008 Highlights” published by the Saskatchewan Renal Program.   
 For some transitions where there is limited historical data available, parameters were set 
through calibrations.  Most of the calibrated rates were for the transplant assessment and waiting 
list process, including rates of withdrawing from the waiting list, the rates associated with 
assessing the eligibility for transplant, and the duration of the assessment.  Moreover, in 
recognition of the shortcomings of the Cox Proportional Hazards model used for calculating the 
mortality risks for dialysis patients, we added a missing and yet important covariate – the 
calendar year period.  We calibrated the value of added covariate for the Cox Proportional 
Hazards model.  
 The model output includes both high level statistics collected on model population, and 
the detailed longitudinal records of an individual patient’s activities in the model. The high level 
statistics were saved into flat data files and can be visualized in graphs created by an R script.  
The high level statistics were used for model validation and sensitivity analysis. The detailed 
records of individuals were saved to a MySQL database specially created for the thesis research, 
which allows investigators to trace the activities of an individual throughout their lifetime in the 
model. 
 To validate the correctness of the model, a number of model outputs were selected for 
comparison with the corresponding historical data.  The model output chosen for model 
validation include the prevalent and incident case count for all DM-ESRD patients, the prevalent 
and incident case count for patients on each ESRD treatment modalities (HD, PD, and 
Transplant), and the mean age of patients initiating HD/PD/Transplant, head count on the 
waiting list and the median days spent on dialysis prior to transplant.  All the model output 
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except the transplant prevalent case count aligns well with the historical data, which suggesting 
that the model captures well relevant processes and is likely to be correctly implemented. 
 To understand the sensitivity of model outputs in response to changes in certain 
parameters and assumptions, a few scenarios were set up.  Critical model outputs were selected 
for making comparisons between the base line scenario and the alternative scenario used for 
sensitivity; such outputs included prevalent case count, cost, and person years lived.  We make a 
few remarks here on some results.  The results suggest that the prevalent case count is not 
sensitive to changes made to graft failure rates (scenario #6), assessment time (scenario #7) and 
even the rates of transplant (scenario #8). The reason is likely to be the small portion of all DM-
ESRD patients occupied by transplant patients.  However, the model prevalent case count is 
sensitive to changes in mortality rates (scenario #5) and selection of treatment modalities 
(scenario #1, #2 and #3), which could be explained with the changes affected by HD in the 
model.  Since HD patients form the majority of DM-ESRD patients, any changes affecting this 
group will be reflected clearly in the overall prevalent case count and cost.  Other than being 
used for sensitivity analysis, results from those scenarios can further be used for lending insights 
regarding the potential impact of broad policy changes.  For instance, scenario #1 allows all 
patients receiving pre-emptive transplant (shedding light on the impact of changing the 
availability of pre-emptive transplants) where scenario #5 reduced the mortality risks in half for 
all patients (giving a sense of many changes likely to result from advances in treatment 
technologies and clinical practice).  Both scenarios increased prevalent case counts and person 
years lived by approximately the same amount.  However, astonishing differences between 
scenario #1 and scenario #5 are found in cost. The cost in scenario #1 is less than in the baseline 
scenario; whereas the cost is more in scenario #5 than in the baseline.  At the end of year 2025, 
 
 
146 
the per year cost in scenario #1 is only about half of the cost in scenario #5.  The results can 
suggest to policy maker which policy could bring more cost effective results.  Also, as in the 
extreme case depicted in scenario #4, where the DM incident cases are reduced to zero at the 
beginning of year 2006 for many years after that, the resource demands associated with caring 
for the existing patients remain at an elevated level and continue at rise.  This result suggests the 
tremendous inertia present in the system, which places limits on the short-term gains that can be 
anticipated even through even the most extreme advances in the prevention of diabetes. 
 Finally, as seen in the baseline projections were made by the model, the prevalent case 
count, cost and person years lived by DM-ESRD patients in Saskatchewan have continued at rise 
throughout the entire projection period.  Bigger increases were seen in the first 20 years prior to 
year 2000, yet for later years, the numbers remain increasing at slower rates.   Also, the model 
reported the shocking amount of money required for caring a small group of patients through the 
projection periods.  For instance, for the set of cost items considered in this thesis, it will cost 
about $54 million dollars (in 2008 dollar values) to care for 1229 DM-ESRD patients in 
Saskatchewan in year 2025. Also, the model findings confirmed that First Nations patients can 
be anticipated to continue to be affected by the DM-ESRD diseases disproportionally compared 
to other Saskatchewan residents. 
9.2 Contributions  
 The thesis research made contributions in two primary areas.  Firstly, the calculation of 
the DM and DM-ESRD prevalent and incident rates contributed (via joint work) to DM and DM-
ESRD research in Saskatchewan featured in three publications [18, 0, 40].  Secondly – and most 
importantly – the development Saskatchewan DM-ESRD model made its own contributions in 
the fields, which will be discussed in great detail in section 9.2.2. 
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9.2.1 Contributions in DM and DM-ESRD Research 
 Using diabetes and ESRD data supplied to our research team by the Saskatchewan 
Ministry of Health and the covered population data collected from the Saskatchewan Ministry of 
Health web site [26], I calculated the standardized prevalence and incidence rates for diabetes 
and diabetic-ESRD in the province of Saskatchewan between 1980 and 2005.  The details of the 
calculation of diabetes and diabetic-ESRD rates are found in Appendix B.  The calculation of 
those rates contributed to the diabetes and DM-ESRD research led by Drs. Dyck and Osgood.  
The DM-ESRD research [20] identified disparities among all the sub-population groups stratified 
by ethnicity, gender and age when experiencing Diabetes and DM-ESRD.  Those findings in 
diabetes [18] and diabetic-ESRD research [19] provided not only the motivations for us to 
develop the Agent Based model presented here to further study the DM-ESRD situations in 
Saskatchewan, but also a concrete base of empirical data for grounding the SK diabetic – ESRD 
model.   
9.2.2 Contributions through the Development of the SK DM-ESRD Model  
 Our model was developed specifically to study DM-ESRD.  Other Canadian projections 
focus on prevalence and cost for diabetes and all its major complications.  Among all diabetes 
related complications, Cardiovascular disease (CVD) complications takes the largest proportion 
in cost, which therefore has been studied the most.  Diabetic CKD and ESRD, which is less 
common compared to CVD, has been addressed in many studies but not in as great detail as 
CVD complications.  Our study recognized that while even fewer diabetics have developed 
ESRD, the cost per capita is the highest of all diabetes complications due to the costly nature of 
renal replacement therapy.  Moreover, supporting ESRD patients requires capital infrastructure – 
in the form of dialysis clinics – whose construction requires planning years before that 
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infrastructure is commissioned.  Therefore, our model was developed to project the prevalence 
and cost for all DM-ESRD patients in Saskatchewan and the prevalent and incident count for 
patients receiving each renal replacement treatment, which can provide valuable information for 
resource planning.  
 In addition to having a more specific focus, our model can offer more refined projections 
of incident and prevalent cases of DM-ESRD than have past projections.  Other Canadian 
research only projects diabetes prevalence on refined age groups but not on other diabetes risk 
factors, and assumes a flat incidence rate of diabetes complications in its projection years [8].   A 
Manitoba study [20] projected diabetes prevalence by age group, by status Indian and gender, 
and by age group and Indian status, but not by all three together; it also projected new persons 
with diabetes on Dialysis by registered Indian status.  Our projected diabetic-ESRD prevalence is 
broken down by age, gender and ethnicity/Indian Status.  Those three factors have been 
demonstrated in previous research [20] as important risk factors for diabetes.  Our most critical 
model inputs are broken down by age, gender and ethnicity: the DM and DM-ESRD prevalent 
cases at 1980 loaded into the model as the initial population, the yearly diabetes incident cases, 
the competing risk analysis for diabetes patients to develop ESRD or die, the Cox Proportional 
Hazards for DM-ESRD patients receiving the three renal replacement modalities (HD, PD and 
kidney transplant). 
 Another advantage with our model is the quality of the data used. The critical data input 
for our model came from published research studies conducted in Saskatchewan as well as data 
requests filled by CIHI, which administrates the national database for organ transplants and end 
stage renal disease in Canada.  Information such as age, sex, ethnicity, age of getting diabetes 
diagnosis for each individual in the model population came from the Saskatchewan Health 
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Administrative database.  The competing risks analysis of developing ESRD or death without 
ESRD for diabetes patients in Saskatchewan conducted in a previous study [37] were based on 
data from the Saskatchewan Health Administrative database as well.  The mortality hazard 
function used for patients receiving renal replacement treatment modalities were provided by 
CIHI using 1999 -2008 data.  The itemised cost information was taken from published research 
conducted using cost information from Calgary.  Both the transplant rates and the possibility of 
receiving one type of dialysis were provided by CIHI data request.    
 Through insightful design, careful implementation of the model, making use data from 
the reliable data authorities and incorporation of relevant research studies, we were aiming to 
build a model correctly representing the DM-ESRD situation in Saskatchewan.  The model 
output which measures different underlying processing within the model haven been extensively 
validated against historical data from multiple sources including over 25 years longitudinal data.    
 Most importantly, the current model has demonstrated the capacity for straightforward 
integration with other Anylogic models such as the model of competing risk analysis for diabetes 
patients [37].  Our model also used the diabetes incident cases projected by the Saskatoon 
Diabetes Model, which is a System Dynamics model.  Though the current interaction between 
the Saskatoon Diabetes Model (System Dynamics model) and our Saskatchewan DM-ESRD 
model (Agent Based Model) is currently merely undertaken by data feed files, Anylogic does 
have the capacity to adopt a System Dynamics Model into its environment and allow the 
incorporation between the two types of models.  While adoption of the Saskatoon Diabetes 
Model using Anylogic is out of scope of this thesis, it is among one of the avenues for future 
work discussed below.   
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 Moreover, given the availability of the model presented here in AnyLogic, the 
Saskatchewan Gestational Diabetes Mellitus (GDM) model – another agent based Anylogic 
model developed based on the findings in the GDM research [31] – can be readily integrated 
with the Saskatchewan DM-ESRD model.  The GDM model captures fact that babies of diabetic 
mothers have a higher risk of developing diabetes during their lifetime, and is used to study the 
impact of GDM on diabetes situation in Saskatchewan.  In conclusion, the Saskatchewan DM-
ESRD Model, the Saskatoon DM Model, and the Saskatchewan GDM model, each focusing 
different aspects of the diabetes research, can all be incorporated together to form a larger and 
richer models for studying diabetes and ESRD as its complications. 
 Most of the previous modelling work following a mathematical modeling approach 
offered a less intuitive interface for policy makers to view and work with the model. Our model 
is built with Anylogic software, which offers an animated presentation layer for people to 
understand structures of the system, and provides tools to help policy makers to try out different 
policies in more effortless way.   
 Other than the benefits offered by using the Anylogic software, our Saskatchewan DM-
ESRD model is equipped with a database which can record demographics information, treatment 
histories, waitlist, assessment and cost data for every patient in the model population.  The 
database allows tracing activities and events relevant to DM and DM-ESRD for each individual, 
so that more analysis can be carried out during simulation time and after simulation ends.  A 
more detailed calibration and validation can be achieved using longitudinal data collected in the 
model (e.g. waiting list time).  Moreover, the capacity to collect such information permits 
treatment choice or design in the model to be based the individual's medical histories retrieved 
from the database. 
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 In addition to a database for saving data at individual level, the Saskatchewan DM-ESRD 
model also saves aggregated data regarding the model population into flat data files.  An R script 
is developed to automatically retrieve the data from those flat files and present data into graphic 
format for interpretations and comparison. 
 In summary, when compared to similar research work, our research is distinguished in 
choosing agent based modeling to study the research question, the sound data used for making 
the projection, and a more detailed projection resulted from the careful design of the model.  To 
the best of our knowledge, our model is the first agent based model being applied to project the 
prevalence and cost of diabetic – ESRD in Saskatchewan, and likely in Canada as well.  The 
ability to project the detailed treatments of Aboriginal population also sets our research apart 
from other research work.  In addition, the data used in our model is from sound research 
conducted in Saskatchewan [18,0] and using Saskatchewan statistics as well as the national 
database for organ replacements CORR.  Our model produces a refined projection of the 
prevalence and cost for sub-population groups which are broken down by critical population 
characteristics such as age, sex and ethnicity. Based on the benefits mentioned above, we believe 
our model offers a substantial contribution to the field.     
9.3 Future Work 
 A few improvements have been identified in model structures and model input data 
sources through the development of the Saskatchewan DM-ESRD model, yet fall outside the 
scope of this thesis due to time or other consideration.  The areas that merit additional work in 
the future are laid out in detail below. 
 More work is required in the transplant assessment and waiting list process as the current 
representation in the model is an over-simplified version of reality.  First of all, an algorithm for 
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evaluating patient’s suitability for kidney transplant based on their health conditions should be 
developed.  The type of medical examinations required as part of the transplant assessment and 
the length of time for completing those examinations require additional investigation.  The result 
of the medical examinations will likely to be used as input parameters in the algorithm for 
determining patient’s suitability for transplant. The length of time required to complete those 
examinations will affect the time spent on dialysis prior to transplant, which is the combined 
time of time spent on assessment and time spent on waiting list.  Secondly, an algorithm for 
determining a patient’s priority on the transplant waiting list should be developed. Currently, the 
priority is randomly generated without basing it on a patient’s characteristics.  In reality, there is 
a complex algorithm for determining patient’s priority, which should be replicated in the model 
(although likely with some stochastic components).  Moreover, additional investigation is 
required regarding the process of placing patients on the waiting list on hold due to temporary 
health condition which made them unsuitable for transplant.  Currently in the model, the 
structure for the “On Hold” and “Active” status on waiting list is implemented but disabled; 
moving forward, the rates for switching patients’ “On Hold” and “Active” status should be found 
and supplied to the model.  Lastly, further research should be conducted with regards to 
withdrawing patients from the waiting list.  Currently, the rate of withdrawing patients from 
waiting list is calibrated through simulations instead of coming from historical data. 
 In addition, the “end of coverage” rates among Diabetes incident patients should be 
researched.  Currently, only patients who have developed Diabetes prior to Jan 1st, 1980 (also 
referred as the 1980 DM Prevalent Cases) could end their health coverage in the model, but not 
the diabetes incident patients. The diabetes incident patients in the model currently have two 
options, including death before developing ESRD or develop ESRD as complication, without the 
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possibility to end their health care coverage, which is the missing third option.  Although the 
number of patients who should have ended their coverage in reality and received ESRD 
diagnosis in the model is likely to be very small, improvement are advised in future versions of 
the model. 
 Lastly, improvement should be made on regarding integration with the Saskatoon 
Diabetes Model. There are two areas that should be improved, including the scaling ratio used 
and the mechanism of receiving input from the Saskatoon Diabetes Model.  The Saskatoon 
Diabetes Model projects the diabetes case count from 2006 to 2025 for the Saskatoon Health 
Region.  To scale up the projection for Saskatoon to Saskatchewan, a simple ratio is used in our 
model.  More research should be carried to either modify the Saskatoon Diabetes Model to 
project for the Saskatchewan Diabetes situation or further refine the ratio used in the DM-ESRD 
model so that the projection is more accurate for the sub-population groups and for later years of 
the projection period.  
 In addition to future improvements made to the model structures and data, more thought 
should be given to the application of the model in policy evaluation.  One possible direction 
could be using the model to evaluate combinations of policies which could impact several 
processes in the model at once – potentially identifying policy synergies where “the whole is 
greater than the sum of the parts”.  An example might be combination of policies focusing on 
upstream issues paired with downstream issues.  The metrics or measurement of the 
effectiveness of the policy could include – but is not limited to – the ratio of saving on resources 
over the investment required for implementation and execution of those policy combinations.  To 
make the model a practical application in the real world, we would expect more thorough 
research and lots of collaborations with practitioners in the field. 
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APPENDIX A 
STATISTICS COLLECTED ON MODEL POPULATION DURING 
SIMULATIONS 
 Statistics were collected on the model population during simulations for the purpose of 
model validation, sensitivity analysis and projections.  In the tables below, those statistics were 
categorized by the process to which they are related. In each table within this section, each 
statistic was described, both in terms of what they are and what model elements were involved 
for collecting and processing them.  The statistics were saved in a comma delimited file for 
future analysis.  In most of the cases, the output statistics were saved with metadata given the 
year it was collected for and identified by the simulation run from which statistics were collected. 
 
Table A-1.  Statistics Related to DM 
Statistics  and Output File Name  Model Elements 
Per-year count of DM Patients who 
died before developing ESRD per year 
DeathB4ESRD.csv 
In the Main class, the number of DM patients who 
died prior to developing ESRD is kept in the variable 
named “deathB4ESRDYearlyCount”.  The entry 
action handler of the state named 
“DeathBeforeESRD” is established so that each time 
a patient enters the state, the variable 
“deathB4ESRDYearlyCount” will get incremented 
by 1.  At the end of each year, the value of variable 
“deathB4ESRDYearlyCount” and the value of the 
current year will be saved to the data set named 
“deathB4ESRDIncidenceDS”.  The values in the data 
set “deathB4ESRDIncidenceDS” will be saved to the 
file named “DeathB4ESRD.csv” at the end of the 
simulation.	  
The person years lived for overall 
model population per year since model 
start time 
PersonYearLived_DM_Yealy.csv 
 
 
 
 
 
The cumulative person years lived for 
the entire model population collected 
The person years lived for the model population 
in a year are accumulated by counting the person 
days lived for the model population for each day 
within the year.  At the end of every day, the person 
days lived for the model population is collected by 
counting the number of people alive in the model at 
that moment.  We assume each of those patients who 
is alive at the end of the day has already lived a full 
day.  This is an approximation, as with this 
assumption, patients who enter the model for only 
half a day will be counted as living in the model for a 
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between the model start time and the end 
of each year.  
PersonYearLived_DM_RunTotal.csv 
full day. Patients who die in the middle of the day 
will not be counted.  In the model, the number of 
DM patients alive was counted by a population 
statistics “DMPatientsAlive”.  In the event 
“personDaysLivedUpdate”, at end of end of every 
day, the count from “DMPatientsAlive” was 
converted from days into years, and was added to a 
variable “runTotalDMPersonYearLived” which 
keeps track of the running total of years lived by all 
DM patients in the model since the model start time. 
At each year end, in the function named 
“updateResultSetYearEnd”, the “person year lived” 
recorded in the variable 
“runTotalDMPersonDayLived” will be saved into 
two data sets “yearlyDMPersonYearDS” and 
“runTotalDMPersonYearDS”.  When the simulation 
ends, the year and value pair in data set 
“yearlyDMPersonYearDS” will be written to file 
named “PersonYearLived_DM_Yealy.csv” and the 
data set “runTotalDMPersonYearDS” will be written 
to file named 
“PersonYearLived_DM_RunTotal.csv”.	  
Table A-2.  Statistics related to DM to ESRD progression 
Statistics  and Output File Name Model Elements 
The number of new patients diagnosed 
with ESRD in a year. 
ESRDIncident.csv 
The variable named “ESRDIncidentCount” in 
the Main class is used to keep track of the new 
patients receiving ESRD diagnosis in a year.  The 
value of the variable “ESRDIncidenceCount” 
should be equal to the sum of the count of patients 
who have initiated  HD, PD and Pre-Emptive 
Transplant. The variable “ESRDIncidenceCount” 
gets incremented in the “ESRD” state each time a 
patient enters the state.  The value of variable 
“ESRDIncidentCount” and the value of the 
current year get saved to the dataset named 
“ESRDIncidenceDS”. At the end of a simulation, 
values in data set “ESRDIncidenceDS” will be 
written to a file named “ESRDIncident.csv”.  	  
The number of patients living with 
ESRD (Prevalent Cases) at each year’s end.  
The total number of patients receiving ESRD 
treatments at the end of Dec 31 of every year was 
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DMESRDPrevalent.csv  collected by adding up the count of patients 
receiving HD, PD and Transplant, kept track by 
the population statistics “CountHD”, “CountPD”, 
and “CountTransplant”, respectively.  The count 
of patients receiving ESRD treatments at each 
year’s end together with the value of the year are 
saved in to the data set named 
“ESRDPrevalentDS”.  At the end of a simulation, 
the values in the data set “ESRDPrevalentDS” 
will be written to the file named 
“DMESRDPrevalent.csv”.	  
The number of DM-ESRD patients who 
died in a year. 
DeathDMESRDPerYear.csv 
The variable named 
“deathDMESRDPerYearCount” in the Main class 
is used to keep track of the number of deaths per 
year for DM-ESRD patients.  In the state named 
“DeathAfterESRD”, the variable 
“deathDMESRDPerYearCount” gets incremented 
each time when a DM-ESRD patient dies.  At the 
end of each year, the value of variable 
“deathDMESRDPerYearCount” and the value of 
the current year will get saved to the data set 
named “deathDMESRDPerYearDS”.  At the end 
of the simulation, the values from data set 
“deathDMESRDPerYearDS” will be written to 
the file named “DeathDMESRDPerYear.csv”.	  
The person years lived for DM-ESRD 
patients per year since the model start time 
PersonYearLived_DMERSD_Yealy.csv 
The accumulated person years lived for 
DM-ESRD patients at year end since the 
model start time 
PersonYearLived_DMESRD_RunTotal.c
sv 
The person years lived was collected for DM-
ESRD patients in a similar fashion to the person 
years lived for all DM patients.  In the model, the 
number of DM-ESRD patients alive at the end of 
every day was counted by population statistic 
“DMESRDPatientsAlive”.  At of the end of every 
day, the event “personDaysLivedUpdate” is 
triggered. This event first converts the count by  
the statistic “DMESRDPatientsAlive” from 
“person days lived” to “person years lived”, and 
adds the result to the variable named 
“runTotalESRDPersonYearLived”, which keeps 
track of the running total of years lived by the 
DM-ESRD patients in the model since the model 
start time.   At the end of each year, in the 
function named “updateResultSetYearEnd”, the 
“personday lived” recorded in the variable 
“runTotalESRDPersonYearLived” gets saved into 
two data sets “yearlyESRDPersonYearDS” and 
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“runTotalESRDPersonYearDS”.  When a 
simulation ends, the year and value pair in the 
data set “yearlESRDPersonYearDS” is written to 
the file named 
“PersonYearLived_DMERSD_Yealy.csv”, and 
the data set “runTotalESRDPersonYearDS” is 
written to the file named 
“PersonYearLived_DMESRD_RunTotal.csv”.	  
The cost for caring for DM-ESRD 
patients in Saskatchewan for a year 
SKYearlyTotalCost.csv 
The accumulated cost for caring DM-
ESRD patients in Saskatchewan at year’s 
end. SKRunningTotalCost.csv 
The cost varied for patients receiving different 
ESRD treatments.  The cost for caring all DM-
ESRD patients per day was calculated by adding 
up the cost for caring HD, PD and transplant 
patients each day.  The per day cost of caring for 
patients on a given ESRD treatment is computed 
by multiplying the number of patients receiving 
that treatment by the average daily, per-patient 
cost of running the treatment .  In the model, the 
number of patients on each treatment was 
collected at the end of each day by querying  the 
population statistics ”CountHD”,  “CountPD”,  
“CountLDKTTXFirst90Days”, 
“CountLDKTTX91DaysToOneYear”, 
“CountLDKTFunctionalTX”, 
“CountDDKTTXFirst90Days”, 
“CountDDKTTX91DaysToOneYear”, and 
“CountDDKTFunctionalTX”.   The cost for a 
kidney transplant operation is considered as one 
time cost rather than the everyday cost so it is 
excluded from the per day cost for caring for 
transplant patients; the operation cost is added to 
total cost at the time an operation takes place.  
The total cost exerted for a given day for caring 
DM-ESRD patients are accumulated on a daily 
basis into per year cost, which gets saved into the 
data set “yearlyCostDS” at the time of a year end.  
The running total cost for caring all DM-ESRD 
patients throughout the model simulation period is 
saved into the “runTotalDMESRDCostDS” data 
set..  At the end of the simulation, the year and 
cost value pair in the “yearlyCostDS” data set will 
be written to file named 
“SKYearlyTotalCost.csv”; the values in the 
“runTotalDMESRDCostDS” data set will get 
written to file named “SKRunningTotalCost.csv”.	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Table A-3.  Statistics for Patients Receiving HD 
Statistics  and Output File Name Model Elements 
Count of new HD patients in a 
year who have never received any 
ESRD treatment before.  
HD_Initial.csv 
 
The “HDIncidenceCountInitial” variable in the main 
object is used to keep track of the number of new 
patients who start HD as initial ESRD treatment.  In the 
entry action of the “Hemodialysis” state, this variable 
gets incremented only when the patients have HD as 
their initial ESRD treatment and they are not among 
those year 1980 DM-ESRD Patients who started on HD 
at model start time.  The value of variable 
“HDIncidenceCountInitial” and the current year value 
will be saved together into the data set named 
“HDIncidenceInitialDS” at each year end.  The data set 
“HDIncidenceInitialDS” will be written to 
“HD_Initial.csv” at the end of the simulation.	  
Count of patients who begin HD 
treatment in a year.  Patients starting 
HD treatments could be returned from 
failed transplant, or be switching from 
PD treatments.  
HD_Activity.csv 
 
The “HDIncidenceCountActivity” variable in the 
Main object is used to keep track of the number of 
patients who began HD treatment.  In the entry action 
handler of the “Hemodialysis” state, this variable gets 
incremented as soon as patients begin HD.  The value of 
variable “HDIncidenceCountActivity” and the current 
year value will be saved together into the data set named 
“HDIncidenceActivityDS” at each year end.  The data 
set “HDIncidenceActivityDS” will be written to 
“HD_Activity.csv” at the end of the simulation.	  
Count of Patients who are 
receiving HD treatment at the end of 
each year (prevalent case count) 
HDPrevalent.csv 
The population statistics “CountHD” is used to keep 
track of the number of patients who are receiving HD 
treatment in the model.  At the end of each year, the 
value of “CountHD” and the value of the year were 
saved together into the “HDPrevalentDS” data set.   At 
the end of the simulation, the values in 
“HDPrevalentDS” will be written to a file named 
“HDPrevalent.csv”.	  
 
The yearly number of patients who 
died while receiving HD treatments in 
a year.  
DeathHDPerYear.csv 
 
The variable named “deathHDPerYearCount” is used 
for keeping track of the death of HD patients in a year.  
In the transition named “dialysisToDeathTrans”, the 
variable “deathHDPerYearCount” gets 
incrementedwhen patients receiving HD treatment die.  
At the end of each year, the value of variable 
“deathHDPerYearCount” and the value of the current 
year will be saved as a pair into the data set named 
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“deathHDPerYearDS”; the value of 
deathHDPerYearCount is then reset to 0.  At the end of 
the simulation, the values in the data set 
“deathHDPerYearDS” will be written to the file named 
“DeathHDPerYear.csv”.	  
 Average age of Patients who start 
dialysis HD as initial treatment in the 
year 
- AvgAgeInitialHD.csv  
In the transition “receivePD” of the DiabeticESRD 
statechart, the age of patients entering the transition 
would be added to a statistics object named 
“ageInitialPDStats” in the Main Class.  At each year 
end, the mean is collected from all the ages in the 
“ageInitialHDStats” object, which gets the average age 
of the patients who initiated HD treatment in that year.  
And the resulting average age will be added to the 
“ageAvgInitialHDDS” data set with the value of the 
year.  At the end of the simulation, the year and mean 
age value pair will be written from the 
“ageAvgInitialHDDS” data set to a file named 
“AvgAgeInitialHD.csv”.  	  
The median of days lived from the 
start of HD treatment to death among 
people who have died in the current 
year and within the last four years. 
DaysLivedToDeathHD.csv 
The vector named 
“HDdayslivedPriorToDeathVector” in main class is 
used to collect the number of days lived during HD 
treatment for each HD patients died in a year.   At the 
end of the year, the vector 
“HDdayslivedPriorToDeathVector” and the value of the 
current year are added to the hash table named  
“HDdayslivedPriorToDeathHT”, and the median 
number of days lived among those HD patients who died 
within last five years are calculated by a function 
“getMedianDayslastNYear” (Note,  the median can be 
calculated from data from many more years.  The 
parameter “nYearBack” of function 
“getMedianDayslastNYear” is for setting the number of 
years to which the median calculation should go back. ).   
The median of days lived by HD patients was then 
added to a data set named 
“HDdayslivedPriorToDeathDS”.  At the end of the 
simulation, the values in the 
“HDdayslivedPriorToDeathDS” data set will be written 
to the file named “DaysLivedToDeathHD.csv”.  	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Table A-4.  Statistics for Patients Receiving PD 
Statistics  and Output File 
Name 
Model Elements 
Count of new PD patients in a 
year who have never received any 
ESRD treatment before.  
PD_Initial.csv 
The “PDIncidenceCountInitial” variable in the main 
object is used to keep track of the number of new patients 
who start PD as initial ESRD treatment.  In the entry 
action handler of the “Peritonealdialysis” state, this 
variable gets incremented only when the patients have PD 
as their initial ESRD treatments and when they are not 
among those year 1980 DM-ESRD patients who started 
on PD at the model start time.  The value of variable 
“PDIncidenceCountInitial” with the current year will be 
saved together into the data set named 
“PDIncidenceInitialDS” at each year end.  The data set 
“PDIncidenceInitialDS” will be written to 
“PD_Initial.csv” at the end of the simulation.	  
Count of patients who begin PD 
treatment in a year.  Patients starting 
PD treatments could be returned 
from failed transplant, or switching 
from HD treatment.  
PD_Activity.csv 
 
The “PDIncidenceCountActivity” variable in the main 
object is used to keep track of the number of patients who 
began PD treatment.  In the entry action of the 
“Peritonealdialysis” state, this variable gets incremented 
only as soon as patients began HD.  The value of variable 
“PDIncidenceCountActivity” and the current year will be 
saved together into the data set named 
“PDIncidenceActivityDS” at each year end.  The data set 
“PDIncidenceActivityDS” will be written to 
“PD_Activity.csv” at the end of the simulation.	  
Count of patients who are 
receiving PD treatment on Dec 31 of 
each year (prevalent case count) 
PDPrevalent.csv 
 
The population statistics “CountPD” is used to keep 
track of the number of patients who are receiving PD 
treatment in the model.  At the end of each year, the value 
of “CountPD” and the year were saved together into the 
“PDPrevalentDS” data set.   At the end of the simulation, 
the values in “PDPrevalentDS” will be written to a file 
named “PDPrevalent.csv”.	  
 
Average age of patients who start 
PD as initial treatment in a year. 
AvgAgeInitialPD.csv 
In the handler for the transition “receiveHD” of the 
DiabeticESRD statechart, the age of patients entering the 
transition is added to a statistics object named 
“ageInitialPDStats” of the Main Class.  At each year end, 
the mean is collected from all ages that have been added 
to the “ageInitialHDStats” object, thereby computing the 
average age of the patients initialized PD treatment in that 
year.  And the resulted averagewill be added to the 
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“ageAvgInitialPDDS” data set with the value of the year.  
At the end of the simulation, the year and mean age value 
pair will be written from the “ageAvgInitialPDDS” data 
set to file named “AvgAgeInitialPD.csv”.  	  
 
The number of patients who died 
while receiving PD treatments in a 
year.  
DeathPDPerYear.csv 
 
The variable named “deathPDPerYearCount” is used 
for keeping track of the death of PD patients in a year.  In 
the transition named “dialysisToDeathTrans”, the variable 
“deathPDPerYearCount” gets updated when patients 
receiving PD treatment died.  At the end of each year, the 
value of variable “deathPDPerYearCount” and the value 
of the current year will be saved as a pair into the data set 
named “deathPDPerYearDS”.  At the end of the 
simulation, the values in the data set 
“deathPDPerYearDS” will be written to the file named 
“DeathPDPerYear.csv”.	  
The median of days lived from 
the starting of PD treatment to death 
among people who have died in the 
current year and within the last four 
years. 
DaysLivedToDeathPD.csv 
The vector named “PDdayslivedPriorToDeathVector” 
in main class is used to collect the number of days lived 
during PD treatment for each PD patient who has died 
within the current year.   At the end of the year, the vector 
“PDdayslivedPriorToDeathVector” and the value of the 
current year are added to the hash table named 
“PDdayslivedPriorToDeathHT”, and the median number 
of days lived among those PD patients died within last 
five years are calculated by a function 
“getMedianDayslastNYear” (Note,  the median can be 
calculated from data from many more years.  The 
parameter “nYearBack” of function 
“getMedianDayslastNYear” is for setting the time 
window over which the median calculation should be 
performed).   The median of days lived for PD patients 
was then added to a data set named 
“PDdayslivedPriorToDeathDS”.  At the end of the 
simulation, the values in the 
“PDdayslivedPriorToDeathDS” data set will be written to 
the file named “DaysLivedToDeathPD.csv”.  	  
Table A-5.  Statistics related to Patients Receiving HD or PD 
Statistics  and Output 
File Name 
Model Elements 
Count of deaths on 
Dialysis (HD or PD) in a 
The dataset named “deathDialysisPerYearDS” are used to 
keep track of the number of patients died while receiving dialysis 
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year. 
DeathDialysisPerYear.csv 
 
treatment (either HD or PD) in a year.  At the end of a 
simulation, the values in data set “deathDialysisPerYearDS” will 
be saved to the file named “DeathDialysisPerYear.csv”. 	  
Table A-6.  Output related to Patients Receiving Kidney Transplants 
Statistics  and Output File 
Name 
 Model Element 
The number of pre-emptive 
kidney transplants per year 
PreEmptKT.csv 
The variable named “PreEmptiveKTIncidentCount” in 
Main object is used for holding the count of the pre-emptive 
kidney transplant that have taken place in a year.  In the 
“PreEmptiveTx” transition, the variable 
“PreEmptiveKTIncidentCount” gets incremented each time a 
pre-emptive transplant gets performed.  At the end of a year, 
the value  of variable “PreEmptiveKTIncidentCount” and the 
value of the current year will get saved to a data set named 
“PreEmptiveKTIncidentDS”;the variable 
“PreEmptiveKTIncidentCount” is reset to 0.  At the end of 
the simulations, values in data set 
“PreEmptiveKTIncidentDS” will be written to a file named 
“PreEmptKT.csv”.	  
The yearly number of living 
donor kidney transplants that 
have taken place (incident case 
count).  The count only includes 
those living donor transplants for 
patients who were on dialysis 
prior to the transplant, and 
excludes pre-emptive transplant.	  
LDKT.csv	  
The variable named “LDKTIncidentCount” in Main Class 
is used to keep track of the cumulative number of living 
donor kidney transplant that have taken place in the current 
year.  In the handler for the transition “receiveTx” transition 
of the “AssessmentStages” statechart, the variable 
“LDKTIncidentCount” gets incremented each time there is a 
living donor kidney transplant performed.  The value of 
variable “LDKTIncidentCount” and the value of the current 
year will be saved to the data set named “LDKTIncidentDS”, 
and the variable LDKTIncidentCount is reset to 0.  At the 
end of the simulation, the values in data set 
“LDKTIncidentDS” will be written to a file named 
“LDKT.csv”.	  
The yearly number of 
deceased donor kidney 
transplants that have taken place 
(incident case count).  The count 
only includes those deceased 
donor transplants for patients 
who were on dialysis prior to the 
transplant, and excludes pre-
emptive transplant.	  
The variable named “DDKTIncidentCount” in Main Class 
is used to keep track of the cumulative number of living 
donor kidney transplants that have taken place in the current 
year.  In the transition “receiveTx” transition of the 
“AssessmentStages” statechart, the variable 
“DDKTIncidentCount” gets incremented each time there is a 
living donor kidney transplant performed.  The value of 
variable “DDKTIncidentCount” and the value of the current 
year will be saved to the data set named “DDKTIncidentDS”, 
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DDKT.csv and the variable DDKTIncidentCount is reset to 0.  At the 
end of the simulation, the values in data set 
“DDKTIncidentDS” will be written to a file named 
“DDKT.csv”.	  
Yearly count of transplants 
following dialysis (incident case 
count) 	  
KT.csv	  
The sum of the living donor and deceased donor kidney 
transplants taking place in each year will be saved to a data 
set named “KTIncidentDS”.  The values in “KTIncidentDS” 
will be written to a file named “KT.csv”.	  
Count of people living with 
functional transplant (prevalent 
case count) 	  
TransplantPrevalent.csv	  
The population statistic “CountTransplant” is used to keep 
track of the number of patients in the model who are living 
with functioningtransplanted kidney.  At the end of each 
year, the value of “CountTransplant” and the value of the 
year were saved together into the “TransplantPrevalentDS” 
data set.   At the end of the simulation, the values in 
“TransplantPrevalentDS” will be written to a file named 
“TransplantPrevalent.csv”.	  
 
Count of Graft Failures per 
year	  
GraftFailure.csv	  
The cumulative number of grafts that have failed in a year 
is recorded in a variable named “graftFailureCount” in the 
Main Class. In the transition named “reEnterDialysis”, this 
variable is incremented each time a graft has failed.  At the 
end of every year, the value of the variable 
“graftFailureCount” and the value of the current year will be 
saved to the data set named “GraftFailureIncidentDS”, and 
the variable graftFailureCount is reset to 0.  At the end of a 
simulation, the values in the data set 
“GraftFailureIncidentDS” will be written to a file named 
“GraftFailure.csv”.	  
The number of patients who 
have died while receiving HD 
treatments in a year. 	  
DeathTXPerYear.csv	  
The variable named “deathTXPerYearCount” in the Main 
class is for keeping track of the cumulative count of patients 
who have died with a functioning kidney transplant in the 
current year.  In the transition named 
“transplantToDeathTrans” in the “DiabetesESRD” statechart, 
the variable “deathTXPerYearCount” get incremented each 
time when patients with functional kidney transplants died.  
At the end of a year, the value of variable 
“deathTXPerYearCount” and the value of the current year 
will be saved to a data set named “deathTXPerYearDS”, and 
the variable deathTXPerYearCount is reset to 0.  At the end 
of a simulation, the values in the data set 
“deathTXPerYearDS” will be written to the file named 
“DeathTXPerYear.csv”	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The average age of patients 
when patients receive kidney 
transplant (first graft)	  
AvgAgeInitialTX.csv	  
 
In the “Transplant” state of the DiabetesESRD statechart, 
the age of patients who first received kidney transplant would 
be added to the statistic object named “ageInitialTXStats” in 
the Main Class.  At each year end, the mean is collected from 
all the ages that have been added to the “ageInitialTXStats” 
object, which will then be added to the 
“ageAvgInitialTXDS” data set with the corresponding year 
value. The “ageAvgInitialTXDS” statistic object will be reset 
after the mean was added to the “ageAvgInitialTXDS” data 
set.  At the end of the simulation, the values in the 
“ageAvgInitialTXDS” data set will be written to file 
“AvgAgeInitialTX.csv”.	  
The median of days lived 
counted from the day of the 
kidney transplant operation to 
the day of death among patients 
who have died in the current year 
and within the last four years.	  
DaysLivedToDeathTX.csv	  
The vector named “TXdayslivedPriorToDeathVector” in 
the Main class is used to collect the number of days lived 
following kidney transplant until death for each kidney 
transplant patients who has died in the current year.   At the 
end of the year, the vector 
“TXdayslivedPriorToDeathVector” and the valued of the 
current year are added to the hash table named  
“TXdayslivedPriorToDeathHT”, and the median number of 
days lived among those transplant patients died within last 
five years are calculated by a function 
“getMedianDayslastNYear” (Note,  the median can be 
calculated from data from many more years.  The parameter 
“nYearBack” of function “getMedianDayslastNYear” is for 
setting the size of the time window over which the median 
calculation should be performed).   The median of days lived 
by transplant patients was then added to a data set named 
“TXdayslivedPriorToDeathDS”.  At the end of the 
simulation, the values in the “TXdayslivedPriorToDeathDS” 
data set will be written to the file named 
“DaysLivedToDeathTX.csv”.  	  
Table A-7.  Output Collected on Assessment Process 
Statistics  and Output File Name Model Element 
Count of patients who weren’t sent for 
kidney assessment in a year. 
NotEligibleAssessment.csv 
The variable named “countNotEligibleForAx” in 
Main class is used to record the number of patients 
who are deemed not suitable for transplant 
assessment in a year.  In the transition named 
“notEligibleAssessmentTrans”, the variable 
“countNotEligibleForAx” gets incremented each 
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time a patient was not sent for transplant assessment.  
At end of a year, the value in variable 
“countNotEligibleForAx” and the value of the year 
will be saved to the data set named 
“countNotEligibleAxDS”, the value of which will be 
written the file named “NotEligibleAssessment.csv” 
at the end of the simulation.  The value of the 
variable countNotEligibleForAx is then reset to 0.	  
Count of patients who got sent for 
transplant assessment in a year. 
EligibleAssessment.csv 
The variable named “countEligibleForAx” in 
Main class is used to record the cumulative number 
of patients who deemed suitable and were sent for 
transplant assessment in the current year.  In the 
handler for the transition named 
“eligibleForAssessmentTrans”, the variable 
“countEligibleForAx” gets incremented each time a 
patient was sent for transplant assessment.  At end of 
a year, the value in variable “countEligibleForAx” 
and the value of the year will be saved to the data set 
named “countEligibleAxDS”, the value of which will 
be written the file named “EligibleAssessment.csv” 
at the end of the simulation.  The variable 
“countEligibleForAx” is then reset to 0.	  
End of year count of patients who 
remain in the assessment process as 
potential candidates for a living donor or 
deceased donor transplant. 
HeadCountAssessment.csv 
The total number of patients who remain in the 
assessment process at the end of the year are 
obtained by adding up the count collected by 
population statistics objects 
“HeadCountDDKTWorkup” and 
“HeadCountLDKTWorkup”.  The count and the 
value of the year are saved into the data set named 
“AssessmentHeadCountDS” at the end of the year  
The values in the data set 
“AssessmentHeadCountDS” will be written to the 
file named “HeadCountAssessment.csv” at the end 
of the simulation. 	  
The fraction of patients who passed 
the assessment and are deemed eligible 
for transplant. 
AssessmentPassRatio.csv 
The fraction is calculated by dividing the number 
of patients passed the assessment by the total number 
of patients who pass or failed the assessment in a 
year.  The variable named “countPassAX” is used for 
recording the number of patients who pass the 
assessment in a year.  This variable gets updated in 
the handler for the transition named 
“putOnTransplantWaitingListTrans.  The variable 
named “countFailAX” is for keeping track of the 
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number of patients who fail the assessment in a year 
and it gets updated in transition 
“failAssessmentTrans”.  The ratio for each year is 
saved to a data set named “AxPassRatioDS”, which 
will be written to the file named 
“AssessmentPassRatio.csv”.  Both of the variables 
“countPassAX” and “countFailAX”  are then reset to 
0.	  
The number of patients who have died 
during the transplant assessment process 
in a year. 
DeathDuringAX.csv 
The variable named “deathDuringAX” in Main 
class is used for keeping track of the number of 
patients died during assessment in a year.  In the 
handler for the transition named 
“AxOrWaitingToDeathTrans”, the variable 
“deathDuringAX” gets incremented when the patient 
was last in the “WorkUpStage” state prior to death.  
At the end of year, the value of the variable 
“deathDuringAX” and the value of the year get saved 
to the data set named “deathDuringAXDS”.  At the 
end of the simulation, the values in data set 
“deathDuringAXDS” will be written to a file named 
“DeathDuriingAX.csv”.  “deathDuringAX” is then 
reset to 0 at the end of the year.	  
Median Days spent on assessment for 
those patients who received transplant in 
this year and within the last two years.  
(Either living donor or deceased donor 
type). 
MedianDaysDDKTAXLast3Y.csv 
MedianDaysLDKTAXLast3Y.csv 
 
 
The vector named “LDKTDaysAXVector” is 
used to collect the number of days spent on 
assessment for each patient who has received a living 
donor transplant within the current.  At the end of a 
year, the contents of the vector 
“LDKTDaysAXVector” are added to the hash table 
“LDKTDaysAXHT”, and the function named 
“getMedianDayslastNYear” is called to calculate the 
median of the days spent on assessment among 
patients who got transplanted in the current year and 
in the last two years.  The median based on three 
year’s data are then added to the data set named 
“LDKTDaysAXDS”, the values of which got written 
to the file named 
“MedianDaysLDKTAXLast3Y.csv”.  The median of 
days spent on assessment for patients who received a 
deceased donor transplant was calculated in a similar 
fashion to that for patients received living donor 
transplant.  The median was written to the file named 
“MedianDaysDDKTAXLast3Y.csv”.	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Table A-8.  Output Related to Waiting List for Kidney Transplant 
Statistics    Model Element 
End of year head count for patients on 
the waiting list for a living donor kidney 
transplant. 
HeadCountOnLDKTWaitList.csv 
The population statistic named 
“HeadCountWaitingListLDKT” is used to 
calculate the number of patients who are waiting 
for a living donor transplant on the waiting list at 
the end of the year.  The count and value of the 
year are saved as a pair into the data set named 
“WaitListLDKTHeadCountDS” at the end of the 
year.  The values in 
“WaitListLDKTHeadCountDS” are written to the 
file named “HeadCountOnLDKTWaitList.csv” at 
the end of a simulation.	  
End of year head count for patients on 
the waiting list for a deceased donor kidney 
transplant 
HeadCountOnDDKTWaitList.csv 
 
The population statistic named 
“HeadCountWaitingListDDKT” is used to 
calculate the number of patients who are waiting 
for deceased donor transplant on the waiting list at 
the end of the year.  The count and value of the 
year are saved as a pair into the data set named 
“WaitListDDKTHeadCountDS” at the end of the 
year.  The values in 
“WaitListDDKTHeadCountDS” are written to the 
file named “HeadCountOnDDKTWaitList.csv” at 
the end of a simulation.	  
End of year head count for patients on 
the waiting list for either the living donor or 
deceased donor transplant. 
 
HeadCountOnWaitList.csv 
 
The total number of patients waiting for either a 
living donor transplant or a deceased donor 
transplant is saved into the data set named 
“WaitListHeadCountDS”.  At end of the 
simulation, the values in the data set 
“WaitListHeadCountDS” are written to the file 
named “HeadCountOnWaitList.csv”.	  
The yearly number of patients who died 
while on the waiting list. 
DeathOnWaitList.csv 
A variable named “deathOnWaitList” in the 
Main class is used to keep track of the cumulative 
number of patients who have died on the waiting 
list in the current year.  In the handler for the 
transition “AxOrWaitingToDeathTrans” of the 
“AssessmentStages” statechart, the variable 
“deathOnWaitList” is incremented if the patient 
was on the waiting list prior to death (i.e. if the 
patient was in state “AwaitingTx”).  The value of 
the variable “deathOnWaitList” and the value of 
the year will be saved to a data set named 
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“deathOnWaitListDS” at the end of each year.  
The variable “deathOnWaitList” is then set to 
0.The values in the data set “deathOnWaitListDS” 
will be written to the file named 
“DeathOnWaitList.csv” at the end of a simulation.  	  
The yearly number of patients who 
withdrew from the transplant waiting list.  
 
WithdrewWaitList.csv 
A variable named “countWithdrawWaitList” in 
the Main class is used to keep track of the number 
of patients who have withdrawn from the waitlist 
during a year.  At the end of a year, the value of 
“countWithdrawWaitList” and the value of the 
year will be saved into the data set named 
“withdrawWaitListDS”.  The value of 
“countWithdrawWaitList” is then set t 0.  At the 
end of the simulation, the values in data set 
“withdrawWaitListDS” will be written to the file 
named “WithdrewWaitList.csv”.  	  
Median Days spent on the transplant 
waiting list for those patients who received 
a transplant (with either living donor or 
deceased donor type) in this year and in the 
last two years.   
MedianDaysLDKTWaitListLast3Y.csv 
MedianDaysDDKTWaitListLast3Y.csv 
The median for days spent on transplant on the 
waiting list is calculated in a similar way as for 
median days spent on assessment. The model 
elements involved are the vector named 
“LDKTDaysWaitListVector”, the hash table 
named “LDKTDaysWaitListHT”  and the data set 
named “LDKTDaysWaitListDS”.  At the end of 
the simulation, the median days spent on waiting 
list are written to the file named 
“MedianDaysLDKTWaitListLast3Y.csv”.	  
 
The median for days spent on transplant waiting 
list is calculated in a similar way as for median 
days spent on assessment. The model elements 
involved are the vector named 
“DDKTDaysWaitListVector”, the hash table 
named “DDKTDaysWaitListHT” and the data set 
named “DDKTDaysWaitListDS”.  At the end of 
the simulation, the median days spent on waiting 
list are written to the file named 
“MedianDaysDDKTWaitListLast3Y.csv”. 
Table A-9.  Output Related to Waiting List and Assessment Process 
Statistics   Model Element 
Median number of days spent in The median for days spent on dialysis 
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assessment and on the wait list prior to 
getting transplant for those patients who 
received a transplant (either living donor or 
deceased donor type) in this year and the last 
two years.   
MedianDaysLDKTDialysisToTXLast3Y.csv 
MedianDaysLDKTDialysisToTXLast3Y.c
sv 
(assessment time + waiting list time) prior to 
getting living donor transplant is calculated in a 
similar way as is used for median days spent on 
assessment. The model elements involved for 
living donor type of transplant are the vector 
named “LDKTDaysDialysisToTXVector”, the 
hash table named 
“LDKTDaysDialysisToTXHT” and the data set 
named “LDKTDaysDialysisToTXDS”.  At the 
end of the simulation, the median days spent on 
waiting list are written to the file named 
“MedianDaysLDKTDialysisToTXLast3Y.csv”.	  
 
The median for days spent on dialysis 
(assessment time + waiting list time) prior to 
receiving a deceased donor transplant is 
calculated in the same way as for median days 
spent on assessment. The model elements 
involved for living donor type of transplant are 
the vector named 
“DDKTDaysDialysisToTXVector”, the hash 
table named “DDKTDaysDialysisToTXHT” and 
the data set named 
“DDKTDaysDialysisToTXDS”.  At the end of 
the simulation, the median days spent on waiting 
list are written to the file named 
“MedianDaysDDKTDialysisToTXLast3Y.csv”. 
 
The average days spent on assessment, 
waiting list and dialysis (assessment and 
waiting list) among all patients receiving 
transplant in the model (over entire 
simulation period).  
WaitAxAvgDays.csv 
The days spent on assessment/waitlist/dialysis 
by patients who are potential candidates for or 
who receive living donor transplant between 
1980 and 2025 are collected in the statistic 
objects named “LDKTAxTime”, 
“LDKTWaitTime”, and “LDKTDialysisTime”.  
For patients who are potential candidates for or 
who receive a deceased donor transplant, the 
relevant statistics objects are “DDKTAxTime”, 
“DDKTWaitTime”, and “DDKTDialysisTime”.   
The means were taken from those statistics 
object and got written to the file named 
“WaitAxAvgDays.csv” by the function named 
“writeMeanWaitToFile”.	  
 
174 
 
APPENDIX B 
CALCULATION OF AGE SPECIFIC AND AGE STANDARDIZED 
PREVALENCE AND INCIDENCE RATES FOR DIABETES AND DIABETIC-
ESRD RESEARCH 
 In the following sections, all information related to the calculation of diabetes incidence 
rates are included: the data sources, preparation of the data, and formula used for calculating the 
incidence and prevalence rates for diabetes and diabetic-ESRD. 
B.1 Data Preparation - Covered Population Data 
 Covered Population data was used as the denominators in the calculation of prevalence 
and incidence rates for diabetes and DM-ESRD.   The covered population data, published yearly 
by Saskatchewan Health, is a count of all persons who held Saskatchewan Government Health 
Coverage on June 30th of that year.  This count excludes members of Canadian Armed Force, 
RCMP, and inmates of federal prisons.  It does not include people who do not meet the residency 
requirement (Health coverage begins on the first day of the third calendar month since the date 
they move to Saskatchewan).  (For more information on methodology and the content of the 
covered population data, please visit the following link: http://www.health.gov.sk.ca/covered-
population2007/NoticetoReaders2007.htm 
For our research purposes, we want to calculate separated rates for Registered Indian (RI) and 
other Saskatchewan Residents (OSK).  The covered population data files were obtained from the 
Saskatchewan Ministry of Health and reformatted to meet our need.  RI is defined as “a person 
who registered under Section 6 of The Indian Act and has been assigned a ten digit number in the 
Indian Registry” [26].    In the covered population data files, RI can be identified by a five digit 
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residence code starting with ‘7’.  OSK are people who are covered under Saskatchewan Health 
Insurance but do not fell into the definition of RI.  The majority of OSK are Caucasian.  A very 
small proportion of OSK are visible minorities, who are Chinese, South Asian, Black and 
Filipino [28].  Most importantly, OSK include people of Aboriginal heritage who cannot be 
classified as RI, such as Métis people.  
 For year 1990 to 2007, 1987, 1986, and 1981, the covered population data are available 
for both RI and OSK.  For RI, the head count is broken down by regional health authority (RHA), 
5 years age group (except for younger than 5 or older than 94) and sex.  For OSK, the head count 
is broken down by residence code, 5 years age group (except for younger than 5 or older than 94) 
and sex.  We are not interested in the head count subdivided by RHA or residence code as 
provided in the original data file.  We want to get the total head count by 5 years group, sex, and 
ethnicity (RI/OSK) in a particular year.  To meet our research needs, I aggregated the head count 
from all the residence codes for OSK by each 5 year age group and sex, and I aggregated the 
head count from all RHA in the case of RI for each 5 year age group and sex.  In the original 
data, there wasn’t an age group for age 0-4, but there were two age groups age < 1 and age 1-4.  I 
combined the head count of those two age groups into one total head count for age group 0-4, 
which is the youngest age group in our study. 
 For year 1988-1989, 1982 – 1985 and 1980, the covered population data files for each 
year are not available on the Saskatchewan Health Ministry of Health website.  We obtained the 
data for those years from Health Information Solution Center, Saskatchewan Ministry of Health 
in Regina.  The head counts are broken down by residence code, 5 year age group (except for 
younger than 5 or older than 94) and sex, but not broken down by RI and OSK.   To place those 
year’s data into the same format as above years (e.g. 1990 and after), the first step is to get the 
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total head counts and the RI head counts.  For a particular year, the total head count for each 5 
year age group and sex is obtained by summing up the head counts from every residence code in 
the file.  The RI head counts for each 5 year age group is then obtained by summing  up the head 
counts for any residence code starting with ‘7’ and followed by another 4 digits.  To get the head 
counts for OSK, the head counts for RI is subtracted from the corresponding total head counts.  
Similar work is done as for the youngest age group in 1990 and after.  To get the head counts for 
age group 0-4 for a particular year, I sum the head counts from the under 1  year age group to 
that for the 1-4 age group. 
 After the above work is completed for each set of years in turn, we have got the head 
counts for RI Male, RI Female, OSK Male and OSK Female broken down by 5 year age group 
and each year between 1980 and 2007.  The result is in a file named as 
“cleaned_covered_population.xls”.  Thus, the covered population data has been reformatted for 
our research need and is ready to be used in the calculating the rates of diabetes incidence and 
prevalence. 
B.2 Other Data Sources  
 Annual Frequency of Incident Diabetes and Prevalent Diabetes.  To calculate the 
diabetes rates, we will use the above reformatted covered population data in the denominators.  
We also need annual frequency of incident diabetes and prevalence information, which is 
obtained from the Saskatchewan Ministry of Health.  The annual frequency of incident diabetes 
and prevalent diabetes are stratified by 5 year age group for age 0-79 (and one group for age 
80+), sex, RI status and each year from 1980 to 2005. 
 Annual Frequency of Incident Diabetic-ESRD and Prevalent Diabetic-ESRD.  To 
calculate the diabetic-ESRD rates, we will need the Annual Frequency of Prevalent Diabetes.  In 
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addition, we also need the Annual Frequency of Incident Diabetic-ESRD and Prevalent Diabetic-
ESRD.  The format of the incident and prevalent diabetic-ESRD are the same as same 
information for diabetes.  The data are stratified by 5 year age group for age 0-79 (and one group 
for age 80+), sex, RI status and each year from 1980 to 2005. 
B.3 Age Specific Diabetic Incidence and Prevalence Rates  
 Formula for Age Specific Diabetes Incidence Rate 
 The formula used for calculating age (a), sex (s) and ethnicity (e) specific diabetes 
incidence for a given year (y) is as follows: 
!"#$%&%'  !"#$%&"#&!"#$ = Cases  of  Incident  Diabetes!"#$Covered  Population!"#$ −   Cases  of  Prevalent  Diabetes!"#$ 
 
Note:  the cases of prevalent diabetes don’t include the diabetes incident cases of that year.  
Therefore, the denominator above will yield the number of people who are at risk of developing 
diabetes for a particular year 
 Formula for Age Specific Diabetes Prevalence Rates 
 The formula used for calculating diabetes prevalence is as follows: 
!"#$%&%'  !"#$%&#'(#!"#$ = Cases  of  Prevalent  Diabetes!"#$Annual  Covered  Population!"#$ 
 
 The following specifications define the time frame and specific populations for which the 
diabetic incidence and prevalence rates are calculated. 
o Annual Diabetes Incidence and Prevalence Rate from year 1980 to 2005.  
The rates are stratified by four factors:  Each year from 1980 to 2005, RI 
status (RI or OSK), sex (Male or Female) and age groups.   The population are 
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broken down by the method as follow: From age 20 to 64, it was broken down 
into 5 years groups (i.e. 0-4 or 40-44); from age 65 to 74, there is one 10 year 
age group; and for year 75 and plus, there is one group. 
 
B.4 Age Specific Diabetic-ESRD Incidence and Prevalence Rates  
 Note, in the following sections, sometimes we use ESRD to refer to Diabetic-ESRD. 
 Formula for Age Specific Diabetic-ESRD Incidence 
!"#$  !"#$%&"#&!"#$ = !"#$#  !"  !"#$%&"'  !"#$!"#$!"#$#  !"  !"#$%&#!"  !"#$%&%'!"#$ − !"#$#  !"  !"#$%&#'(  !"#$!"#$   
 
Note: Someone who is an incident case of diabetes and ESRD in the same year won’t be 
included in the denominator here.  Therefore, the ESRD incidence calculated could be 
overestimated (bigger than its real number).   
 
 Formula for Age Specific Diabetic-ESRD Prevalence 
!"#$  !"#$%&#'(#!"#$ = !""#$%  !"#$%#&'(  !"  !"#$%&#'(  !"#$!"#$!""#$%  !"#$%#&'(  !!  !"#$%&#'(  !"#$%&%'!"#$   
 The following specifications specify the time frame and specific populations for which 
the diabetic-ESRD rates are calculated for. 
o Annual Diabetic-ESRD Incidence and Prevalence Rate from year 1980 to 
2005.  The time frame is each year from 1980 to 2005.  The rates are also 
stratified by RI status (RI/OSK), sex (Male/Female) and different age groups.   
The age of subjects is from age 0 to 80+ and it has been broken down into 
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three groups: children and youth (Age 0-19), adults (20-80+) and all age 
groups combined (0 – 80+; also known as the crude rate).   
o Three or Five Year Average Diabetic-ESRD Incidence and Prevalence 
Rates.  There are three versions of diabetic-ESRD prevalence rates calculated, 
and each one is prepared for the studied population stratified by a different 
group of factors.  The three group factors are explained as follows: 
§ Stratifying factor group #1: Five-year-length time period, age 
group, RI status and sex.  For the time period, we excluded the first 
year in our study and broke down the remainder of the 25 years from 
1981 to 2005 into 5 five- year-length periods: 1981 - 1985, 1986 - 
1990, 1991 - 1995, 1996 - 2000, and 2001 to 2005.  In addition to the 
time period, the studied population is broken down into six age groups 
as follows:  Children and Youth (Age 0-19), Young Adults (Age 20-
39), Middle Age Adults (Age 40-59), Elders (Age 60+), all Adults 
(Age 20+), and Older Adults (Age 40+).  The studied population is 
also broken down by RI status, which has two values: RI or non-RI 
(also known as OSK).  Last, the studied population is broken down by 
sex. 
§ Stratifying factor group #2: Five-year-length time period, age 
group and RI status.   There are three same stratifying factors in 
group #2 as in group #1: five-year-length time period, age group and 
RI status.  The definitions are exactly the same for those three factors.  
The difference is that sex is not included in the second group of 
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stratifying factors.  Therefore, the rates defined by factor group #1 are 
sex specific, whereas the rates specified by factor group #2 are sex-
combined rates. 
§ Stratifying factor group #3: Five or three-year-length time period, 
age group, RI status and sex.   The rates defined by factor group #3 
are later to be age-standardized, and the definitions for time period and 
age group are different than what was used for factor group #1 and #2.  
The five - year - length time periods were used in group #1 and #2, 
because we have concern on the limited number of ESRD cases in a 
shorter time frame.  However, we believed that after 1990s, the 
number of ESRD cases in three year time windows would still give us 
a sufficient number of cases to perform calculations.  Therefore, for 
the time period, we divided the total 25 years into 7 groups as follows:  
1981 – 1985, 1986 – 1990, 1991 – 1993, 1994 – 1996, 1997 - 1999, 
2000 - 2002 and 2003 - 2005. For age groups, we decided not to 
calculate rates for the younger than 20 age group because there are 
hardly any ESRD cases in that age range.  The older than 20 study 
populations are broken down into five age groups as follows: 20-39, 
40-49, 50-59, 60-74, and 75+.  In addition to time period and age 
groups specified above, the populations are further broken down by RI 
status (RI or OSK) and sex. 
§ Stratifying factor group #4: Five or three-year-length time period, 
age group and RI status.   The definitions of the sharing factors are 
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the same for group # 3 and #4.   The difference is that sex is absent 
from the factors breaking down the study population.  Therefore, the 
rates defined using group #4 are sex-combined rates. 
B5. Age Standardized Diabetes Incidence and Prevalence Rates 
B5-1 Introduction to Age standardization 
 Age can be a very important risk factor which confounds comparisons made on the 
findings of a health condition among population groups with different age distributions.   Age 
standardization is a way of controlling the confounding effects of age, and allows fairer 
comparisons to be made among different population groups.  In short, age standardization takes 
away the distortion of different age structures among groups from the research results, thereby 
allowing us to compare rates across different points in time or different populations.   Our 
research involves the comparison of the prevalence and incidence rates for diabetes and diabetic-
ESRD among four sex and ethnicity divided subgroups (RI Female, RI Male, OSK Female and 
OSK Male).   Since age is a confounding factor in both diabetes and diabetic-ESRD, we want to 
age-standardize the prevalence and incidence rates for those two diseases for each of these 
subgroups in turns.  Generally, there are two steps taken to age-standardize rates [29].  The first 
step is to choose a standard population which should be widely used in related studies so that 
comparisons can be draw.  The second step is to apply the age specific rates (the ones to be age 
standardized) to the proportion of the people in that age group within the standard population.  
Given a population with pa people in each age category, and with age-specific rates (Wa) to be 
age-standardized, the equation below is used for age standardization.  In essence, this is a 
weighted sum of the prevalence within each age group in turn, with the weighting given by the 
proportion of the standardized population that lies within this age group.   
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B5-2. Age standardization of Diabetes Prevalence and Incidence Rates 
 We age standardized the diabetes prevalence and incidence rate s by following  the two 
steps introduced in the section above.  First of all, we choose a standard population.  We decided 
to use the 1991 Canadian census tables for standardizing prevalence and incidence rates of 
diabetes and diabetic-ESRD, because it was widely used for age standardization of rates in the 
health studies led by most of the Canadian agencies like Statistics Canada, the Public Health 
Agency of Canada and Canadian Diabetes Associations.  The 1991 Canadian census table was 
derived from an e-stat  Statistics Canada Table called "1991, 2A Profile, Provinces and 
Territories in Canada".  The population count was broken down by sex, provinces/territories, and 
age groups.  We are only interested in the head counts for Canada but not at the 
provinces/territories level, so the population counts from provinces and territories have been 
aggregated into a total for Canada for each sex and age group.  The 1991 census age group was 
broken down as follows: from age 0 to 64, it was broken down into 5 years groups (i.e. 0-4 or 
40-44); from age 65 to 74, there is one 10 year age group; and for year 75 and plus, there is one 
group. 
 The second step is to standardize the age specific prevalence and incidence rates against 
the 1991 census.  We decide to ignore the 0 to 19 age group because the diabetes cases for those 
under 20 years old is very small.  Also, there is nearly zero ESRD case in less than 20 year old 
age group.   The standardization is being conducted by following the procedures as listed below:  
1. For a given RI status and sex, multiply the age specific diabetes prevalence or 
incidence rates of each age group (RI status and sex stratified) by the fraction of 
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people of that RI status and sex who are in the corresponding age group in the 1991 
census.  Add up the products obtained by procedure 1 into a total. 
2. This is the age standardized diabetes prevalence or incidence rates. 
 Using the procedures illustrated above, the following rates have been the result of the age 
standardization: 
• Age standardized diabetes incidence rates by sex and RI status, age group, and each 
year from 1980 to 2005. 
• Age standardized diabetes incidence rates by RI status (sex combined), age group and 
each year from 1980 to 2005. 
• Age standardized diabetes prevalence rates by sex and RI status, age group, and each 
year from 1980 to 2005. 
• Age standardized diabetes prevalence rates by RI status (sex combined), age group, 
and each year from 1980 to 2005. 
B5-3 Age standardization of ESRD Prevalence and Incidence Rates 
 Similar steps are taken to standardize the diabetic-ESRD prevalence and incidence rates.  
As noted above, the 1991 Canadian census is chosen as standard population because it was 
widely used as standard population in other literatures.  The following diabetic-ESRD rates have 
been the result of age standardization: 
• Age standardized diabetic-ESRD incidence rates by sex and RI status, age groups, and 
five/three year length time period. 
• Age standardized diabetic-ESRD incidence rates by RI status (sex combined), age 
groups, and five/three year length time periods. 
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• Age standardized diabetic-ESRD prevalence rates by sex and RI status, age groups, 
and five/three year length time periods. 
• Age standardized diabetic-ESRD prevalence rates by RI status (sex combined), age 
groups, and five/three year length time periods. 
 Note #1: The way in which the age group were  broken down was used method #2 as 
illustrated in earlier sections. 
 Note #2:  The definition of “The five/three year time period” can be found in the earlier 
section under the title Stratifying factor group #3.
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APPENDIX C 
PROGRAM CODE FOR GENERATING DAYS REQUIRED FOR 
ASSESSMENT 
 Figure C-1 shows that the pseudo code used in the model for drawing the days required 
for the assessment.   Each step in Figure C regarding the prediction of the assessment time will 
be discussed next. 
 
Figure C-1.  Pseudo Code for Predicting the Duration of the Assessment in Days 
 Firstly, a geometric distribution is used to draw the number of tests needed during 
assessment, where the input probability is calculated from the average number of tests required 
in the assessment process.  Then, based on the donor type of the transplant for which the 
assessment is being performed, the average days spent on assessment for the particular type of 
transplant was looked up from a table function based on the year when the assessment begins.  
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The use of a table function to capture the days spent on assessment from different time periods 
reflects the fact that the assessment time was not the same over the years.  Even without any 
historical source regarding the assessment time, historical data has shown the total wait time 
prior to transplant, which is the sum of the time spent on assessment and on transplant waiting 
list, has increased over years.  For instance, the wait time was within half a year before year 1990 
[38],  but is close to three or four years currently.  As part of the total wait time prior to 
transplant, the assessment time may be following the same trend: the duration of assessment has 
become longer and longer.  We estimated assessment time required in a table function 
“historicalAssessmentLDKTDuration”, which is used for looking up the average assessment 
time required for living donor transplant candidates.  For candidates for deceased donor 
transplants, the historical data has shown that the assessment took longer compared to the 
assessment of candidates for living donor transplant.   A variable named 
“DDvsLDWorkUpDaysRatioAdjustFactor” was created to save the ratio obtained by comparing 
the assessment time required for candidates of deceased donor transplant over the time spent by 
candidates of living donor transplant.  This ratio is used for calculating the average days required 
to assess deceased donor candidates by applying the ratio to the assessment time required for 
living donor transplant candidates.   With the duration of assessment and the average number of 
tests needed in assessment process, the average time per test was calculated which, together with 
the average number of tests, was supplied as inputs to an Erlang distribution to get the number of 
days required to finish the assessment. 
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APPENDIX D 
DATABASE CREATED FOR SASKATCHEWAN DM-ESRD MODEL 
 Figure D-1 shows an Enhanced Entity Relationship (EER) diagram illustrated the design 
of the “sk_dm_esrd_model” database.  A total of nine database tables were designed and created 
for saving data regarding to realizations, patients, and processes.  Each table will be described in 
greater details in the next section. 
  
Figure D-1.  EER Diagram for the “sk_dm_esrd_model” Database 
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 Model versions.  The model can evolve in successive versions, each associated with 
distinct structure. The “model_versions” table saves information on versions of the model.  The 
“vid” field is a unique identifier for each model version.  The “comments” field saves a 
description of the version.  The creation date saves the time when the version of the model was 
last modified.  Experiments can be run from different versions of the model. That is why the vid 
serves as a foreign key in the experiment table. 
 Experiments.  An Experiment in the database can be viewed as a container, and it can be 
associated with one single realization or a group of realizations.  Each experiment is uniquely 
assigned and identified by an experiment ID “eid”.  The start time of the experiment and finish 
time for the experiment are recorded in fields “start_time” and “end_time”, respectively.  The 
version of the model on which the experiment was run is recorded in the field “vid”.  
 Simulations.  A Simulation in the database represents one single realization of the model.  
Simulation is uniquely identified by primary key “sid”.   One experiment might consist of one or 
multiple simulations.  Each simulation can only belong to one experiment, the identification of 
which is recorded as “eid” in the Simulations table.  For a simulation, the start time and end time 
is recorded in fields “start _time” and “end_time”, respectively.   
 Simulation Parameters.  The parameters used to run the simulations are saved into the 
“simulation_parameters” table.  A “sid” identifies to which simulation a parameter name and 
value pair is attached.  The name and values of the parameters are saved in fields 
“parameter_name” and “parameter_value”. 
 SK DM Patients.  Information on the simulated Saskatchewan Diabetes Patients (the 
model population) are saved into “sk_dm_patients” table.  The “pid” is used for uniquely 
identifying patients. The “sid” identifies the simulation in which the patient was created/to which 
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the patient belongs.  The “person_type” field indicates the type of the patient in the model, the 
value of which ranged from 0 to 4.  Type 0 indicates patient is a member of the incident DM 
patients; Type 1, 2, 3 indicates that patients belong to the 1980 DM-ESRD prevalent patients 
group, and were receiving HD, PD and Transplant treatment on Jan 1st, 1980.  Type 4 indicates 
patients are a member of the 1980 DM patient group.  More details regarding the patient type can 
be found in the Model Population Chapter of this thesis. 
 The demographic information of the patients is saved in “sex”, “ethnicity”, and 
“dm_diganosis_age”.  The data in the “dm_diagnosis_age” field is the age when the patient first 
entered the model (the diabetic population).   
 Several of the sk_dm_patients fields are used to store available historical data for the 
1980 DM and DM-ESRD prevalent patients.  Specifically, the fields store any information 
available in the year of receiving diabetes diagnosis, year of receiving ESRD diagnosis, the year 
of death and year of coverage termination. The corresponding fields are “dm_diagnosis_year”, 
“esrd_diagnosis_year”, “death_year_known” and “end_coverage_year”, respectively.  
 In contrast to the historical data – which only provides information on the year – the 
events of diagnosis, death and exiting occur at a specific date and time within the model.  The 
actual time of those events are saved into “sk_dm_patients” in fields “time_dm” and “time_esrd”, 
and “time_death_exit”.  The “time_death_exit” field is used to record the time when patients 
either die or exit their health coverage, since only one of those two events can take place, but not 
both.  
 Treatments.  Information regarding ESRD treatments received by patients are saved in 
the “treatments” table.  Treatment is uniquely identified by the field “tid”.  The “pid” is the id of 
the patient who received the treatment.  The type of the treatment is recorded in field 
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“treatment_type”.  The begin and end time of the treatment are saved into the “start_time” and 
“end_time” fields, respectively.  When patient leaves the treatment due to a change in treatment 
type, death or end of coverage, the reason will be recorded in field “leaving_cause”. 
 Waitlist.  Following the addition of a patient to the kidney transplant waiting list, the 
information regarding the wait will be recorded in the table named “waitlist”.  The “wid” field 
uniquely identifies each record in the waiting list table.  The pid indicates which patient is on the 
waiting list.  The “type” field records the type of transplant for which the patient is waiting.  The 
“priority” saves the assigned priority of the patients.  The “start_time” and “end_time” fields are 
used to save the time when the patients were put on and taken off the waiting list.  Patients can 
leave the waiting list because of death, some unclear reasons (withdrawing from waiting list), or 
undergoing a kidney transplant.  The reason for leaving the waitlist is then recorded in the 
“leaving_cause” field.   
 Assessment.  The “assessment” table is for recording information regarding patients 
going through the assessment process.  The “aid” field has the unique identifier for each 
assessment record.  Each assessment record has a “pid” which identifies the patient who has 
undergone assessment.  The “type” field is used to store the type of kidney transplant (Living 
Donor or Deceased Donor) for which the patient is being assessed.  The “start_time” and 
“end_time” fields are used for saving the time when patients start and finish the assessment, 
respectively. A patient’s overall health condition represented by a health coefficient number is 
being evaluated during the assessment.  The health coefficient is saved to “health_coeff” field.  
When the assessment is completed, a decision will be made regarding to whether the patient is 
suitable for kidney transplant. The decision will be recorded in the “status” field. 
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 Cost ESRD.  The “cost_ esrd” table records the per year cost (accumulated across the 
year) for treating ESRD for a patient.  The “pid” identifies the patient to whom the cost is 
associated in a given year. 
